1 **DRAFT SCIENTIFIC OPINION**

2 Scientific Opinion on Dietary Reference Values for vitamin E as 3 α-tocopherol[1]

4 **EFSA Panel on Dietetic Products, Nutrition, and Allergies (NDA)**[2,3]

5 European Food Safety Authority (EFSA), Parma, Italy

6 **ABSTRACT**

7 Following a request from the European Commission, the Panel on Dietetic Products, Nutrition and Allergies
8 (NDA) derived Dietary Reference Values (DRVs) for vitamin E. In this opinion, the Panel considers vitamin E as
9 α-tocopherol only. The Panel considers that Average Requirements (ARs) and Population Reference Intakes
10 (PRIs) for vitamin E (as α-tocopherol) cannot be derived for adults, infants and children, and therefore defines
11 Adequate Intakes (AIs), based on observed intakes in healthy populations in the EU. This approach considers the
12 range of average intakes of α-tocopherol and of α-tocopherol equivalents estimated by EFSA from dietary
13 surveys in children and adults in nine countries. The Panel notes the uncertainties in the available food
14 composition and consumption data, the fact that most EU food composition databases contain values for
15 vitamin E as α-tocopherol equivalents, as well as the contribution of average α-tocopherol intakes to average α-
16 tocopherol equivalent intakes in these countries. For adults, an AI for α-tocopherol is set at 13 mg/day for men
17 and 11 mg/day for women. For children aged 1 to < 3 years, an AI for α-tocopherol is set at 6 mg/day for both
18 sexes. For children aged 3 to < 10 years, an AI for α-tocopherol is set at 9 mg/day for both sexes. For children
19 aged 10 to < 18 years, an AI for α-tocopherol is set at 13 mg/day for boys and 11 mg/day for girls. For infants
20 aged 7–11 months, an AI for α-tocopherol of 5 mg/day is derived by extrapolating upwards from the estimated α-
21 tocopherol intake in exclusively breast-fed infants aged 0–6 months and rounding. For pregnant or lactating
22 women, the Panel considers that there is no evidence for an increased need for α-tocopherol, and the same AI is
23 set as for non-pregnant non-lactating women.

25 **KEY WORDS**

26 vitamin E, α-tocopherol, α-tocopherol equivalent, Adequate Intake, Dietary Reference Value

27

[1] On request from the European Commission, Question No EFSA-Q-2011-01231, endorsed for public consultation on 5 February 2015.

[2] Panel members: Carlo Agostoni, Roberto Berni Canani, Susan Fairweather-Tait, Marina Heinonen, Hannu Korhonen, Sébastien La Vieille, Rosangela Marchelli, Ambroise Martin, Androniki Naska, Monika Neuhäuser-Berthold, Grażyna Nowicka, Yolanda Sanz, Alfonso Siani, Anders Sjödin, Martin Stern, Sean (J.J.) Strain, Inge Tetens, Daniel Tomé, Dominique Turck and Hans Verhagen. Correspondence: nda@efsa.europa.eu

[3] Acknowledgement: The Panel wishes to thank the members of the Working Group on Dietary Reference Values for vitamins: Christel Lamberg-Allardt, Monika Neuhäuser-Berthold, Grażyna Nowicka, Kristina Pentieva, Hildegard Przyrembel, Sean (J.J.) Strain, Inge Tetens, Daniel Tomé, Dominique Turck for the preparatory work on this scientific opinion.

Suggested citation: EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition and Allergies), 20XX. Draft Scientific Opinion on Dietary Reference Values for vitamin E as α-tocopherol. EFSA Journal 20YY;volume(issue):NNNN, 76 pp. doi:10.2903/j.efsa.20YY.NNNN

Available online: www.efsa.europa.eu/efsajournal

SUMMARY

Following a request from the European Commission, the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver a scientific opinion on Dietary Reference Values (DRVs) for the European population, including vitamin E.

Vitamin E is a fat soluble vitamin. Previously, the term vitamin E was used as the generic term for four tocopherols (α, β, γ, δ) and four tocotrienols (α, β, γ, δ), that are organic compounds which possess antioxidant activity to a different degree. Factors have been used to convert food contents of tocopherols and tocotrienols to α-tocopherol equivalents. In this opinion, based on the available evidence and in line with other authoritative bodies, the Panel considers vitamin E as being α-tocopherol only. Its naturally occurring form is RRR-α-tocopherol. Commercially available forms of α-tocopherol include either RRR-α-tocopherol, or a synthetic form that contains in equal proportions the eight stereoisomers of α-tocopherol (RRR-, RRS-, RSR-, RSS- and their enantiomers SSS-, SSR-, SRS-, SRR-) and is called all-rac-α-tocopherol, or their esterified forms.

Efficient α-tocopherol absorption requires the presence of fat. The Panel considered that the average α-tocopherol absorption from a usual diet is about 75 %. This is based on the means observed in two balance studies and in a kinetic study using a multi-compartmental model of α-tocopherol metabolism. After its intestinal absorption, α-tocopherol is incorporated into chylomicrons, and transported to the liver. There, the α-tocopherol transfer protein (α-TTP), which preferentially binds α-tocopherol compared to other tocopherols or tocotrienols, is responsible for its incorporation into nascent very low-density lipoproteins to be secreted by the liver into the circulation and distributed to body tissues. Alpha-tocopherol not bound to α-TTP is catabolised in the liver (to 2,5,7,8-tetramethyl-2-(2'-carboxyethyl)-6-hydroxychroman, i.e. α-CEHC) by hepatic ω-hydroxylase, which catabolizes tocopherols and has a stronger activity towards tocopherols other than α-tocopherol. Because of differences in activities of α-TTP and ω-hydroxylase towards α-tocopherol and other tocopherols, α-tocopherol predominantly accumulates in body tissues, whereas other tocopherols are preferentially catabolized in the liver.

Blood α-tocopherol concentrations are maintained by the preferential binding of α-tocopherol by α-TTP. Among chemically synthesized α-tocopherol forms, only 2R-α-tocopherol stereoisomers (i.e. RRR-, RRS-, RSR-, RSS-) were found to meet human requirements for the vitamin, because the 2S-stereoisomers (i.e. SSS-, SSR-, SRS-, SRR-) present in all-rac-α-tocopherol possess low affinity for α-TTP and are rapidly metabolized in the liver. Currently, only RRR-α-tocopherol is considered to be the physiologically active vitamer.

Alpha-tocopherol is part of the antioxidant defence system and is a peroxyl radical scavenger and especially protects polyunsaturated fatty acids (PUFAs) within membrane phospholipids and plasma lipoproteins. Primary α-tocopherol deficiency, a result of mutations in the α-TTP gene, is associated with neurological symptoms including ataxia. Symptomatic α-tocopherol deficiency in individuals without any disease and who consume diets 'low' in α-tocopherol has not been reported.

The Panel considers that there is, at present, insufficient data on markers of α-tocopherol intake/status/function (e.g. plasma/serum α-tocopherol concentration, hydrogen peroxide-induced haemolysis, urinary α-CEHC excretion, markers of oxidative damage) to derive the requirement for α-tocopherol. The Panel notes the lack of convergence of the values that would be derived from the use of data on markers of α-tocopherol intake/status or on α-tocopherol kinetics and body pools. The Panel considers that available data on markers of α-tocopherol intake/status/function, on α-tocopherol kinetics and body pools, on the relationship between PUFA intake and α-tocopherol intake/requirement can be used neither on their own nor in combination to derive the requirement for α-tocopherol in adults. The Panel considers that data on the relationship between vitamin E (unspecified form) or α-tocopherol intake and health consequences are inconsistent or limited and

cannot be used to derive the requirement for α-tocopherol. The Panel also considers that there are no data that can be used to derive the requirement for α-tocopherol for infants or children.

The Panel considers that Average Requirements (ARs) and Population Reference Intakes (PRIs) cannot be set for α-tocopherol. Therefore, the Panel proposes to set Adequate Intakes (AIs) for α-tocopherol for all population groups.

For adults and children, the AIs are based on observed dietary intakes in healthy populations and such intakes were estimated by EFSA using the EFSA Comprehensive European Food Consumption Database and the EFSA Food Composition Database. This intake assessment considered 13 dietary surveys in nine EU countries (Finland, France, Germany, Ireland, Italy, Latvia, the Netherlands, Sweden and the United Kingdom). As most food composition databases in EU countries contain values for vitamin E as α-tocopherol equivalents (α-TEs) and only two countries (Finland and Sweden) considered in the intake assessment by EFSA have vitamin E values in their food composition databases as α-tocopherol values, dietary intakes of both α-tocopherol and α-TE were estimated by EFSA for males and females for all included countries. The Panel noted the uncertainties in the available food composition and consumption data and dietary assessment methods, the contribution of average α-tocopherol intakes to average α-TE intakes in the nine EU countries considered, as well as the specific methodological uncertainties of the EFSA intake estimates for α-tocopherol. The Panel considered the range of average EFSA intake estimates for α-tocopherol as well as the range of average EFSA intake estimates for α-TEs, and combined the approximate mid-points of both ranges of average EFSA intake estimates to set AIs for α-tocopherol for children and adults, after rounding.

For adults, an AI for α-tocopherol is set at 13 mg/day for men and 11 mg/day for women. For children aged 1 to < 3 years, an AI for α-tocopherol is set at 6 mg/day for both sexes. For children aged 3 to < 10 years, an AI for α-tocopherol is set at 9 mg/day for both sexes. For children aged 10 to < 18 years, an AI for α-tocopherol is set at 13 mg/day for boys and 11 mg/day for girls.

For infants aged 7–11 months, an AI for α-tocopherol of 5 mg/day is extrapolated upwards from the estimated α-tocopherol intake in exclusively breast-fed infants aged 0–6 months, using allometric scaling and rounding to the closest unit.

The Panel considers that the available data do not indicate an additional α-tocopherol requirement during pregnancy or during lactation, and that a full compensation of the transitory secretion of α-tocopherol in breast milk is not justified for the derivation of DRVs for α-tocopherol for lactating women. The Panel therefore considers that the AI for pregnant or lactating women is the same (11 mg/day of α-tocopherol) as for non-pregnant non-lactating women.

TABLE OF CONTENTS

BACKGROUND AS PROVIDED BY THE EUROPEAN COMMISSION

The scientific advice on nutrient intakes is important as the basis of Community action in the field of nutrition, for example such advice has in the past been used as the basis of nutrition labelling. The Scientific Committee for Food (SCF) report on nutrient and energy intakes for the European Community dates from 1993. There is a need to review and, if necessary, to update these earlier recommendations to ensure that the Community action in the area of nutrition is underpinned by the latest scientific advice.

In 1993, the SCF adopted an opinion on the nutrient and energy intakes for the European Community.[4] The report provided Reference Intakes for energy, certain macronutrients and micronutrients, but it did not include certain substances of physiological importance, for example dietary fibre.

Since then new scientific data have become available for some of the nutrients, and scientific advisory bodies in many European Union Member States and in the United States have reported on recommended dietary intakes. For a number of nutrients these newly established (national) recommendations differ from the reference intakes in the SCF (1993) report. Although there is considerable consensus between these newly derived (national) recommendations, differing opinions remain on some of the recommendations. Therefore, there is a need to review the existing EU Reference Intakes in the light of new scientific evidence, and taking into account the more recently reported national recommendations. There is also a need to include dietary components that were not covered in the SCF opinion of 1993, such as dietary fibre, and to consider whether it might be appropriate to establish reference intakes for other (essential) substances with a physiological effect.

In this context EFSA is requested to consider the existing Population Reference Intakes for energy, micro- and macronutrients and certain other dietary components, to review and complete the SCF recommendations, in the light of new evidence, and in addition advise on a Population Reference Intake for dietary fibre.

For communication of nutrition and healthy eating messages to the public it is generally more appropriate to express recommendations for the intake of individual nutrients or substances in food-based terms. In this context the EFSA is asked to provide assistance on the translation of nutrient based recommendations for a healthy diet into food based recommendations intended for the population as a whole.

TERMS OF REFERENCE AS PROVIDED BY THE EUROPEAN COMMISSION

In accordance with Article 29 (1)(a) and Article 31 of Regulation (EC) No. 178/2002,[5] the Commission requests EFSA to review the existing advice of the Scientific Committee for Food on population reference intakes for energy, nutrients and other substances with a nutritional or physiological effect in the context of a balanced diet which, when part of an overall healthy lifestyle, contribute to good health through optimal nutrition.

In the first instance EFSA is asked to provide advice on energy, macronutrients and dietary fibre. Specifically advice is requested on the following dietary components:

- Carbohydrates, including sugars;

[4] Scientific Committee for Food, Nutrient and energy intakes for the European Community, Reports of the Scientific Committee for Food 31st series, Office for Official Publication of the European Communities, Luxembourg, 1993.

[5] Regulation (EC) No 178/2002 of the European Parliament and of the Council of 28 January 2002 laying down the general principles and requirements of food law, establishing the European Food Safety Authority and laying down procedures in matters of food safety. OJ L 31, 1.2.2002, p. 1-24.

- Fats, including saturated fatty acids, polyunsaturated fatty acids and monounsaturated fatty acids, *trans* fatty acids;
- Protein;
- Dietary fibre.

Following on from the first part of the task, EFSA is asked to advise on population reference intakes of micronutrients in the diet and, if considered appropriate, other essential substances with a nutritional or physiological effect in the context of a balanced diet which, when part of an overall healthy lifestyle, contribute to good health through optimal nutrition.

Finally, EFSA is asked to provide guidance on the translation of nutrient based dietary advice into guidance, intended for the European population as a whole, on the contribution of different foods or categories of foods to an overall diet that would help to maintain good health through optimal nutrition (food-based dietary guidelines).

ASSESSMENT

1. Introduction

In 1993, the Scientific Committee for Food (SCF) adopted an opinion on nutrient and energy intakes for the European Community, in which they did not set an Average Requirement (AR) or a Population Reference Intake (PRI) for vitamin E in absolute terms (SCF, 1993). Instead, the SCF considered an amount of 0.4 mg α-tocopherol equivalents (α-TEs) per gram of dietary polyunsaturated fatty acids (PUFAs) to fulfil the requirement of children and adults (including pregnant or lactating women), with a minimal intake of 4 mg α-TE/day for men and 3 mg α-TE/day for women regardless of PUFA intake.

The purpose of this opinion is to review Dietary reference Values (DRVs) for vitamin E. Previously, the term vitamin E was used as the generic term for four tocopherols (α, β, γ, δ) and four tocotrienols (α, β, γ, δ). In this opinion, based on the available evidence and in line with other authoritative bodies (IOM, 2000; Nordic Council of Ministers, 2014), the Panel considers vitamin E as being α-tocopherol only.

2. Definition/category

2.1. Chemistry

Alpha-tocopherol is formed from a trimethylated chromanol ring and a saturated phytyl side chain, and its molecular mass is 430.71 Da (Figure 1). Different methylation levels and positions on the chromanol ring define the other three members of the tocopherol family (β, γ, δ). Three double-bonds present in the side chain characterize the four corresponding forms of the tocotrienol series (α, β, γ, δ). Alpha-tocopherol has three chiral (i.e. asymmetric) carbons, at position 2 on the ring and 4' and 8' in the side chain; thus, there are potentially eight stereoisomers (identified by the configuration R or S of the three chiral centers). Commercially available forms of α-tocopherol are either natural RRR-α-tocopherol (formerly d-α-tocopherol), obtained by chemical methylation of by-products of soy oil production, or a synthetic form that contains in equal proportions the eight stereoisomers of α-tocopherol (RRR-, RRS-, RSR-, RSS- and their enantiomers SSS-, SSR-, SRS-, SRR-) and is called all-rac-α-tocopherol (formerly dl-α-tocopherol), or their esterified forms (e.g. RRR-α-tocopheryl acetate, all-rac-α-tocopheryl acetate). Bioactivity of each stereoisomer of α-tocopheryl acetate has been determined using the resorption–gestation test in the rat (Weiser and Vecchi, 1982) and ranges from 21 % for the SSR isomer to 90 % for the RRS isomer, compared to RRR-α-tocopheryl acetate.



5	7	8	
CH_3	CH_3	CH_3	α-tocopherol
CH_3	H	CH_3	β-tocopherol
H	CH_3	CH_3	γ-tocopherol
H	H	CH_3	δ-tocopherol

Figure 1: Structure of the four tocopherols (α, β, γ, δ)

Previously, the generic term vitamin E comprised tocopherols and tocotrienols, that are organic compounds which possess antioxidant activity to a different degree (Wang and Quinn, 1999). Currently, however, only the naturally occurring RRR-α-tocopherol is considered to be the physiologically active vitamer, as blood α-tocopherol concentrations are maintained by the preferential binding of α-tocopherol by the α-tocopherol transfer protein (α-TTP) compared to other tocopherols or tocotrienols (Hosomi et al., 1997; IOM, 2000). Among chemically synthesized α-tocopherol forms, only 2R-α-tocopherol stereoisomers (i.e. RRR-, RRS-, RSR-, RSS-) were found to meet human vitamin E requirements (Weiser and Vecchi, 1982; IOM, 2000), because the 2S-stereoisomers (i.e. SSS-, SSR-, SRS-, SRR-) present in all-rac-α-tocopherol possess low affinity to α-TTP and are rapidly metabolized in the liver (Acuff et al., 1994; Hosomi et al., 1997; Kiyose et al., 1997; Burton et al., 1998).

Contents of vitamin E have been presented in the literature in mg, µmol, α-TEs or in international units (IU). The factors to convert tocopherols and tocotrienols to α-TEs[6] are based on the bioactivity of these tocopherols and tocotrienols assessed using the resorption–gestation test in rats (IOM, 2000). The United States Pharmacopoeia (USP) defined the IU for vitamin E (USP, 1979, 1980) and expressed it relative to the synthetic form, racemic all-rac-α-tocopheryl acetate[7].

IOM (2000) considered that the difference in relative activity of all-rac-α-tocopherol compared to RRR-α-tocopherol is 50 % and defined 1 mg all-rac-α-tocopherol as equal to 0.5 mg RRR-α-tocopherol, 1 IU all-rac-α-tocopherol or its esters as equal to 0.45 mg 2R-stereoisomeric forms of α-tocopherol and 1 IU RRR-α-tocopherol or its esters as equal to 0.67 mg 2R-α-tocopherol. The Panel agrees with this definition.

In this opinion, the Panel considers α-tocopherol, i.e. the naturally occurring form RRR-α-tocopherol and the other three synthetic 2R-stereoisomer forms (RSR-, RRS- and RSS-), to set DRVs for vitamin E. Contents in food and intakes are presented in this opinion as mg α-tocopherol. The term 'vitamin E' is used in this opinion when the papers cited do not report the form ingested (from foods or via supplementation), and e.g. the terms 'α-tocopherol as well as other tocopherols and tocotrienols' when considerations apply to all these forms.

2.2. Function of α-tocopherol

2.2.1. Biochemical functions

Alpha-tocopherol is part of the antioxidant defense system, which is a complex network including endogenous and dietary antioxidants, antioxidant enzymes, and repair mechanisms, with mutual interactions and synergetic effects among the various components.

Alpha-tocopherol mainly functions as a lipid-soluble non-specific chain-breaking antioxidant that prevents propagation of free-radical reactions. The vitamin is a peroxyl radical scavenger and especially protects PUFAs within membrane phospholipids and plasma lipoproteins (Wang and Quinn, 1999; Traber and Atkinson, 2007; Niki, 2014). When peroxyl radicals are formed, these react 1 000-times faster with α-tocopherol than with PUFAs (Buettner, 1993). By protecting PUFAs within membrane phospholipids, α-tocopherol preserves intracellular and cellular membrane integrity and stability, plays an important role in the stability of erythrocytes and the conductivity in central and

[6] Alpha-tocopherol equivalents were defined as 1.0 mg α-tocopherol, 0.5 mg β-tocopherol, 0.1 mg γ-tocopherol, 0.03 mg δ-tocopherol, 0.3 mg α-tocotrienol, 0.05 mg β-tocotrienol; the biological activities of γ- and δ-tocotrienols were considered to be below the limit of detection (IOM, 2000; WHO/FAO, 2004).

[7] One IU was defined as equivalent to 1 mg of all-rac-α-tocopheryl acetate. One IU was provided by 0.91 mg of all-rac-α-tocopherol (thus, 1 mg of all-rac-α-tocopherol was equivalent to 1.10 IU), or 0.67 mg RRR-α-tocopherol (thus, 1 mg of RRR-α-tocopherol was equivalent to 1.49 IU), or 0.74 mg RRR-α-tocopheryl acetate (thus, 1 mg of RRR-α-tocopheryl acetate was equivalent to 1.35 IU).

peripheral nerves, and prevents haemolytic anaemia and neurological symptoms (ataxia, peripheral neuropathy, myopathy, pigmented retinopathy) occurring in α-tocopherol-deficient individuals (Muller, 1986).

The phenolic hydrogen at position 6 is the active site for scavenging radicals. Alpha-tocopherol scavenges free radicals primarily by hydrogen atom transfer reaction to yield a non-radical product and α-tocopherol radical. Alpha-tocopherol may also scavenge radicals by a mechanism in which an electron is transferred from α-tocopherol to give a vitamin cation-radical, which undergoes rapid deprotonation to provide an α-tocopherol radical. When α-tocopherol scavenges lipid peroxyl radicals, lipid hydroperoxide and α-tocopherol radical are formed (Niki et al., 1993; Yamauchi, 2007; Niki, 2014). The α-tocopherol radical may react with another radical to give stable products, attack lipids, or react with a reducing agent such as ascorbate or ubiquinol to regenerate the vitamin (Packer et al., 1979; Niki et al., 1982). The *in vivo* role of vitamin C and of selenium in sustaining the antioxidant capacity of α-tocopherol is indicated by animal (Igarashi et al., 1991; Hill et al., 2001) and human (Bruno et al., 2006b) studies. The interaction of α-tocopherol and vitamin C has led to the concept of 'vitamin E recycling', where the antioxidant function of oxidized α-tocopherol is continuously restored by other antioxidants, and this antioxidant network depends on the supply of aqueous antioxidants and the metabolic activity of cells.

2.2.2. Health consequences of deficiency and excess

2.2.2.1. Deficiency

The classification of 'vitamin E' as an essential nutrient is based on animal studies and primary and secondary α-tocopherol deficiency in humans. The need for α-tocopherol in order to prevent fetal resorption in pregnant rats fed lard-containing diets is at the origin of the discovery of the vitamin (Evans and Bishop, 1922). The chemical name 'tocopherol' derives from its essentiality for normal reproduction in animals, though the essentiality for this function has never been demonstrated in humans (Brigelius-Flohe et al., 2002). However, a human case report of recurrent spontaneous abortions, which disappeared by administration of 300 mg/day of tocopherol nicotinate, has been published (Harada et al., 2005).

Primary α-tocopherol deficiency, i.e. familial isolated α-tocopherol deficiency, is associated with neurological symptoms including ataxia. The primary defect is a result of mutations in the α-TTP gene (Ouahchi et al., 1995). In carriers of variant alleles in the α-TPP gene, serum α-tocopherol concentrations even lower than 2.3 µmol/L have been reported (Cavalier et al., 1998; IOM, 2000; Mariotti et al., 2004).

Secondary α-tocopherol deficiency has been observed in cases of abetalipoproteinaemia, cholestatic liver diseases, severe malnutrition, fat malabsorption, and cystic fibrosis (Farrell et al., 1977; Jeffrey et al., 1987; Eggermont, 2006; Zamel et al., 2008), for whom plasma/serum α-tocopherol concentrations of about 2.5-12 µmol/L have been reported.

Symptomatic α-tocopherol deficiency in individuals without any disease and who consume diets 'low' in α-tocopherol has not been reported (IOM, 2000).

2.2.2.2. Excess

In order to set a Tolerable Upper Intake Level (UL), SCF (2003) considered the impact on blood clotting as the critical adverse effect and identified a No Observed Adverse Effect Level (NOAEL) of 540 mg α-TE/day from the study by Meydani et al. (1998). In this study, 88 healthy subjects over 65 years of age, who were supplemented for four months with either no, 40, 134 or 537 mg α-TE/day (all-rac-α-tocopherol), were reported to develop no adverse effects, including on bleeding time. SCF

(2003) set a UL for adults of 270 mg α-TE/day, rounded to 300 mg α-TE/day using an uncertainty factor of 2. This UL also applies to pregnant and lactating women as there was no indication from animal studies of a specific risk for these population groups. The ULs for children were derived from the adult UL by allometric scaling on the basis of body weight to the power of 0.75, and ranged from 100 mg α-TE/day (1-3 years) to 260 mg α-TE/day (15-17 years).

2.3. Physiology and metabolism

2.3.1. Intestinal absorption

The absorption of tocopherols and tocotrienols is similar to that of other lipid compounds, takes place in the upper gastrointestinal tract, and involves transporters non-specific to α-tocopherol (Rigotti, 2007; Iqbal and Hussain, 2009; Reboul et al., 2011). Absorption includes emulsification, incorporation into micelles (or lipid droplets and vesicles), transport through the unstirred water layer, uptake by the apical membrane of the enterocyte, solubilisation into intestinal lipoproteins, and secretion out of the intestinal cell into the lymph or into the portal vein (Bender, 2003; Borel et al., 2013). Tocopherol esters are hydrolysed in the duodenum by pancreatic hydrolases and the bioavailability of the free and ester forms is similar (Cheeseman et al., 1995). The main fraction of absorbed tocopherols and tocotrienols is secreted in chylomicrons via the apolipoprotein B pathway, and only a small fraction via an apolipoprotein A I pathway (Reboul et al., 2009; Shichiri et al., 2010).

In eight healthy subjects consuming 150 mg [^{2}H]-labelled RRR-α-tocopheryl acetate with four different test meals (Jeanes et al., 2004), labelled α-tocopherol uptake into chylomicrons and plasma up to nine hours after ingestion was highest after toasts with butter (17.5 g fat). It was significantly higher after ingestion of cereal with full-fat milk (17.5 g fat) than after cereal with semi-skimmed milk (2.7 g fat). It was lowest after water (no fat) intake or cereal with semi-skimmed milk (2.7 g fat) (not significantly different). Percentage absorption was not assessed as such. This study indicates that the amount of fat influenced absorption of α-tocopherol.

A balance study using [^{3}H]-labelled all-rac-α-tocopherol (0.2 mg) in oily solution in humans reported a mean fractional absorption of α-tocopherol of 75 % (range: 61–90 %) in normal adults who provided blood, urine, and faecal samples for 14 days (Kelleher and Losowsky, 1968). In another balance study, mean fractional absorption of [^{3}H]-all-rac-α-tocopherol (3-6 µg in 1 mg unlabelled form, consumed with milk) was about 69 % (range: 55–79 %) in normal adults (blood, urine and faecal samples collected for 120 hours, three days and six days, respectively) (MacMahon and Neale, 1970).

A kinetic study involved 12 healthy adults, who ingested 0.78 µg [^{14}C]-labelled RRR-α-tocopherol mixed with milk (2 % fat) before breakfast (containing 8 g fat) and provided blood (for 70 days), urine and faecal samples (for 21 days) (Novotny et al., 2012)[8]. A compartmental model of α-tocopherol metabolism was developed to determine kinetic parameters, and mean absorption (± SD) of the labelled α-tocopherol dose was calculated to be 80.8 ± 5.98 %[9].

Five healthy adults consumed apples, as a low-fat vitamin delivery system, fortified with D6-RRR-α-tocopheryl acetate[10] (22 mg per 80 g serving), in controlled breakfasts containing 0 %, 6 %, or 21 % of energy from fat, then provided blood samples for 72 hours (Bruno et al., 2006a). Mean absorption

[8] The dose of [^{14}C]-labelled RRR-α-tocopherol was reported to be 0.78 mg in Novotny et al. (2012), but 0.78 µg in Chuang et al. (2011) (Section 2.3.3), and also expressed in both papers as 1.81 nmol. Thus, the value of 0.78 µg is reported in this Opinion.

[9] Using the formula [dose - (faeces - faecal metabolic loss)] × 100/dose.

[10] Deuterium (i.e. [^{2}H]) labelled α-tocopherol molecules are called D_0-, D_3- or D_6- according to the number of deuterium atoms on the ring (D_0: no deuterium).

of the labelled α-tocopherol increased from 10 % after the 0 % fat meal to 20 % and 33 % after the 6 % and 21 % of energy from fat meals, respectively. The Panel notes that calculation of the area under the curve would have been a better method than the estimation from the plasma Cmax of the labelled α-tocopherol multiplied by the plasma volume applied in this study, which is insufficient for an accurate estimation of α-tocopherol absorption.

The Panel notes that studies on the efficiency of α-tocopherol absorption used different models and techniques, with wide-ranging doses of labelled α-tocopherol (0.78 µg-22 mg) embedded into different food matrices and test meals. The Panel also notes that there is a large range of reported mean α-tocopherol absorption (from about 10 % to 80 %, for different fat intakes). Efficient α-tocopherol absorption requires the presence of fat, but the precise quantity and quality of fat for optimizing α-tocopherol absorption is unknown. The Panel notes that, in a usual diet, α-tocopherol is accompanied by fat and the mechanism of α-tocopherol absorption is similar to that of lipid components. The Panel considers that the average α-tocopherol absorption from a usual diet is about 75 %, which is based on the means observed in two balance studies (75 and 69 %) and in a kinetic study using a multi-compartmental model of α-tocopherol metabolism (81 %). The Panel notes that such a value is consistent with the high efficiency of lipid absorption from the diet (EFSA NDA Panel, 2010).

2.3.2. Transport in blood

After its intestinal absorption, α-tocopherol is incorporated into chylomicrons, which, along the lymphatic pathway, are secreted into the systemic circulation. By the action of lipoprotein lipase (LPL), extra-hepatic tissues may take up part of the α-tocopherol transported in chylomicrons, while the remnant chylomicrons transport α-tocopherol to the liver. (Traber, 2007; Wu and Croft, 2007; Gee, 2011).

2.3.3. Distribution to tissues and estimation of body pools

In hepatocytes, α-TTP binds RRR-α-tocopherol with the highest affinity and is responsible for the incorporation of this stereoisomer into nascent very low-density lipoproteins (VLDL), and thus, for its preferential distribution to peripheral tissues (Traber and Kayden, 1989; Traber et al., 1992; Traber et al., 1994; Stocker and Azzi, 2000; Manor and Morley, 2007; Mustacich et al., 2007). Once secreted into the circulation, VLDL are converted into intermediate-density lipoproteins (IDL) and low-density lipoproteins (LDL) by the action of LPL, and the excess of VLDL surface components including α-tocopherol is transferred to high-density lipoproteins (HDL) (Traber, 2007; Wu and Croft, 2007; Gee, 2011).

Humans discriminate between RRR- and SRR-α-tocopherol stereoisomers: after intake of equal amounts of D_6-RRR-α-tocopheryl and D_3-SRR-α-tocopheryl acetates, the chylomicrons contained similar concentrations of both forms, while VLDL, LDL and HDL were preferentially enriched in RRR-α-tocopheryl acetate (Traber et al., 1990). The rate of disappearance of SRR-α-tocopherol from plasma was similar to that of RRR-γ-tocopherol and significantly quicker than that of RRR-α-tocopherol, after intake of D_6-RRR-α-tocopheryl acetate, D_3-SRR-α-tocopheryl acetate and D_2-RRR-γ-tocopherol (Traber et al., 1992).

At least two mechanisms are responsible for α-tocopherol delivery to tissues: the release during the hydrolysis of triglyceride-rich lipoproteins and the receptor uptake of LDL- and HDL-bound α-tocopherol (Traber and Kayden, 1984; Rigotti, 2007; Parks et al., 2000). The LDL receptor pathway delivers to the cells the major part of α-tocopherol (Traber and Kayden, 1984). Deficiency in the receptor, however, does not lead to a phenotype of α-tocopherol deficiency: patients with homozygous familial hypercholesterolaemia do not manifest any biochemical or clinical evidence of α-tocopherol

deficiency (Traber and Kayden, 1984), so that other mechanisms are likely to be active (Rigotti, 2007).

A kinetic study (Chuang et al., 2011) involved 12 healthy adults, who ingested 0.78 µg [^{14}C]-labelled RRR-α-tocopherol mixed with milk (2 % fat) before breakfast, provided blood (for 460 days), urine and faeces (for 21 days) samples, and had a mean (± SD) α-tocopherol intake (assessed by a food frequency questionnaire FFQ) of 7.6 ± 2.8 mg/day. The turnover of α-tocopherol was slow: the mean half-life of the dose was 44 days in plasma and 96 days in red blood cells (RBC). However, high individual differences were observed.

In another publication about the first 70 days of the same kinetic study (Novotny et al., 2012)[11], a multi-compartmental model of α-tocopherol metabolism was developed to determine mean transfer rates among body compartments (Figure 2). The model, with 11 compartments, three delay compartments, and reservoirs for urine and faeces, took into account the observed plasma α-tocopherol concentrations in these 12 healthy subjects (mean [range]: 23 [19-27] µmol/L) and the intake of RRR-α-tocopherol necessary to maintain these values, which was estimated by the authors to be 4 mg/day. The model shows that α-tocopherol is mainly absorbed via chylomicrons (81 % of ingested dose), transferred to hepatocytes (78 % of ingested dose) and from hepatocytes to plasma lipoproteins (75 % of ingested dose). Plasma lipoproteins distribute and exchange α-tocopherol with three main compartments. Among these, the highest rate of transfer of α-tocopherol is between plasma lipoproteins and a multi-organ compartment (e.g. hepatic stellate cells, brain, spleen). The exchange flow and the net flux from plasma lipoproteins to this multi-organ compartment were estimated to be, respectively, about 84 and 3 mg/day. The exchange flow and the net flux from RBC to plasma lipoproteins were estimated to be, respectively, about 19 and 0.1 mg/day. The exchange flow and the net flux from the adipose tissue to plasma lipoproteins were estimated to be, respectively, approximately 45 and 0 mg/day. Due to the very large compartment size of the adipose tissue, this flow was achieved with a very small fractional transfer rate of 0.4 ± 0.1 % of the pool per day.



Figure 2: Alpha-tocopherol exchanges between body compartments. Figures denote daily fluxes between compartments. Based on data from Novotny et al. (2012)

Traber and Kayden (1987) estimated that the adipose tissue contains about 90 % of the total body α-tocopherol pool, and that 99 % of α-tocopherol of the adipose tissue is in the bulk lipid. The compartmental model of Novotny et al. (2012) indicates a mean total body RRR-α-tocopherol pool of about 11 g (about 26 mmol), of which about 99 % was associated with a slowly turning-over compartment, which was assumed to be primarily adipose tissue.

[11] The dose of [^{14}C]-labelled RRR-α-tocopherol was reported to be 0.78 mg in Novotny et al. (2012), but 0.78 µg in Chuang et al. (2011), and also expressed in both papers as 1.81 nmol. Thus, the value of 0.78 µg is reported in this Opinion.

Considering the average body weight (67 kg) and the estimated percentage of body fat (25 %) of the participants, Novotny et al. (2012) calculated that the α-tocopherol concentration in adipose tissue was 657 µg/g (1.53 µmol/g). However, measurements of α-tocopherol concentrations in adipose tissue in adults provide variable results. Indeed, α-tocopherol concentrations ranged from 61 to 811 µg/g (0.14–1.89 µmol/g) (Parker, 1988), and means varied from 73 to 245 µg/g (four groups studied post mortem) (0.17–0.57 µmol/g) (Dju et al., 1958), and from 83 to 268 µg/g in men (0.19–0.62 µmol/g) and from 123 to 355 µg/g in women (0.29–0.82 µmol/g) (biopsies) (Kardinaal et al., 1995; Su et al., 1998; El-Sohemy et al., 2001).

Changes in adipose tissue α-tocopherol concentrations take years (Schaefer et al., 1983; Handelman et al., 1994). In adults, Handelman et al. (1994) found that adipose tissue α-tocopherol concentration increased (10 to 60 % according to subjects) with 800 mg/day all-rac-α-tocopherol supplementation for one year compared to before supplementation, but that it did not decrease after one year of discontinuation of the supplement. Data suggest that efflux of α-tocopherol from adipocytes may be tightly regulated, since during weight loss, the triglyceride content of adipocytes and their size significantly decreased (three subjects) without any change in 'tocopherol' content per cell (one subject) (Schaefer et al., 1983).

Alpha-tocopherol is transported in plasma lipoproteins and distributed to tissues. The Panel notes that 90 to 99 % of the total body RRR-α-tocopherol pool are contained in the adipose tissue and that the net flux of α-tocopherol from the adipose tissue to plasma lipoproteins is very low (close to 0 mg/day).

2.3.4. Metabolism

The liver plays a key role in the metabolism of tocopherols and tocotrienols, in the α-tocopherol preference relative to the other tocopherols and tocotrienols, in determining the circulating concentrations of the various tocopherols and tocotrienols and in limiting α-tocopherol accumulation in tissues (Traber, 2007; Wu and Croft, 2007; Traber, 2013).

In hepatocytes, α-TTP binds RRR-α-tocopherol with the highest affinity and is responsible for the preferential secretion of this stereoisomer into nascent VLDL, and thus, for its preferential distribution to peripheral tissues (Section 2.3.3). Oxidative stress may increase α-TTP gene expression (Ulatowski et al., 2012), and it may be hypothesized that hepatic α-TTP may increase with decreasing α-tocopherol intake.

Tocopherols and tocotrienols are metabolized in the liver by ω-hydroxylation, followed by β-oxidation, conjugation, and excretion. Different metabolites from tocopherols and tocotrienols have been identified (Zhao et al., 2010). In particular, α-tocopherol may be catabolised to 2,5,7,8-tetramethyl-2-(2'-carboxyethyl)-6-hydroxychroman (α-CEHC) (Schultz et al., 1995). The enzyme CYP4F2 ω-hydroxylates tocopherols (Sontag and Parker, 2002), and its activity towards α-tocopherol is lower than towards other tocopherols (Sontag and Parker, 2007). β-oxidation reactions may occur both in peroxisomes and mitochondria, but mitochondria were the only site for α-CEHC production in rat liver homogenates (Mustacich et al., 2010).

Conjugates of α-CEHC in plasma and in urine have been described, such as glucuronide conjugates of CEHC, CEHC sulfate and CEHC glycoside (Pope et al., 2002; Cho et al., 2009; Johnson et al., 2012), α-CEHC glycine, α-CEHC glycine glucuronide, and α-CEHC taurine (Johnson et al., 2012).

The Panel notes that both α-TTP and ω-hydroxylase play critical roles in controlling the metabolism of α-tocopherol. The Panel notes that α-TTP, which preferentially binds α-tocopherol compared to other tocopherols or tocotrienols, is responsible for its incorporation into nascent VLDL to be secreted by the liver into the circulation and distributed to body tissues, and that α-tocopherol bound

to α-TTP is therefore not catabolized in the liver by the liver ω-hydroxylase, which catabolizes tocopherols and has a stronger activity towards tocopherols other than α-tocopherol. Because of differences in activities of α-TTP and ω-hydroxylase towards α-tocopherol and other tocopherols, α-tocopherol is predominantly accumulated in body tissues, whereas other tocopherols are preferentially metabolized in the liver.

2.3.5. Elimination

A kinetic study (Bruno et al., 2005) in ten adult non-smokers, who consumed D_3-RRR-α-tocopheryl acetate and D_6-all-rac-α-tocopheryl acetate (one dose of 75 mg each, for six days) and provided blood and urine samples for up to 17 days, showed that tissue α-tocopherol efflux rate was 0.191 pools/day. Considering this efflux rate, as well as the baseline plasma α-tocopherol concentrations and plasma volume of the participants from another study (Bruno et al., 2006a) (Section 2.3.1), the authors considered that 5.1 ± 0.9 mg α-tocopherol was excreted daily from the body. Based on a compartmental model of α-tocopherol metabolism and the assessment of both total and radioactive RRR-α-tocopherol concentration in samples, daily losses of α-tocopherol in faeces and urine were estimated to be 4 mg, including 0.8 mg/day of non-absorbed fraction (Novotny et al., 2012) (Figure 2) (Section 2.3.3).

Excess α-tocopherol (i.e. not incorporated into nascent VLDL or entering the liver by reverse lipoprotein uptake), other tocopherols and tocotrienols are secreted in the bile. Considering a mean α-tocopherol concentration in human bile of 8.4 ± 0.9 µmol/L (Leo et al., 1995), and a bile production in humans of about 750 mL/day (Boyer and Bloomer, 1974; Boyer, 2013), about 2.7 mg (6.3 µmol) of α-tocopherol is secreted in the bile per day. Oxidative metabolites of α-tocopherol are also secreted in the bile (Schultz et al., 1995; Wu and Croft, 2007).

2.3.5.1. Faeces

In the kinetic study in adults who ingested 0.78 µg [^{14}C]-labelled-RRR-α-tocopherol and provided faecal samples over 21 days (Chuang et al., 2011) (Section 2.3.3), 23.2 ± 5.8 % of the labelled dose was eliminated via the faeces. In another publication on the same study, but based on a compartmental model of α-tocopherol metabolism and assessment of both total and radioactive RRR-α-tocopherol concentration in the samples, Novotny et al. (2012) found mean faecal losses of α-tocopherol to be about 3.15 mg/day (Figure 2) (Section 2.3.3).

2.3.5.2. Urine

α-CEHC is formed directly from α-tocopherol by side-chain oxidation and is eliminated in the urine (Schultz et al., 1995). In the kinetic study in adults who provided urine samples over 21 days (Chuang et al., 2011) (Sections 2.3.3 and 2.3.5.1), 4.26 ± 1.38 % of the radioactive dose was eliminated via urine. In the other publication on the same study based on a compartmental model of α-tocopherol metabolism, Novotny et al. (2012) found mean daily total urine losses of α-tocopherol to be about 0.85 mg/day (Figure 2) (Sections 2.3.3 and 2.3.5.1).

2.3.5.3. Skin

Alpha-tocopherol is secreted by sebaceous glands, though dermal losses have not been quantified (Wu and Croft, 2007).

2.3.5.4. Breast milk

Lactating women secrete α-tocopherol via their breast milk. Alpha-tocopherol content in human milk of about 3.5 mg/L has been noted (EFSA NDA Panel, 2013), based on Antonakou et al. (2011). A comprehensive search of the literature published after January 2000 was performed as preparatory work to the present opinion in order to identify data on breast milk α-tocopherol concentration (LASER Analytica, 2014). Considering the amount of available data, the Panel excluded studies explicitly undertaken in non-European countries and/or on a mixed population of infants born pre-term or at term. Finally, Appendix A reports on the mean α-tocopherol concentration of human milk from healthy lactating mothers in 14 studies. Among them, seven studies did not explicitly indicate whether the infants were born pre-term or at term (Romeu-Nadal et al., 2008a; Romeu-Nadal et al., 2008b; Duda et al., 2009; Molto-Puigmarti et al., 2009; Molto-Puigmarti et al., 2011; Kasparova et al., 2012; Martysiak-Zurowska et al., 2013), and two studies in mothers of full-term infants were not undertaken in the EU (Tokusoglu et al., 2008; Orhon et al., 2009). These nine studies are listed in the Appendix, for completeness.

The other five studies (Schweigert et al., 2004; Quiles et al., 2006; Romeu-Nadal et al., 2006; Sziklai-Laszlo et al., 2009; Antonakou et al., 2011) were conducted in mothers of full-term infants in the EU. In these studies, mean α-tocopherol concentration in human milk, measured by HPLC, ranged from about 3 to about 25 mg/L (including all stages of lactation). The highest value (25 mg/L) was observed in colostrum samples (three days post partum) (Quiles et al., 2006). Mean maternal 'vitamin E' intake was reported in two studies (Quiles et al., 2006; Antonakou et al., 2011) and ranged from about 6 to 11 mg/day. It was explicitly indicated that the women did not receive supplements in two studies (Schweigert et al., 2004; Antonakou et al., 2011) (n = 85 women in total at baseline). The remaining two studies did not mention a possible α-tocopherol supplementation. Focussing more specifically on the two studies in the EU (Schweigert et al., 2004; Antonakou et al., 2011) in unsupplemented women, the mean α-tocopherol concentration in mature milk ranged between 3.5 and 5.7 mg/L (mid-point of 4.6 mg/L).

Considering a mean milk transfer of 0.8 L/day during the first six months of lactation in exclusively breastfeeding women (Butte et al., 2002; FAO/WHO/UNU, 2004; EFSA NDA Panel, 2009), and a concentration of α-tocopherol in mature human milk of 4.6 mg/L, the secretion of α-tocopherol into milk during lactation is estimated to be 3.7 mg/day.

2.3.5.5. Conclusions on elimination

The Panel notes that the main route of α-tocopherol excretion is via the faeces. The Panel notes that daily losses of α-tocopherol in healthy non-lactating adults are about 4–5 mg/day based on two kinetic studies (Bruno et al., 2006a; Novotny et al., 2012). The Panel also considers that secretion of α-tocopherol into breast milk during the first six months of exclusive breastfeeding is about 4 mg/day.

2.3.6. Interaction with other nutrients

2.3.6.1. Interaction with PUFAs

Alpha-tocopherol is needed to prevent oxidation of PUFAs in membrane phospholipids and plasma lipoproteins.

Based on data on α-tocopherol depletion and supplementation in men consuming different diets of known PUFA content and the effect on the percentage of hydrogen peroxide-induced haemolysis (Horwitt et al., 1956; Horwitt, 1960) (Section 2.4.2), Harris and Embree (1963) considered that the minimum α-tocopherol/PUFA intake ratio needed to prevent α-tocopherol deficiency was in the range

0.5–0.8 mg/g. The authors also noted a ratio of 0.6 mg α-tocopherol/g PUFAs (mainly linoleic acid) in the American diet and considered this ratio to be protective against α-tocopherol deficiency.

In the 1970s, the ratio of mg α-tocopherol/g PUFAs[12] in typical US breakfasts, lunches and dinners ranged from 0.16 to 0.71, with a mean at 0.43 (Bieri and Evarts, 1973). In female students consuming a repetitive series of diets over about nine months in the US, Witting and Lee (1975) observed a mean plasma total tocopherol concentration of 1.09 mg/dL[13] for a daily mean intake of 17.9 g of 18:2 n-6, 1.6 g of 18:3 n-3 and 7.5 mg RRR-α-tocopherol. The authors thus proposed a ratio of 0.4 mg α-tocopherol/g PUFA to describe the relationship between both nutrients in a diet. The Panel notes that these ratios of mg α-tocopherol/g PUFA, which have been used in the past to set DRVs (Section 4.1), were not related to a functional outcome.

In order to define the compositional requirement for RRR-α-tocopherol in infant formulae, the SCF (1997) considered the results of an *in vitro* (Holman, 1954) and an animal study (Witting and Horwitt, 1964). The *in vitro* study (Holman, 1954) found that the relative rate of oxidation of fatty acids was 0.025: 1: 2: 4: 6: 8 for the number of double bonds in fatty acids increasing from 1 to 6. The animal study in tocopherol-deficient rats showed that the relative ratio of fatty acid oxidation was slightly different: 0.3, 2, 3, 4, 5, 6 for mono-, di-, tri-, tetra-, penta- and hexaenoic fatty acids (Witting and Horwitt, 1964). Thus, SCF (1997) proposed the relative requirement of RRR-α-tocopherol in infant formulae according to the degree of unsaturation of PUFA to be: 0.5 mg/g linoleic acid, 0.75 mg/α-linolenic acid, 1 mg/g arachidonic acid, 1.25 mg/g EPA and 1.50 mg/g DHA.

2.3.6.2. Interaction with vitamin C

The interactions of α-tocopherol and vitamin C depend on their roles as antioxidants, and vitamin C can reduce the oxidized form of α-tocopherol. Smokers had higher plasma F_2-isoprostane concentrations and faster plasma α-tocopherol disappearance rates than non-smokers and, when they received vitamin C supplementation (500 mg twice daily) for two weeks, α-tocopherol disappearance rates were normalised (Bruno et al., 2005; Bruno et al., 2006b).

2.3.6.3. Interaction with selenium, niacin and vitamin K

Both, selenium and niacin, are required to maintain glutathione peroxidase activity. The membrane-specific isoenzyme of glutathione peroxidase catalyses the reduction of the tocopheroxyl radical back to tocopherol. Glutathione peroxidase reduces hydrogen peroxide and thereby lowers the amount of peroxide available for the generation of radicals, whereas α-tocopherol is involved in removing the products of attack by these radicals on lipids (Bender, 2003).

A competitive inhibition was described between tocopherol quinone and the phylloquinone hydroquinone for the vitamin K-dependent gamma-carboxylase. This carboxylase is required for the conversion of specific glutamyl residues to γ-carboxyglutamyl residues in certain proteins, including factors II, VII, IX, and X, and proteins C and S involved in normal haemostatic function (Furie et al., 1999).

2.3.6.4. Conclusions on interactions with other nutrients

The Panel considers that α-tocopherol, as a lipid soluble antioxidant, prevents PUFA oxidation and that PUFA intake should be associated with an adequate α-tocopherol intake. However, the Panel notes that the required amount of α-tocopherol may differ according to the degree of saturation of the various PUFAs, the intakes of which are variable in the EU (EFSA NDA Panel, 2010). The Panel

[12] PUFAs considered in this publication: 18:2 and 20:4.
[13] This would be equivalent to about 25 µmol/L α-tocopherol.

considers that there is little evidence to support the ratios of 0.4 mg or 0.6 mg of α-tocopherol per g of dietary PUFAs, and that there were uncertainties in the intake measurements based on which both ratios were proposed.

The Panel therefore considers that data on interactions of α-tocopherol with PUFAs, vitamin C, selenium, niacin and vitamin K cannot be used for deriving the requirement for α-tocopherol.

2.4. Biomarkers

2.4.1. Plasma/serum α-tocopherol concentration

Dietary α-tocopherol intake (assessed six times over 13 weeks by 24-hour dietary recall) was significantly correlated with plasma α-tocopherol in 233 adults (men and women), without or with adjustment for plasma cholesterol and triglycerides, body mass index (BMI), age, sex, ethnicity and total energy intake (respectively, correlation coefficient r = 0.40 and r = 0.43, p = 0.001) (Lebold et al., 2012). The (unadjusted) correlation was also significant in the sub-group with plasma α-tocopherol concentrations ≤ 33 µmol/L (p = 0.001, n = 200, non-supplement users, median α-tocopherol intake 8.6 mg/day). There was no significant association in the sub-group with plasma α-tocopherol concentrations > 33 µmol/L (n = 33, including supplement users, median α-tocopherol intake: 17.8 mg/day).

Dietary α-tocopherol intake adjusted for energy intake (and measured by a FFQ) correlated weakly (r = 0.16, 95 % CI: 0.07, 0.25) with plasma α-tocopherol concentration (adjusted for plasma triacylglycerol) in 361 men and 121 women, after adjustments for age, sex, BMI and smoking (El-Sohemy et al., 2001). In non-supplement users (n = 458), α-tocopherol intake (mean ± SEM) was 8.7 ± 0.2 mg/day for men and 9.7 ± 0.6 mg/day for women, adjusted for energy intake.

Alpha-tocopherol intake, as assessed by a 180-item FFQ (median, P25-P75: 11.4, 7.7–15.5 mg/day, including supplements) and serum α-tocopherol concentration (expressed either in µmol/L or α-tocopherol/cholesterol) were not associated in 135 healthy men (Andersen et al., 1999). In addition, plasma α-tocopherol concentration did not correlate with intake assessed by a 24-hour dietary recall in the Third National Health and Nutrition Examination Survey (IOM, 2000).

In seven healthy men receiving a controlled diet (α-tocopherol content: 2.1 ± 1.9 mg/day), and supplemented with 50 (week 2), 150 (week 3), 350 (week 4) and 800 (week 5) mg/day RRR-α-tocopherol, average plasma α-tocopherol concentration increased with supplementation dose (from 24.6 ± 3.6 to 61.8 ± 18.1 µmol/L) (Schultz et al., 1995). The curve of plasma α-tocopherol concentration showed saturation features (levelling-off) for the two highest doses.

In adults (supplement users included), mean plasma/serum α-tocopherol concentrations were between 27 and 38 µmol/L, in the UK National Diet and Nutrition Survey (Bates et al., 1999) or at baseline in the SU.VI.MAX study (Preziosi et al., 1998) and the Alpha-Tocopherol Beta-Carotene Cancer Prevention Study (Wright et al., 2006). In children aged 9-17 years, mean/median serum α-tocopherol concentration was between about 15-30 µmol/L in seven European countries (Valtuena et al., 2011)

Plasma or serum α-tocopherol concentrations (after 12-14 hours of fasting) are commonly used to assess α-tocopherol status. Clinical symptoms such as impaired skeletal muscle function and accumulation of ceroid pigments in smooth muscle tissue have been reported at plasma α-tocopherol concentrations below 12 µmol/L (Stamp and Evans, 1987) and ataxia below 8 µmol/L (IOM, 2000). Plasma/serum α-tocopherol concentrations of 2.3-12 µmol/L have been reported in primary or secondary α-tocopherol deficiency (see Section 2.2.2.1). Change in plasma/serum α-tocopherol concentration has also been related to the percentage of red blood cell haemolysis (see Section 2.4.2).

The Panel notes that an association between dietary α-tocopherol intake and plasma/serum α-tocopherol concentrations has not consistently been observed, and that, when observed, this correlation was weak. The Panel thus considers that plasma/serum α-tocopherol concentration is not a sensitive marker of dietary α-tocopherol intake. As regards to α-tocopherol status, the Panel notes that there is a lack of data on the relationship between plasma/serum α-tocopherol concentrations and α-tocopherol concentrations in peripheral tissues. The Panel notes that data show that plasma/serum α-tocopherol concentrations below about 12 µmol/L may be indicative of α-tocopherol deficiency, but that there is a lack of data to set a precise cut-off above which α-tocopherol status may be considered as adequate.

2.4.2. Hydrogen peroxide-induced haemolysis and its relationship with plasma α-tocopherol concentration

Red blood cells (RBC) are incapable of *de novo* lipid synthesis, and peroxidative damage resulting from oxidative stress can lead to shortening of RBC life and possibly precipitate haemolysis in α-tocopherol deficiency. This has been exploited as a method of assessing α-tocopherol status by measuring the degree of haemolysis induced by hydrogen peroxide (or dialuric acid) *in vitro*.

In a depletion-repletion study of over eight years (Horwitt et al., 1956; Horwitt, 1960; Horwitt and 1962; Horwitt et al., 1963), 38 men received either a basal diet providing about 3 mg/day of α-tocopherol ('depletion', n = 19), the basal diet supplemented with RRR-α-tocopheryl acetate[14] (n = 9), or a hospital diet *ad libitum* (n = 10). In the depleted group (over 70 months), plasma 'tocopherol' concentration decreased from about 23 µmol/L to about 4.5 µmol/L and haemolysis increased from about 0 % to remain at about 80 % after approximately 28 months, while in the supplemented group, haemolysis remained close to 0 % for about 60 months (Horwitt, 1960). In some subjects who had been on the depleted diet for 54 months, haemolysis and plasma 'tocopherol' concentration responded to supplementation (at varying doses between 7.5 to 320 mg/day RRR-α-tocopheryl acetate for 138 days, one subject per dose) (Horwitt, 1960). In four subjects depleted for 72–76 months (Horwitt et al., 1963), haemolysis was 80–97 % and plasma 'tocopherol' concentration was about 1.5–5 µmol/L. However, in one subject on the basal diet supplemented for 74 months and five subjects on the hospital diet for 74–76 months, haemolysis was 1–12 % and plasma 'tocopherol' concentration was 11.5–21.5 µmol/L (average at about 16 µmol/L). The authors stated that percentages of haemolysis between 3 and 12 % should be considered as similar, as precautions regarding the age and standardisation of the peroxide solutions were not taken.

In 31 cystic fibrosis patients (males and females aged 1–42 years) with pancreatic insufficiency, not receiving α-tocopherol supplements or salicylates and not iron-deficient (Farrell et al., 1977), mean (± SE) RBC haemolysis (78 ± 4.5 %, range: 5–98 %) was significantly higher than that of 32 adult controls (aged 18–40 years) (mean = 0.53 ± 0.12 %; range = 0–2 %, $p < 0.001$). Haemolysis was close to 0 % for a plasma α-tocopherol concentration above about 11.5–14 µmol/L, was approximately below 2 % for a concentration higher than about 9 µmol/L and below 10 % for a concentration higher than about 8 µmol/L, and increased sharply for a concentration below about 4.5 µmol/L.

Eight children (age range: 1–17 years) with α-tocopherol deficiency secondary to chronic severe liver disease, were compared with five healthy controls (age range: 7–17 years) (Refat et al., 1991). Serum 'vitamin E' concentrations of the patients ranged from < 1 mg/L to 4 mg/L (which would be equivalent to about 2.3-9.3 µmol/L α-tocopherol) and RBC haemolysis induced by peroxide was 100 % for five subjects, and 96, 41 and 0 % for the three others. In the controls, serum 'vitamin E' concentrations were 10–13 mg/L (mean ± SD: 11 ± 1 mg/L) and RBC haemolysis 0 %–2 %, for the three subjects for whom it was determined.

[14] Supplementation with 15 mg/day of RRR-alpha-tocopherol acetate for 46 months, then 30, 105 or 140 mg/day for seven months, then supplementation was discontinued after the fifth year.

The Panel considers that, while *in vitro* hydrogen peroxide-induced haemolysis is used to identify α-tocopherol deficiency, it is less useful as a criterion for deriving the requirement for α-tocopherol.

2.4.3. Urinary α-CEHC excretion

A cross-sectional study investigated the relationship between α-tocopherol intake and urinary α-CEHC excretion in 76 free-living healthy Japanese women (18–33 years) consuming their usual diet without dietary supplements (Imai et al., 2011). Intake of α-tocopherol was assessed by a four-day weighed food record (mean: 5.9 ± 1.6 mg/day) and α-CEHC excretion was measured in a single 24 hour urine sample collected on day 4. Intake of α-tocopherol was significantly related ($r = 0.29$, $p = 0.0147$) to urinary α-CEHC excretion.

Other studies investigated the response of urinary α-CEHC excretion to α-tocopherol supplementation. Indeed, seven healthy men received a controlled diet providing 2.1 ± 1.9 mg/day of α-tocopherol (week 1), and were then supplemented with 50 (week 2), 150 (week 3), 350 (week 4) and 800 (week 5) mg/day of RRR-α-tocopherol (Schultz et al., 1995). Alpha-CEHC in 24-hour urine was not detectable in case of no supplementation or supplementation with 50 mg/day and increased with higher supplementation doses (150–800 mg/day). Urinary α-CEHC appeared in detectable concentrations above a plasma α-tocopherol concentration of 30–50 µmol/L.

Healthy men and women (18–35 years, non-smokers and smokers, n = 10 per group), with a baseline α-tocopherol intake (assessed by a three-day food record) of 5.3–5.5 mg/day, received D_3-RRR-α-tocopheryl acetate and D_6-all-rac-α-tocopheryl acetate (one dose of 75 mg each, for six days) (Bruno et al., 2005) (Section 2.3.5). Alpha-CEHC concentrations in 24-hour urine were variable between subjects, were not different between groups before supplementation, increased 4–5.5-fold after six days of supplementation, then decreased to pre-study concentrations, or even below, after 17 days.

Ten apparently healthy Japanese men (18–25 years) who consumed the same basal diet providing 8.7 mg/day of α-tocopherol for five days per week[15] for four weeks, also took α-tocopheryl acetate supplements in the last three weeks (Imai et al., 2011). This supplementation was about 10 mg/day[16] in week 2, about 30 mg/day[16] in week 3, and about 59 mg/day[16] in week 4. Total α-tocopherol intake was associated with mean 24 hour urinary excretion of α-CEHC measured once each week ($r = 0.99$, $p = 0.0043$).

A study in 233 adults (median age ± SD: 33.3 ± 12.5 years) (Lebold et al., 2012) (Section 2.4.1) investigated the relationship between plasma α-tocopherol, urinary excretion of α-tocopherol metabolites (α-CEHC and α-carboxymethylbutyl hydrochroman α-CMBHC, averaged from two 24-hour urine collections) and dietary α-tocopherol intake (assessed six times over 13 weeks by 24-hour dietary recall). The sub-group with plasma α-tocopherol concentrations > 33 µmol/L (n = 33) had a significantly higher urinary α-CEHC concentration than the sub-group with plasma α-tocopherol concentrations ≤ 33 µmol/L (n = 200). Median α-tocopherol intake and urinary α-CEHC concentration were respectively 17.8 mg/day and 4.1 µmol/g creatinine in the sub-group with plasma α-tocopherol concentrations > 33 µmol/L, and 8.6 mg/day and 1.6 µmol/g creatinine in the other sub-group. Urinary α-CEHC excretion was significantly correlated with plasma α-tocopherol (mmol/mol cholesterol) in the whole population (with or without adjustments[17], $p = 0.001$) and in both sub-groups (without adjustments, $p \leq 0.01$). Urinary α-CEHC excretion was also significantly correlated with usual α-tocopherol intake in the whole population (with or without adjustments, $r_{adjusted} = 0.39$, $p = 0.001$), and in both sub-groups (without adjustments, $p \leq 0.01$). Multiple regression with adjustment for confounders showed that urinary α-CEHC excretion increased by 0.086 µmol/g

[15] Subjects were free to eat what they wished on the two remaining days.
[16] Intakes of α-tocopheryl acetate expressed in µmol/day in the publication were converted to mg/day using a molecular mass of 472.74 Da.
[17] Adjustments for total plasma cholesterol, plasma triglycerides, BMI, age, sex, ethnicity, and energy intake.

creatinine for every 1 mg increase in dietary α-tocopherol. From a spline curve of median daily urinary α-CEHC excretion according to dietary α-tocopherol, the authors visually estimated that the median excretion remained at a plateau of about 1.39 µmol/g creatinine until an intake of about 9 mg α-tocopherol/day, then the slope of the curve increased. The Panel notes that the derivation of a cut-off for urinary α-CEHC excretion and the related α-tocopherol intake by visual inspection remains uncertain.

The comparison of urinary α-CEHC concentration in three patients with 'ataxia with vitamin E deficiency' (AVED) lacking α-TTP (two adults, one child, with or without supplementation with all-rac-α-tocopheryl acetate or RRR-α-tocopherol), and in six healthy unsupplemented controls, indicates that α-CEHC excretion in urine reflects the amount of liver α-tocopherol which has exceeded the capacity of binding to α-TTP (Schuelke et al., 2000). Two of the controls were supplemented with 400 mg RRR or all-rac-α-tocopherol for five days. Combining all available data on urinary α-CEHC in healthy supplemented or unsupplemented subjects, the curve of urinary α-CEHC according to plasma α-tocopherol concentration showed that urinary α-CEHC was close to 0 for plasma concentrations below about 30–40 µmol/L, above which urinary α-CEHC excretion increased.

The Panel considers that urinary α-CEHC excretion responds to α-tocopherol supplementation and is a marker of saturation of the liver α-TPP binding capacity. The Panel also considers that insufficient evidence is available, on its relationship with dietary α-tocopherol intake and saturation of body tissues with α-tocopherol, for urinary α-CEHC excretion to be a criterion for deriving the requirement for α-tocopherol.

2.4.4. Adipose tissue α-tocopherol concentration

In 85 healthy Dutch adults (men and women, aged 50–70 years) who were not taking vitamin supplements (Kardinaal et al., 1995), 'vitamin E' intake assessed by FFQ was significantly correlated with α-tocopherol concentrations in adipose tissue from biopsies of the buttock ($r = 0.24$, adjusted for age and sex, $p < 0.05$, $n = 74$).

In Costa Rican men ($n = 361$, mean age ± SD: 56 ± 11 years) and women ($n = 121$, mean age ± SD: 60 ± 10 years) (El-Sohemy et al., 2001) (Section 2.4.1), dietary α-tocopherol intake adjusted for energy intake (assessed by FFQ) was significantly correlated with α-tocopherol concentrations in adipose tissue from biopsies of the buttock, after adjustments for age, sex, BMI and smoking. However, correlations were low either for the whole sample ($r = 0.15$, $p < 0.01$) or when vitamin supplement users ($n = 24$) were excluded ($r = 0.10$, $p < 0.05$).

A study in healthy men (aged 20–55 years) from Norway found no association between α-tocopherol intake assessed by FFQ (median, P25–P75: 11.4, 7.7–15.5 mg/day, including supplements) and the concentration of α-tocopherol in adipose tissue (µg/g total fatty acid methyl esters, $n = 119$ biopsies from the buttock) (Andersen et al., 1999).

Changes in adipose tissue α-tocopherol concentrations take years (Schaefer et al., 1983; Handelman et al., 1994) (Section 2.3.3).

The Panel considers that adipose tissue α-tocopherol concentration is neither a good marker of α-tocopherol intake nor of α-tocopherol status.

2.4.5. Biomarkers of function

2.4.5.1. Markers of oxidative damage

Oxidative damage to DNA, proteins and lipids can be measured *in vivo* using biomarkers validated for that purpose, e.g. plasma or preferably urinary F2-isoprostanes (EFSA NDA Panel, 2011).

Athlete runners consumed at dinner, before each trial, 75 mg each of D_3-RRR and D_6-all rac-α-tocopheryl acetates: deuterated α-tocopherol disappearance rates and plasma F2-isoprostane concentrations increased during a marathon race as compared with a rest period in the same subjects one month later (Mastaloudis et al., 2001). All-rac-α-tocopheryl acetate supplementation was found to decrease urinary F2-isoprostanes in subjects with hypercholesterolaemia (Davi et al., 1997) and in diabetics (Davi et al., 1999). Roberts et al. (2007) found a linear trend between the dosage of RRR-α-tocopherol and the percentage reduction in plasma F2-isoprostane concentrations in subjects with polygenic hypercholesterolaemia supplemented with RRR-α-tocopherol (0–2 144 mg/day) for 16 weeks. In a randomised controlled trial (RCT) in 30 healthy men and women, who received for eight weeks either a placebo or α-tocopherol (at five different doses ranging from 134 to 1 340 mg/day, n = 5 in each group), followed by an eight-week washout period, supplementation had no effect on two urinary isoprostanes, iPF(2α)-III and iPF(2α)-VI, measured *in vivo* at baseline, 4, 8 and 16 weeks (Meagher et al., 2001).

The Panel considers that these markers of oxidative damage are not specific to the antioxidative effect of α-tocopherol, that information on the relationship between α-tocopherol intake and these markers is missing and that these markers cannot be considered suitable biomarkers of function for α-tocopherol.

2.4.5.2. Other biomarkers of function

In healthy subjects, supplementation with 'vitamin E' for two weeks up to 400 IU/day (which would be equivalent to 267 mg/day of α-tocopherol) resulted in a significant dose-dependent decrease in platelet adhesion (Richardson and Steiner, 1993). In normal subjects, oral supplementation with α-tocopherol (267–805 mg/day) resulted in an increase in platelet α-tocopherol concentration that correlated with a marked inhibition of platelet aggregation (Freedman et al., 1996).

The Panel notes that there are limited data on other functions of α-tocopherol and considers that markers of these functions are not specific to effects of α-tocopherol.

2.5. Effects of genotypes

In a cohort of 128 volunteers, single-nucleotide polymorphisms in SCARB1, the gene coding for scavenger receptor B type 1 (SR-BI), were related to plasma α-tocopherol concentration, suggesting an effect of these variants on α-tocopherol distribution in the body (Borel et al., 2007). Some polymorphisms of the cluster of differentiation 36 (CD36) might modestly influence plasma α-tocopherol concentrations especially in people with low triglyceride concentrations (Lecompte et al., 2011). Variants in genes involved in lipid absorption, transport, uptake and metabolism may modulate the efficiency of α-tocopherol absorption, transport and intracellular metabolism and may influence plasma α-tocopherol concentrations (Zingg et al., 2008). The CYP4F2 variant Rs2108622 was associated with increased serum α-tocopherol in subjects from the ATBC trial, suggesting that this variant has reduced ω-hydroxylation activity (Major et al., 2012).

The Panel considers that data on the effect of genotypes on α-tocopherol absorption and distribution are insufficient to be used for deriving the requirement for α-tocopherol according to genotype variants.

3. Dietary sources and intake data

3.1. Dietary sources

The main dietary sources of α-tocopherol include vegetable oils, fat spreads from vegetable oils, nuts and seeds, some fatty fish, egg yolk, and whole grain cereals. The proportions of the four tocopherols vary according to the food source, the more abundant being α-tocopherol and γ-tocopherol. In particular, vegetable oils vary in their content of the different tocopherol forms: wheat germ, sunflower, olive and rapeseed oils are good sources of α-tocopherol, wheat germ oil of ß-tocopherol, soybean, corn and rapeseed oils of γ-tocopherol and soybean oil of δ-tocopherol.

Currently, d-α-tocopherol, dl-α-tocopherol, d-α-tocopheryl acetate, dl-α-tocopheryl acetate and d-α-tocopheryl succinate (Section 2.1 on chemistry) may be added to foods[18] and food supplements[19], whereas mixed tocopherols[20] and 'tocotrienol tocopherol'[21] may be added to food supplements only[19]. The vitamin E (mg α-TE) content of infant and follow-on formulae and of processed cereal-based foods and baby foods for infants and children is regulated[22].

3.2. Dietary intake

Published data suggest that mean α-tocopherol intakes in adults in some European countries (Finland, Sweden) (Amcoff et al., 2012; Helldán et al., 2013) are higher than those observed in the USA, where γ-tocopherol intakes are generally reported to be higher than in the EU (Gao et al., 2004; Maras et al., 2004; Dixon et al., 2006; Mahabir et al., 2008; Signorello et al., 2010; Yang et al., 2014b; Yang et al., 2014a).

In this context, the Panel aimed at presenting in this section observed α-tocopherol intakes in Europe, estimated by EFSA using the EFSA Comprehensive European Food Consumption Database (EFSA, 2011b) and the EFSA Food Composition Database. However, most food composition databases in EU countries still contain values for 'vitamin E' as α-tocopherol equivalents (α-TEs). For only two countries, Finland and Sweden, the national database compilers indicated to EFSA that the vitamin E values in their food composition databases were α-tocopherol values, contrary to the other countries considered in this intake assessment. Therefore, this section reports on both estimated dietary intakes of α-tocopherol and α-TEs.

This assessment includes food consumption data from 13 dietary surveys (Appendix B) from nine countries (Finland, France, Germany, Ireland, Italy, Latvia, the Netherlands, Sweden and the UK), classified according to the FoodEx2 food classification system (EFSA, 2011a). Nutrient intake calculations were performed only on subjects with at least two reporting days. The EFSA Food Composition Database was compiled during a procurement project (Roe et al., 2013) involving fourteen national food database compiler organisations, who were allowed to borrow compatible data from other countries in case no original composition data were available. Food composition information of Finland, France, Germany, Italy, the Netherlands, Sweden and the UK were used to

[18] Regulation (EC) No 1925/2006 of the European Parliament and of the Council of 20 December 2006 on the addition of vitamins and minerals and of certain other substances to foods, OJ L 404, 30.12.2006, p. 26.

[19] Directive 2002/46/EC of the European Parliament and of the Council of 10 June 2002 on the approximation of the laws of the Member States relating to food supplements, OJ L 183, 12.7.2002, p. 51.

[20] α-tocopherol < 20 %, β-tocopherol < 10 %, γ-tocopherol 50-70 % and δ-tocopherol 10-30 %.

[21] Typical levels of individual tocopherols and tocotrienols: 115 mg/g α-tocopherol (101 mg/g minimum), 5 mg/g β-tocopherol (< 1 mg/g minimum), 45 mg/g γ-tocopherol (25 mg/g minimum), 12 mg/g δ-tocopherol (3 mg/g minimum), 67 mg/g α-tocotrienol (30 mg/g minimum), < 1 mg/g β-tocotrienol (< 1 mg/g minimum), 82 mg/g γ-tocotrienol (45 mg/g minimum), 5 mg/g δ-tocotrienol (< 1 mg/g minimum), according to Directive 2002/46/EC.

[22] Commission Directive 2006/141/EC of 22 December 2006 on infant formulae and follow-on formulae and amending Directive 1999/21/EC, OJ L 401, 30.12.2006, p.1. and Commission Directive 2006/125/EC of 5 December 2006 on processed cereal-based foods and baby foods for infants and young children, OJ L 339, 06.12.2006, p. 16-35.

calculate α-tocopherol and α–TE intakes in these countries. It was assumed that the best intake estimates would be obtained when both the consumption data and the composition data are from the same country. EFSA estimates are based on consumption of foods, either fortified or not (i.e. without dietary supplements). The data covers all age groups from infants to adults. The Panel notes the limitations in the methods used for assessing breast milk consumption in infants (Appendices C-F) and related uncertainties in the α-tocopherol and α–TE intake estimates for infants.

3.2.1. Dietary intake of α-tocopherol

For this intake assessment of α-tocopherol, the average values of the food contents in the Finnish and Swedish databases were used to calculate α-tocopherol intake in France, Germany, Italy, the Netherlands, and the UK, using the respective food consumption data from these five countries.

Appendices C (males) and D (females) show the α-tocopherol intake estimates for all included countries, expressed in mg/day and mg/MJ. In infants (1–11 months), the average α-tocopherol intakes ranged between 2.9 and 4.9 mg/day in girls and between 3.2 and 5.4 mg/day in boys. In children aged 1 to < 3 years, they ranged between 4 and 5 mg/day in girls and between 4.5 and 5.7 mg/day in boys. In children aged 3 to < 10 years, they ranged between 5.4 and 10.3 mg/day in girls and between 5.8 and 10.9 mg/day in boys. In children aged 10 to < 18 years, they ranged between 8.2 and 13.2 mg/day in girls and between 9.1 and 14.3 mg/day in boys. In adults (≥ 18 years), the average α-tocopherol intakes ranged between 7.8 and 12.5 mg/day in women and between 8.2 and 16 mg/day in men.

The overall number of values (including '0' values) in the included national databases ranged between 2 183 and 2 204 for α-tocopherol in Finland and Sweden. Alpha-tocopherol values were specified to be based on analyses in < 1 %. Alpha-tocopherol values were missing for 796 foods, for which imputation of missing composition values was undertaken by EFSA.

The Finnish α-tocopherol values of the EFSA Food Composition Database were originating from Finland in 29 % of the cases and were borrowed from Sweden in 6 % of the cases. Only 16 % of Swedish α-tocopherol values of the EFSA Food Composition Database originated from Sweden, and 18 % were borrowed from Finland. The main source of borrowed values was Germany, i.e. 46–50 % for Finland and Sweden, which means that α-tocopherol and α-TE data may have been combined, in the case of Finland and Sweden, in the composition data provided to EFSA. Further evaluation of the EFSA Food Composition Database and contacts of the national database compilers for Finland and Sweden showed that only about 200 Swedish foods out of the about 2 000 foods with non-missing information for 'vitamin E' in the EFSA Food Composition database were originating from Sweden and were fully compatible with the original Swedish composition database for α-tocopherol. Similarly, for Finland, there were about 650 foods fully compatible and originating from the Finnish database.

The Panel notes that these methodological limitations may induce uncertainty in the α-tocopherol intake estimates for the included European countries.

3.2.2. Dietary intake of α-tocopherol equivalents (α-TEs)

For the α-TE intake assessment, for countries not having any food composition database, i.e. Ireland and Latvia, α-TE food composition data from the UK and Germany, respectively, were used. To calculate α-TE intake in Finland and Sweden, the average values of the food contents in France, Germany, Italy, the Netherlands, and the UK were used, with the respective food consumption data from Finland and Sweden.

Appendices E (males) and F (females) show the α-TE intake estimates for all included countries, expressed in mg/day and mg/MJ. In infants (1–11 months), average α-TE intakes ranged between 3.2 and 5.3 mg/day in girls and between 3.4 and 5.9 mg/day in boys. In children aged 1 to < 3 years, they ranged between 4.4 and 6.8 mg/day in girls and between 4.7 and 7.3 mg/day in boys. In children aged 3 to < 10 years, they ranged between 6.5 and 11.8 mg/day in girls and between 7.1 and 12.4 mg/day in boys. In children aged 10 to < 18 years, they ranged between 8.8 and 13.8 mg/day in girls and between 9.6 and 15.9 mg/day in boys. In adults (≥ 18 years), the average α-TE intakes ranged between 8.9 and 13.5 mg/day in females and between 10.1 and 16.0 mg/day in males.

Vegetable fats and oils, grains and grain-based products, and the sum of fruits and vegetables and derived products were among the main food groups contributing to α-TE intakes in all sex and age groups (Appendices G and H), as well as to α-tocopherol intakes (data not shown). Differences between sexes in the main contributors to intakes were minor.

The overall number of values (including '0' values) in the included national databases ranged between 2 322 and 2 414 for α-TE. For 63–93 % of the α-TE values, the analytical or estimation/calculation method (e.g. recipe calculations, scientific publications or borrowed from other composition databases) applied for the determination of the values was not specified by the data provider of the EFSA Food Composition Database. Alpha-TE values were specified to be based on analyses for 1–21 % of the values. The amount of borrowed values in the α-TE datasets of the EFSA Food Composition Database varied between 12 % and 92 %. Most of the borrowed α-TE values, 35–56 %, originated from Germany. Alpha-TE values were missing for 796 foods, for which imputation of missing composition values was undertaken by EFSA.

Alpha-TE intake estimates of this assessment were compared to published α-TE intake estimates when they were available from the same survey and dataset: for the Dutch national survey (van Rossum et al., 2011), the French INCA2 survey (Afssa, 2009), the German EsKiMo study (Mensink et al., 2007), the German VELS study (Kersting and Clausen, 2003), the Irish NANS (IUNA, online), the Italian INRAN-SCAI survey (Sette et al., 2010) and the UK NDNS (Bates et al., 2012). No published α-TE intake data was available from the DNSIYC-2011 surveys of the UK children (Lennox et al., 2013). Publication was not available for the dataset of the Latvian survey of pregnant women. The EFSA estimates were found to deviate by < 10 % in the Dutch, French and German surveys (excluding infants) and were higher by > 10 % and in some age groups by > 20 % in the Italian, Irish and UK surveys and in German infants (Table 1).

Table 1: EFSA's average α–TE intake estimates, expressed as percentages of published intakes

Country	% of published intake, range over different age classes in a specific survey
France	92–107 % (INCA2)
Germany	80–86 % (VELS infants), 106–108 % (VELS children), 90–101 % (EsKiMo)
Ireland	118–128 % (NANS)
Italy	126 % (INRAN-SCAI, infants and children aged 1–< 3 years), 113–117 % (other age classes)
Netherlands	102–105 % (Dutch National Dietary Survey)
UK	108–119 % (NDNS Rolling Programme Years 1–3)

Comparing the EFSA α-tocopherol intake estimates (Section 3.2.1) with the EFSA α-TE intake estimates per each age class in each country (i.e. comparing exactly both intakes in the same population sub-groups), suggests that α-tocopherol intake is the major contributor to α-TE intake in these EU countries. However, methodological limitations in the α-tocopherol data used for this intake

assessment may have induced uncertainty in the intake estimates for the included European countries (Section 3.2.1).

Additional uncertainties in the intake estimates may be caused by inaccuracies in mapping food consumption data according to the FoodEx2 classification, analytical errors or errors in the estimation of the concentration in foods in the food composition databases, the use of borrowed values from other countries in the food composition databases, and the replacement of missing composition values by available values for similar foods or food groups in the intake estimation process by EFSA. These uncertainties may, in principle, cause too high or too low estimates. Regarding vitamin losses from processed foods, the losses in this intake assessment were based on the data available in the individual national food composition databases (Roe et al., 2013).

The Panel notes that the EFSA α-tocopherol intake estimates and the EFSA α-TE intake estimates per each age class in each country are close. The Panel also notes the sources of uncertainty in the α-TE intake estimates for the included European countries.

4. Overview of Dietary Reference Values and recommendations

4.1. Adults

The Nordic countries (Nordic Council of Ministers, 2014) maintained their previous Recommended Intake (RI), underlining that RIs apply to 2R-isomers of α-tocopherol only (RRR-, RSR-, RRS- and RSS). In the absence of data on deficiency due to low dietary intake in healthy people, the Nordic countries considered possible cut-off values for plasma α-tocopherol concentration to assess status (12 or 16.2 µmol/L (Horwitt et al., 1963; Morrissey and Sheehy, 1999), mean α–tocopherol intakes and plasma concentrations in Nordic populations (Piironen et al., 1984; Wallstrom et al., 2001; Ylonen et al., 2003; Tomten and Hostmark, 2009) and possible ratios of 0.6 (Valk and Hornstra, 2000) or 0.4 (SCF, 1993) mg α–TE/g PUFA. Based on a ratio of 0.4 mg α-TE/g PUFA and an average PUFA intake of 5 % of energy intake, ARs and RIs were set at, respectively, 5 and 8 mg α-TE/day for women, and 6 and 10 mg α-TE/day for men. A lower intake level was set at 3 and 4 mg α-TE/day for women and men, respectively.

The German-speaking countries (D-A-CH, 2013) derived Adequate Intakes (AIs) of 12–15 mg α-TE/day for men and 11–12 mg α-TE/day for women according to age. This was based on a 'basal requirement' of 4 mg α-TE/day for adults independently of unsaturated fat intake, to which varying amounts of α-TE were added based on the guiding value for total fat and the percentage contributions of fatty acids with one to three double bonds and assuming that, respectively, 0.06, 0.4 and 0.6 mg α–TE are required to protect 1 g of fatty acid with one, two or three double bonds from oxidation (Horwitt, 1974; Witting and Lee, 1975). Intake of PUFA with more double bounds would increase the AI by about 0.5 mg α–TE/day.

The World Health Organization (WHO/FAO, 2004) considered that the data were not sufficient to set a PRI for 'vitamin E', mentioned median intakes in the UK (10 and 7 mg α-TE/day for men and women, respectively (DH, 1991)) and the USA (10 and 8 mg α-TE/day for men and women, respectively (NRC, 1989)), and proposed 'best estimates of requirements' of 10 and 7.5 mg α-TE/day for men and women, respectively.

The French Food Safety Agency (Afssa, 2001) retained their previous reference value from 1992 of 12 mg/day 'vitamin E (tocopherol)' for men and women. For adults aged 75 years and over, they derived a reference value of 20–50 mg/day in relation to possible benefits with respect to age-related diseases like cancer and cardiovascular diseases.

The US Institute of Medicine (IOM, 2000) set a Recommended Dietary Allowance (RDA) for the naturally occurring form (RRR-) and the synthetic 2R-stereoisomers (RSR-, RRS- and RSS-) of α-tocopherol, because the other naturally occurring tocopherols and tocotrienols (β-, γ-, and δ-tocopherols and the tocotrienols) are not converted to α-tocopherol by humans and are recognized poorly by the α-TTP in the liver. Data investigating the relationship of the intake of the vitamin to chronic diseases were reviewed but could not be used to set DRVs. The Estimated Average Requirement (EAR) of 12 mg α-tocopherol/day was based on data on induced deficiency in men (Horwitt et al., 1956; Horwitt, 1960; Horwitt and 1962; Horwitt et al., 1963; Horwitt et al., 1972; Horwitt, 1974; Farrell et al., 1977). In particular, IOM used and adapted rather the data from Horwitt et al. (1963) instead of Farrell et al. (1977) to consider that a plasma α-tocopherol concentration of 12 µmol/L was associated with *in vitro* hydrogen peroxide induced haemolysis below 12 % (which was considered as normal). Using data from Horwitt (1960), i.e. estimating α-tocopherol intake from food and supplements and plotting the intake against plasma α-tocopherol concentration of each subject averaged on four different days of measurement[23], IOM determined that plasma α-tocopherol concentration was above the cut-off of 12 µmol/L for an intake of at least 12 mg α-tocopherol/day. Similar data were not available for women or for older adults. IOM concluded that there was no scientific basis for assuming different requirements for these population groups. The amount of α-tocopherol required daily, based on the ratio of at least 0.4 mg α-tocopherol per g of PUFAs for adults (Bieri and Evarts, 1973; Horwitt, 1974; Witting and Lee, 1975) and mean PUFA intakes from NHANES II (Murphy et al., 1990), was considered to be covered by the EAR of 12 mg α-tocopherol/day. As no information was available on the standard deviation (SD) of the requirement, the RDA of 15 mg α-tocopherol/day for adults was derived from the EAR by assuming a coefficient of variation (CV) of 10 %.

SCF (1993) considered that concentrations higher than 11.6 µmol/L for plasma tocopherol or 2.25 µmol serum tocopherol/mmol cholesterol (values below which the erythrocytes tend to have a reduced survival time *in vivo* (Horwitt, 1980a)) are maintained in men on low PUFA intakes for intakes of about 3 mg α-TE/day (Bunnell et al., 1975). Noting the lack of evidence on clinical 'vitamin E' deficiency due to inadequate intake, the SCF (1993) defined the requirement as 0.4 mg α-TE/g PUFAs (Bieri and Evarts, 1973; Witting and Lee, 1975). SCF (1993) also considered that the intake of the vitamin should be above 4 mg α-TE/day for men and 3 mg α-TE/day for women, as women were considered to have lower PUFA amounts in their tissues because of their smaller body size than men.

The Netherlands Food and Nutrition Council (1992) considered that the 'vitamin E' amount to attain a plasma 'vitamin E' concentration of at least 11.6 µmol/L would be the requirement, corresponding to about 0.4 mg α-TE per g PUFAs (Horwitt et al., 1972; Horwitt, 1974; Farrell, 1980; Horwitt, 1980b), and that, at low PUFA intake, the diet should provide at least 4 mg α-TE/day. The PRI was defined as the quantity to maintain plasma 'vitamin E' concentrations considered as normal by the Council, i.e. on average 24.4 µmol/L (range: 11.6-37.1 µmol/L). This average concentration was maintained by an average intake of 0.67 mg α-TE/g PUFA (Horwitt et al., 1972; Horwitt, 1974; Farrell, 1980; Horwitt, 1980b).

The UK COMA (DH, 1991) could not set DRVs for 'vitamin E', but considered that intakes above 4 (men) and 3 (women) mg α-TE/day could be adequate, based on observed intakes in the UK (Black et al., 1986; Gregory et al., 1990). It was noted that the range of PUFA intake was wide in the UK, and that average 'vitamin E' amounts required for adults consuming the DRVs for PUFAs were below average UK intakes (Gregory et al., 1990).

An overview of DRVs for 'vitamin E' for adults is presented in Table 2.

[23] Reported by IOM as days 13, 21, 30 and 138.

1079 **Table 2:** Overview of Dietary Reference Values for 'vitamin E' for adults

	NCM (2014)[a, b]	D-A-CH (2013)[c]	WHO/FAO (2004)[d]	Afssa (2001)	IOM (2000)[a, b]	SCF (1993)[e, f]	NL (1992)[b, f]	UK (1991)[g]
Age (years)	≥ 18	19–< 25	≥ 19	20–74	≥ 19-50	≥ 18	≥ 18	> 18
Men (mg/day)	10	15	10	12	15	0.4	0.67	> 4
Women (mg/day)	8	12	7.5	12	15	0.4	0.67	> 3
Age (years)		25–< 51						
Men (mg/day)		14						
Women (mg/day)		12						
Age (years)		51–< 65						
Men (mg/day)		13						
Women (mg/day)		12						
Age (years)		≥ 65		≥ 75				
Men (mg/day)		12		20–50				
Women (mg/day)		11		20–50				

1080 DRVs in α-tocopherol equivalents except for IOM. NL, Netherlands Food and Nutrition Council; NCM, Nordic Council of
1081 Ministers.
1082 (a): Applicable to RRR-, RSR-, RRS- and RSS-isomers of α-tocopherol only.
1083 (b): PRI.
1084 (c): Adequate Intake.
1085 (d): Data were insufficient to set PRIs; the indicated figures represent the 'best estimates of requirements' (WHO/FAO,
1086 2004).
1087 (e): 'vitamin E requirement'.
1088 (f): mg α-TE/g PUFA.
1089 (g): 'Safe' intakes.

1090 ## 4.2. Infants and children

1091 The Nordic countries (Nordic Council of Ministers, 2014) based their RIs for infants and children on
1092 the 'vitamin E' concentration of human milk, the relationship between α-TE, linoleic acid or total
1093 PUFA (Aggett et al., 1998), a ratio of at least 0.6 mg α-TE/g PUFA and an average PUFA intake
1094 corresponding to 5 % of energy intake.

1095 For children aged 1–14 years, D-A-CH (2013) set AIs in mg α-TE/day by interpolation between the
1096 AI for infants and that for adults.

1097 WHO/FAO (2004) set an AI of 2.7 mg α-TE/day for infants, based on the average concentration of
1098 3.2 mg α-TE/mL of human milk (Kelly et al., 1990) and a breast-milk consumption of 0.85 L/day. For
1099 children, only 'best estimates of requirements' could be proposed.

1100 Afssa (2001) derived PRIs for children from the adult value, adjusted for energy requirement.

1101 For infants aged 7–11 months, the IOM (2000) derived an AI of 5 mg α-tocopherol/day by allometric
1102 scaling (body weight to the power of 0.75, using reference body weights from NHANES III 1988-
1103 1994, and rounding up) from the intake of younger infants calculated considering a breast milk
1104 consumption of 0.78 L/day and an average α-tocopherol concentration in breast milk of 4.9 mg/L
1105 (Jansson et al., 1981; Chappell et al., 1985; Lammi-Keefe et al., 1985; Lammi-Keefe et al., 1990;
1106 Boersma et al., 1991). For children aged 1–18 years, no data were available on which to base EARs,
1107 which were thus derived from the adult EAR by allometric scaling (body weight to the power of 0.75,
1108 using reference body weights from NHANES III 1988-1994 and growth factors). The RDAs were
1109 derived from the EARs by assuming a CV of 10 %.

The SCF (1993) stated that a diet containing 0.4 mg α-TE/g PUFAs (as for adults) seemed also adequate for infants aged 6–11 months and children, but that there was no information on the basal requirement for the vitamin in case of a very low PUFA intake.

For infants after six months and children, the Netherlands Food and Nutrition Council (1992) set the same PRI of 0.67 mg α-TE/g PUFA as for adults.

The UK COMA (DH, 1991) set a 'safe intake' of 0.4 mg α-TE/g PUFAs and explained that infant formulas should not contain less than this amount (DHSS, 1980). No DRVs were set for children.

An overview of DRVs for 'vitamin E' for infants and children is presented in Table 3.

Table 3: Overview of Dietary Reference Values for 'vitamin E' for infants and children

	NCM (2014)[a, b]	D-A-CH (2013)[c]	WHO/FAO (2004)	Afssa (2001)	IOM (2000)[a]	SCF (1993)[e, f]	NL (1992)[f]	DH (1991)[f, g]
Age (months)	6–11	6–< 12	7–12	6–12	6–12	6–11	6–11	Infants
All (mg/day)	3	4	2.7[c]	4	5[c]	0.4	0.67	0.4
Age (years)	1–< 2	1–< 4	1–3	1–3	1–3	1–18	1–18	
Boys (mg/day)	4	6	5[d]	6	6[b]	0.4	0.67	
Girls (mg/day)	4	5	5[d]	6	6[b]	0.4	0.67	
Age (years)	2–5	4-< 7	4–6	4–6	4–8			
All (mg/day)	5	8	5[d]	7.5	7[b]			
Age (years)	6–9	7–< 10	7–9	7–9	9–13			
Boys (mg/day)	6	10	7[d]	9	11[b]			
Girls (mg/day)	6	9	7[d]	9	11[b]			
Age (years)	10–13	10–< 13	10–18	10–12	14–18			
Boys (mg/day)	8	13	10[d]	11	15[b]			
Girls (mg/day)	7	11	7.5[d]	11	15[b]			
Age (years)	14–17	13–< 15		13–19				
Boys (mg/day)	10	14		12				
Girls (mg/day)	8	12		12				
Age (years)		15–< 19						
Boys (mg/day)		15						
Girls (mg/day)		12						

DRVs in α-tocopherol equivalents except for IOM. NL, Netherlands Food and Nutrition Council; NCM, Nordic Council of Ministers.
(a): Applicable to RRR-, RSR-, RRS- and RSS isomers of α-tocopherol only.
(b): PRI.
(c): Adequate Intake.
(d): Data were insufficient to set PRIs; the indicated figures represent the 'best estimates of requirements' (WHO/FAO, 2004).
(e): 'vitamin E requirement'.
(f): mg α-TE/g PUFA.
(g): 'Safe' intakes.

4.3. Pregnancy and lactation

The Nordic countries (Nordic Council of Ministers, 2014) set an RI of 10 mg α-TE/day for the last two trimesters of pregnancy, to cover the increased intake of energy and PUFAs, and an RI of 11 mg α-TE/day for lactating women, to cover secretion of the vitamin in human milk.

D-A-CH (2013) set an AI of 13 mg α-TE/day for pregnant women and of 17 mg α-TE/day for lactating women, resulting from the increased energy requirement and concomitant higher intake of unsaturated fatty acids. For lactating women, the AI was considered to cover the additional requirement of 0.26 mg α-TE/100 g of secreted milk.

IOM (2000) considered the increase in blood concentrations of α-tocopherol and total lipids during pregnancy (Horwitt et al., 1972), the constant placental transfer of the vitamin (Abbasi et al., 1990), and the lack of reported deficiency of the vitamin during pregnancy, and set the same EAR and RDA as for non-pregnant women. The IOM set an RDA of 19 mg α-tocopherol/day for lactating women, adding to the EAR for non-lactating women the average amount of about 4 mg α-tocopherol/day secreted in human milk (see Section 4.2), and using a CV of 10 %.

For pregnancy, the Netherlands Food and Nutrition Council (1992) mentioned the increased plasma concentrations of 'vitamin E' and lipids during pregnancy and the low placental transfer of the vitamin (Takahashi et al., 1978; Haga et al., 1982), and considered the same PRI as for other adults (0.67 mg α-TE/g PUFA). For lactation, they added to this PRI an extra 2.7 mg α-TE/day to compensate for 'vitamin E' secretion in human milk, based on a breast milk volume of 0.8 L/day (Jansson et al., 1981; Van Zoeren-Grobben et al., 1987)).

WHO/FAO (2004) did not report specific reference values for pregnant or lactating women. WHO/FAO (2004) stated that other authorities (e.g. DH (1991)) considered that there was no evidence that the requirement for the vitamin was different in pregnant or lactating women compared to other women and that their increased energy intake would likely compensate for the increased needs for infant growth and milk synthesis. Afssa (2001) and SCF (1993) did not identify evidence for a different requirement for the vitamin in pregnant or lactating women compared to other women. DH (1991) did not set specific DRVs for pregnant or lactating women, thus the minimal intake set for non-pregnant non-lactating women (i.e. above 3 mg α-TE/day) applies.

An overview of DRVs for 'vitamin E' for pregnant and lactating women is presented in Table 4.

Table 4: Overview of Dietary Reference Values for 'vitamin E' for pregnant and lactating women

	NCM (2014) [b, c]	D-A-CH (2013)[a]	WHO/FAO (2004)[e]	Afssa (2001)	IOM (2000)[b, c]	SCF (1993)[f, g]	NL (1992)	DH (1991)[g, h]
Pregnancy (mg/day)	10 [d]	13	-	12	15	0.4	0.67[g]	> 3
Lactation (mg/day)	11	17	-	12	19	0.4	+ 2.7	> 3

DRVs in α-tocopherol equivalents except for IOM. NL, Netherlands Food and Nutrition Council; NCM, Nordic Council of Ministers.
(a): Adequate Intake.
(b): Applicable to RRR-, RSR-, RRS- and RSS isomers of α-tocopherol only.
(c): PRI.
(d): For the last two trimesters of pregnancy.
(e): No values.
(f): 'vitamin E requirement'.
(g): mg α-TE/g PUFA.
(h): 'Safe' intakes.

5. Criteria (endpoints) on which to base Dietary Reference Values

5.1. Indicators of α-tocopherol requirement

5.1.1. Adults

5.1.1.1. PUFA intake

It has been proposed to relate the requirement for α-tocopherol to the amount and degree of unsaturation of dietary PUFAs (Horwitt, 1960; Harris and Embree, 1963; Witting and Horwitt, 1964) (Section 2.3.6.1).

Based on the available data (Sections 2.3.6.1 and 2.3.6.4), the Panel considers that no conclusions can be drawn on the relationship between PUFA intake and α-tocopherol requirement.

5.1.1.2. Markers of α-tocopherol intake/status/function

Based on the available data (Section 2.4) on plasma/serum α-tocopherol concentration, hydrogen peroxide-induced haemolysis and its relationship with plasma α-tocopherol concentration, urinary α-CEHC excretion, adipose tissue α-tocopherol concentration, markers of oxidative damage and other biomarkers of function, the Panel considers that there is, at present, insufficient data on biomarkers to derive α-tocopherol requirement.

5.1.1.3. Kinetic studies

Data on α-tocopherol kinetics and body pools are limited (Sections 2.3.1 and 2.3.5). Daily losses of α-tocopherol in healthy non-lactating adults were estimated to be about 4–5 mg/day based on two kinetic studies (Bruno et al., 2006a; Novotny et al., 2012). However, the Panel notes that the estimation of these daily losses of α-tocopherol was based on observed plasma α-tocopherol concentrations (mean of about 20–23 µmol/L) of the participants included in the two studies. The Panel considers that there is no indication that such plasma α-tocopherol concentrations should be a target for α-tocopherol sufficiency.

The Panel considers that the available data on α-tocopherol kinetics and body pools cannot be used to derive α-tocopherol requirement.

5.1.1.4. Conclusions on indicators of α-tocopherol requirement for adults

The Panel considers that data on markers of α-tocopherol intake/status/function, available data on α-tocopherol kinetics and body pools, as well as on the relationship between PUFA intake and α-tocopherol intake/requirement cannot be used to derive DRVs for α-tocopherol.

The Panel also investigated whether the limitations mentioned above suggest that a combination of (some of) these biomarkers/criteria could be used to derive DRVs for α-tocopherol.

IOM (2000) considered the long-term depletion–repletion study in men by Horwitt et al. (Sections 2.4.2 and 4.1) to set DRVs for α-tocopherol. Based on data from Horwitt et al. (1963), they concluded that a plasma α-tocopherol concentration of 12 µmol/L was associated with *in vitro* hydrogen peroxide induced haemolysis below 12 % which was considered as normal by IOM. Using data from Horwitt (1960), i.e. estimating α-tocopherol intake from food and supplements and plotting the intake against plasma α-tocopherol concentration of each subject averaged on four different days of

measurement[24], plasma α-tocopherol concentration was shown to be above the cut-off of 12 µmol/L for an intake of at least 12 mg α-tocopherol/day (IOM, 2000).

From a spline curve of median daily urinary α-CEHC excretion according to dietary α-tocopherol, Lebold et al. (2012) visually estimated that the median excretion remained at a plateau of about 1.39 µmol/g creatinine until an intake of about 9 mg α-tocopherol/day, then the slope of the curve increased (Section 2.4.3).

Taking into account the estimation of daily losses of α-tocopherol of about 4–5 mg/day in healthy adults (with mean plasma α-tocopherol concentrations of about 20–23 µmol/L) from two kinetic studies (Bruno et al., 2006a; Novotny et al., 2012) (Sections 2.3.5 and 5.1.1.3), and an average α-tocopherol absorption from a usual diet of about 75 % (Section 2.3.1), about 6 mg α-tocopherol/day would need to be consumed to provide an amount of absorbed α-tocopherol to compensate these total daily losses.

The Panel notes the lack of convergence of the values that would be derived from the use of data on markers of α-tocopherol intake/status or on α-tocopherol kinetics and body pools. Thus, the Panel concludes that a combination of these biomarkers/criteria cannot be used to derive DRVs for α-tocopherol.

5.1.2. Infants and children

The Panel notes the lack of data in infants aged 7–11 months and children on α-tocopherol requirement.

5.2. Specific requirements during pregnancy and lactation

The presence of α-TTP in the placenta has been shown (Kaempf-Rotzoll et al., 2003; Muller-Schmehl et al., 2004). Based on immunohistochemical localisation of α-TTP and estimated staining intensity, it was found that α-TTP expression in the placenta doubled from the first trimester (six to eight weeks) to term (Rotzoll et al., 2008).

Three prospective cohort studies investigated the association between maternal 'vitamin E' intake from foods and supplements during pregnancy and the risk of wheeze (Martindale et al., 2005; Devereux et al., 2006; Litonjua et al., 2006), asthma (Devereux et al., 2006) or eczema (Martindale et al., 2005) in children at age two or five years and generally did not find any significant association.

In an RCT (Pressman et al., 2003), pregnant women received a daily prenatal vitamin C- and 'vitamin E'-containing supplement, either with or without additional 500 mg vitamin C and 'vitamin E' (400 IU, which would be equivalent to 268 mg/day of α-tocopherol), from week 35 of gestation onwards. Mean maternal plasma α-tocopherol concentrations were 31.3 µmol/L and 50.4 µmol/L at delivery, while cord plasma α-tocopherol at delivery was only 6.97 µmol/L in the two groups (differences between groups not statistically significant). In addition, maternal plasma and chorioamnion α-tocopherol concentrations were correlated ($r = 0.87$, $p < 0.001$).

An observational study followed 19 pregnant women, with α-tocopherol intakes (mean; range) of 8.1 (1.4–22.7) mg/day from foods and consuming 'vitamin E' supplements (mean of 30 IU/day, range of 11–100 IU/day, which would be equivalent to about 20 [7.4–67] mg/day of α-tocopherol) (Didenco et al., 2011). Mean (± SD) maternal α-tocopherol concentration measured during the course of pregnancy (exact period not specified) was significantly higher than mean α-tocopherol cord blood concentration (33.4 ± 7.7 µmol/L vs 6.7 ± 2.5 µmol/L). This suggests that the placenta limits α-

[24] Reported by IOM as days 13, 21, 30 and 138.

tocopherol transfer to the fetus (Didenco et al., 2011). There was no significant correlation between maternal and cord blood α-tocopherol concentrations, but a significant correlation was observed between maternal and cord blood α-CEHC (r = 0.70, log transformed α-CEHC). Mean concentration of umbilical cord blood α-CEHC (30.2 ± 28.9 nmol/L) was not significantly different from maternal concentrations.

In 26 mothers at delivery, mean (± SE) maternal plasma concentrations were significantly higher than mean cord plasma α-tocopherol concentrations, both when expressed as µmol/L (26.1 ± 1.1 vs 5.5 ± 0.4 vs, p = 0.0001) or µmol/mol total lipids (2.6 ± 0.1 vs 1.9 ± 0.1, p = 0.0001). The relationship between maternal plasma and cord plasma α-tocopherol concentrations was significant after adjustment for total lipids (r = 0.54, p = 0.007), but not when expressed as µmol/L (r = 0.09, p = 0.64) (Jain et al., 1996).

In another study on 66 mothers and 40 samples of umbilical cord blood of full-term newborns, mean (± SD) α-tocopherol concentration in maternal blood measured between 10 and 20 weeks of gestation was significantly higher than cord blood α-tocopherol at delivery (20.6 ± 4.0 µmol/L vs 7.2 ± 1.9 µmol/L) (Kiely et al., 1999). There was no correlation between maternal and cord blood α-tocopherol concentrations as well as lipid-adjusted α-tocopherol concentrations (Kiely et al., 1999).

Fifteen pregnant women were supplemented with 30 mg/day of all-rac-α-tocopheryl acetate during pregnancy, and with different doses (15, 30, 75, 150 or 300 mg/day, n = 3 per dose) of D_3-RRR-α-tocopheryl acetate and D_6-all-rac-α-tocopheryl acetate (1:1 by weight, n = 3 per dose) within five to nine days before delivery (Acuff et al., 1998). Maternal plasma total (i.e. deuterated or not) α-tocopherol concentrations of the five groups at delivery (mean ± SEM) were between 39.35 ± 2.86 µmol/L and 59.03 ± 0.73 µmol/L, while corresponding mean total α-tocopherol concentrations in cord blood were between 6.71 ± 0.49 µmol/L and 9.52 ± 0.90 µmol/L. Maternal plasma and cord plasma at delivery had significantly higher concentrations of D_3-RRR-α-tocopherol than D_6-all-rac-α-tocopherol, whatever the dose received. Maternal D_3-RRR-α-tocopherol concentrations were significantly higher with the two highest doses (150 and 300 mg/day) than with the three lowest ones, and cord plasma D_3-RRR-α-tocopherol concentrations were significantly higher with the two highest doses than with the lowest one (15 mg/day).

Placental transfer was investigated by analysis of α-tocopherol concentration according to gestational age, in fifty-two fetal blood samples (umbilical cord) and maternal blood (Abbasi et al., 1990). Mean α-tocopherol concentration was 9.2 ± 3.3 µmol/L in samples from 13 fetuses with a gestational age up to 22 weeks, 9.2 ± 4.9 µmol/L in 12 fetuses at 23–27 weeks of gestation, and 8.6 ± 4.2 µmol/L in 27 fetuses with a gestational age of 28–38 weeks. Maternal plasma α-tocopherol concentrations were measured in six mothers at ≤ 22 and also at 23–27 weeks, and in 20 mothers at ≥ 28 weeks of gestation. Maternal plasma α-tocopherol concentrations correlated significantly with those in the fetus (r = 0.551, p < 0.002). There were no significant differences in serum α-tocopherol concentrations in samples from early, mid, or late gestation in either the mother or the fetus. This study suggests that placental transfer of α-tocopherol is relatively constant throughout gestation.

For lactating women, the secretion of α-tocopherol in mature human milk during the first six months of exclusive breastfeeding was estimated by the Panel to be 3.7 mg/day (Section 2.3.5.4).

The Panel notes that, despite the presence of α-TTP in the placenta and the existence of a correlation between maternal plasma and chorioamnion α-tocopherol concentrations, the α-tocopherol concentration of cord blood is much lower than that of maternal blood. In addition, maternal 'vitamin E' supplementation increases maternal but not fetal (cord) plasma α-tocopherol concentrations. The Panel also notes that placental transfer of α-tocopherol is relatively constant throughout gestation and that α-tocopherol deficiency in pregnant women has not been reported. The Panel considers that the available data do not indicate an additional α-tocopherol requirement during pregnancy.

The Panel notes the scarcity of data in lactating women on α-tocopherol requirement. The Panel also notes the size of the theoretical α-tocopherol store in adipose tissue (Section 2.3.3), that the increase in the percentage of red blood cell haemolysis up to 'high' values took several months in depleted men receiving a basal diet providing about 3 mg/day of α-tocopherol (Section 2.4.2), and the absence of any report about α-tocopherol deficiency during lactation. The Panel considers that the available data do not indicate an additional α-tocopherol requirement during lactation.

5.3. 'Vitamin E'/α-tocopherol intake and health consequences

The relationship between α-tocopherol/'vitamin E' intakes and chronic disease outcomes has been investigated in systematic reviews, RCTs, and also in observational (prospective cohort, case-control, cross-sectional) studies, where associations between intakes and disease outcomes may be confounded by uncertainties inherent to the methodology used for the assessment of α-tocopherol/'vitamin E' intakes and by the effect of other dietary, lifestyle, or undefined factors on the disease outcomes investigated. Systematic reviews, RCTs, and observational studies are discussed in this Section.

IOM (2000) reviewed the available evidence (*in vitro*, animal, observational, intervention studies) in relation to 'vitamin E'/α-tocopherol intake and the risk of cardiovascular diseases, diabetes mellitus, cancer, cataract, and central nervous system disorders (e.g. risk of Parkinson's disease, Alzheimer's disease or tardive dyskinesia) or markers of immune function. Although useful in the generation of hypotheses about the role of 'vitamin E'/α-tocopherol in chronic disease development, the results from these studies were insufficient to set reference values for the vitamin and it was noted that even positive outcomes from trials targeting high-risk groups may not necessarily lead to a change in reference values for the whole healthy population (IOM, 2000).

A comprehensive search of the literature published between 1990 and 2011 was performed as preparatory work to this assessment in order to identify new data on health outcomes upon which DRVs for 'vitamin E' may potentially be based (Heinonen et al., 2012). An additional literature search (in PubMed) was performed to identify new data published afterwards and until the end of 2014 on α-tocopherol intake and health outcomes.

The relationship between supplementation with all-rac-α-tocopherol and markers of immune function has been investigated by Meydani et al. (1997; 2004). Outcome measures were delayed-type hypersensitivity skin response, antibody responses to hepatitis B, tetanus and diphterian and pneumococcal vaccines, autoantibodies to DNA and thyroglobulin before and after supplementation, incidence of respiratory tract infections, number of persons and number of days with respiratory tract infections (upper and lower), and number of new antibiotic prescriptions for respiratory tract infections. The Panel considers that the available evidence does not establish that modulation of any of these markers is in itself a health outcome, which could be considered as a suitable criterion for deriving a DRV for α-tocopherol.

Studies also investigated the relationship between 'vitamin E'/α-tocopherol and diabetes (cohort studies (Arnlov et al., 2009; Song et al., 2011)), osteoporosis (one case-control study (Zhang et al., 2006)), and hearing loss (one cohort study (Shargorodsky et al., 2010)). One study (Song et al., 2011) investigated the relationship between the frequency of use (number of times per week) of single or multivitamin supplements including 'vitamin E' on diabetes risk, from which no conclusions can be drawn to set DRVs for α-tocopherol. In addition, the low number of studies available for these outcomes does not allow conclusions to be drawn on a putative role of α-tocopherol in the pathogenesis of these conditions.

Since the reports by SCF (1993) or IOM (2000), more data have become available on the relationship between 'vitamin E'/α-tocopherol intake and the risk of cardiovascular disease-related outcomes,

cancer, Parkinson's and Alzheimer's diseases and vision-related outcomes, as well as on all-cause mortality.

5.3.1. Cardiovascular disease-related outcomes

The relationship between 'vitamin E' or α-tocopherol through diet or supplementation (alone or in combination) and cardiovascular disease (CVD)-related outcomes has been investigated in a number of systematic reviews, RCTs, prospective cohort studies, case-control studies (Heinonen et al., 2012).

In an RCT, the effect of aspirin or 300 mg/day of 'synthetic α-tocopherol' supplementation compared to respective placebos was investigated in the primary prevention of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke (de Gaetano and Collaborative Group of the Primary Prevention, 2001). The Panel notes the high dose of supplementation and the specific population (including diseased populations) investigated in this study, and considers that this study cannot be used to set DRVs for α-tocopherol. In RCTs, α-tocopherol supplementation of at least 50 mg/day did not have an effect on intermittent claudication (Tornwall et al., 1997; Tornwall et al., 1999), abdominal aortic aneurysm (Tornwall et al., 2001), intima-media thickness (Hodis et al., 2002), and cardiovascular events (fatal and non-fatal) (Tornwall et al., 2004a). Alpha-tocopherol supplementation (50 mg/day, background α-tocopherol intake not reported) did not have any significant effect on primary stroke incidence or mortality in normotensive male smokers (50–69 years at inclusion) during an RCT (median duration: six years) or post-trial (Leppala et al., 2000b; Leppala et al., 2000a; Tornwall et al., 2004b).

In a prospective cohort study in 34 492 post-menopausal women followed for 11 years and whose intake from foods and supplements was assessed by a FFQ, 215 deaths from stroke were identified (Yochum et al., 2000). Overall, after adjustments, there was no relationship between risk of death from stroke and quintiles of intake of 'vitamin E' from food and supplements, food only or supplements only. In another prospective cohort study in 559 men (mean age: 72 years), who were free of chronic diseases in 1985 (n = 375 in 1990 and 202 in 1995), mean α-tocopherol intake (± SD), without dietary supplements, was 9.1 ± 4.6, 9.1 ± 4.9 and 7.5 ± 3.5 mg/day in 1985, 1990, and 1995, respectively, and 197 men had died from CVD after 15 years of follow-up (1985–2000) (Buijsse et al., 2008). Alpha-tocopherol dietary intake at baseline was not associated with 15-year CVD mortality after adjustments, in all the models tested.

5.3.2. Cancer

The World Cancer Research Fund (WCRF/AICR, 2007) found that there is limited evidence suggesting that foods containing 'vitamin E' protect against oesophageal cancer or prostate cancer (mostly case-control studies) and also limited evidence suggesting that α-tocopherol supplements protect against prostate cancer in smokers (one RCT).

The relationship between 'vitamin E' or α-tocopherol intake through diet or supplementation (alone or in combination) and various types of cancers has been investigated in a number of systematic reviews, RCTs, prospective cohort studies, and case-control studies (Heinonen et al., 2012). The Panel notes the high dose of supplementation in some of the studies investigated.

No relationship was observed between 'vitamin E' or α-tocopherol intake and breast cancer (Yuan et al., 1995; Freudenheim et al., 1996; Do et al., 2003; Nissen et al., 2003; Frazier et al., 2004; Nagel et al., 2010), bladder cancer (Riboli et al., 1991; Albanes et al., 1995; Jacobs et al., 2002; Brinkman et al., 2010), cervical, endometrial and ovarian cancers (Fairfield et al., 2001; Xu et al., 2007; Ghosh et al., 2008; Kim et al., 2010), renal cancer (Hu et al., 2009), pancreatic cancer (Rautalahti et al., 1999), stomach cancer (Alkhenizan and Hafez, 2007), testicular cancer (Bonner et al., 2002), skin

carcinomas (Kirkpatrick et al., 1994; Fung et al., 2002) as well as lung cancer (1994; Albanes et al., 1995; Ocke et al., 1997; Alkhenizan and Hafez, 2007).

Inconsistent results were observed between studies (RCTS and observational studies) on intake of the vitamin and risk of colorectal carcinoma (Bostick et al., 1993; Ferraroni et al., 1994; Albanes et al., 1995; Slattery et al., 1998; Malila et al., 1999; Jacobs et al., 2001; Wu et al., 2002; Chiu et al., 2003; Satia-Abouta et al., 2003; Murtaugh et al., 2004; Kune and Watson, 2006; Arain and Abdul Qadeer, 2010).

Inconsistent results were also observed between studies (RCTS and observational studies) on intake of the vitamin and risk of prostate cancer (Albanes et al., 1995; Rautalahti et al., 1999; Alkhenizan and Hafez, 2007; Wright et al., 2007; Bidoli et al., 2009; Gaziano et al., 2009; Lippman et al., 2009; Klein et al., 2011; Kristal et al., 2014; Wang et al., 2014).

5.3.3. Other health outcomes

The relationship between 'vitamin E' or α-tocopherol through diet or supplementation (alone or in combination) and a variety of other health outcomes (e.g. risk of Parkinson's and Alzheimer's diseases, vision-related outcomes) has been investigated in a number of systematic reviews, RCTs, prospective cohort studies, and case-control studies, reviewed in Heinonen et al. (2012).

In a case-control study in Japan (Miyake et al., 2011), 'vitamin E' intake from food only was assessed by a diet history questionnaire. After adjustments, 'vitamin E' intake (in each quartile compared to the first one) was significantly associated with a reduced risk of Parkinson's disease (e.g. highest quartile, above 9.8 mg/day: odds ratio (OR) [95 % CI]: 0.45 [0.25–0.79], p for trend 0.009). A systematic review with meta-analysis of observational studies considered seven studies (five case-control, one cohort, and one cross-sectional) investigating the relationship between 'vitamin E' intake and the risk of Parkinson's disease (Etminan et al., 2005). ORs or relative risks (RRs) were pooled by the authors by 'moderate' or 'high' intakes: 'moderate' was defined as intake in the second or third quartiles or second, third, or fourth quintiles in each study, and 'high' was defined as intake in the last quartile or quintile. Only 'moderate' dietary intake of 'vitamin E' (value not given) was associated with a significantly reduced risk of Parkinson's disease (RR 0.81, 95 % CI 0.67–0.98). In a systematic review with meta-analysis of seven observational studies (Li et al., 2012), there was a significant inverse association between dietary intake of 'vitamin E' from food and the risk of Alzheimer's disease (pooled RR [95 % CI] 0.76 [0.67–0.84]). The Panel notes that no quantitative data can be derived from these two systematic reviews in order to set DRVs for α-tocopherol.

Meta-analysis of two RCTs which provided α-tocopherol supplementation above 50 mg/day did not show any significant effect of supplementation on the risk of age-related maculopathy compared to placebo (Evans, 2008). In a pooled analysis combining two large prospective cohort studies (one in men and the other in women, ≥ 40 years at baseline), overall, no significant association was found between 'vitamin E' intake (total or from food only, assessed by FFQs) and the risk of primary open-angle glaucoma (Kang et al., 2003).

5.3.4. All-cause mortality

Three meta-analyses of RCTs (Miller et al., 2005; Bjelakovic et al., 2007; Abner et al., 2011) investigated the relationship between 'vitamin E' supplementation, alone or in combination with other micronutrients, and all-cause mortality.

The Panel notes that the trials included in these meta-analyses were often performed in patients with chronic diseases, the form of 'vitamin E' was often unknown, and that the trials often used doses of the vitamin exceeding the UL.

5.3.5. Conclusions on α-tocopherol intake and health consequences

The Panel considers that the data available on α-tocopherol/'vitamin E' intakes and health consequences are inconsistent or limited and cannot be used to derive DRVs for α-tocopherol.

6. Data on which to base Dietary Reference Values

The Panel considers that available data on markers of α-tocopherol intake/status/function, on α-tocopherol kinetics and body pools, on the relationship between PUFA intake and α-tocopherol intake/requirement can be used neither on their own nor in combination to derive the requirement for α-tocopherol in adults. The Panel also considers that there are no data that can be used to derive the requirement for α-tocopherol for infants or children, and that data on the relationship between 'vitamin E'/α-tocopherol intake and health consequences are inconsistent or limited and cannot be used to derive DRVs for α-tocopherol (Section 5).

The Panel chose to set an Adequate Intake (AI) for α-tocopherol for all population groups based on observed intakes in healthy populations with no apparent α-tocopherol deficiency, suggesting that current intake levels are adequate. Except for infants 7–11 months (Section 6.2), the Panel considered the range of average EFSA intake estimates for α-tocopherol as well as the range of average EFSA intake estimates for α-tocopherol equivalents (α-TEs). As these average intakes were estimated by sex, age class and survey (these surveys having different methodologies) for nine EU countries (Sections 3.2.1 and 3.2.2, Appendix B), the Panel combined the approximate mid-points of both ranges of average EFSA intake estimates (and rounded) to set AIs for α-tocopherol for children and adults. It was not considered necessary to set sex-specific AIs for infants and children aged less than 10 years. The Panel notes the uncertainties in the food composition and consumption data and dietary assessment methods used to estimate dietary intakes, and the specific methodological uncertainties of the EFSA intake estimates for α-tocopherol (Sections 3.2).

6.1. Adults

In adults (≥ 18 years) in EU countries, average α-tocopherol intakes ranged between 7.8 and 12.5 mg/day in women and between 8.2 and 16 mg/day in men, and average α-TE intakes ranged between 8.9 and 13.5 mg/day in women and between 10.1 and 16.0 mg/day in men. The Panel considered the approximate mid-points of the range of mean intakes for α-tocopherol and for α-TEs and, after rounding, set an AI for α-tocopherol at 13 mg/day for men and 11 mg/day for women.

The Panel notes that these AIs are close to or above the values that are suggested to be physiologically adequate by available studies on markers of α-tocopherol intake/status or on α-tocopherol kinetics and body pools (Section 5.1.1.4).

6.2. Infants

Because of the methodological uncertainties of the EFSA intake estimates in infants (Appendixes C–F and Section 3.2), the Panel considers it preferable to set an AI for older infants (7–11 months) based on estimated α-tocopherol intakes of breast-fed younger infants and upward extrapolation.

Assuming an average breast milk α-tocopherol concentration of 4.6 mg/L in mature human milk of unsupplemented mothers of term infants (Section 2.3.5.5) and an average breast milk intake of infants aged 0–6 months of 0.8 L/day (Butte et al., 2002; FAO/WHO/UNU, 2004; EFSA NDA Panel, 2009), the estimated α-tocopherol intake of infants in the first half-year of life is 3.7 mg/day. Averages of the median weight-for-age of male and female infants aged three months (6.1 kg) and nine months (8.6 kg) according to the WHO Growth Standards (WHO Multicentre Growth Reference Study Group, 2006) are used for the calculation. The AI for α-tocopherol for infants aged 7–11 months is

derived by allometric scaling assuming that the requirement for this vitamin is related to metabolically active body mass, using the formula below. Rounding to the nearest unit, the AI for α-tocopherol for infants aged 7–11 months is 5 mg/day.

$$AI_{\text{infants 7–11 months}} = \alpha\text{-tocopherol intake}_{\text{infants 0–6 months}} \times (\text{weight}_{\text{infants 9 months}} / \text{weight}_{\text{infants 3 months}})^{0.75}$$

6.3. Children

In children aged 1 to < 3 years in EU countries, average α-tocopherol intakes ranged between 4 and 5 mg/day in girls and between 4.5 and 5.7 mg/day in boys, and average α-TE intakes ranged between 4.4 and 6.8 mg/day in girls and between 4.7 and 7.3 mg/day in boys. The Panel considered the approximate mid-points of the range of mean intakes for α-tocopherol and for α-TEs and, after rounding, set an AI for α-tocopherol at 6 mg/day for both sexes for children aged 1 to < 3 years.

In children aged 3 to < 10 years in EU countries, average α-tocopherol intakes ranged between 5.4 and 10.3 mg/day in girls and between 5.8 and 10.9 mg/day in boys, and average α-TE intakes ranged between 6.5 and 11.8 mg/day in girls and between 7.1 and 12.4 mg/day in boys. The Panel considered the approximate mid-points of the range of mean intakes for α-tocopherol and for α-TEs and, after rounding, set an AI for α-tocopherol at 9 mg/day for both sexes for children aged 3 to < 10 years.

In children aged 10 to < 18 years in European countries, average α-tocopherol intakes ranged between 8.2 and 13.2 mg/day in girls and between 9.1 and 14.3 mg/day in boys, and average α-TE intakes ranged between 8.8 and 13.8 mg/day in girls and between 9.6 and 15.9 mg/day in boys. The Panel considered the approximate mid-points of the range of mean intakes for α-tocopherol and for α-TEs and, after rounding, set an AI for α-tocopherol at 11 mg/day for girls and 13 mg/day for boys aged 10 to < 18 years.

6.4. Pregnancy

The Panel considers that there is no evidence for an increased need for α-tocopherol in pregnancy (Section 5.2), and the same AI for α-tocopherol is set as for non-pregnant women, i.e. 11 mg/day. The Panel also notes that the mean α-tocopherol and α-TE intakes from the EFSA intake assessment for the Latvian survey on pregnant adult women are, respectively, 12.4 and 12.5 mg/day (Appendices D and F).

6.5. Lactation

The secretion of α-tocopherol in milk during the first six months of lactation in exclusively breastfeeding women is about 3.7 mg/day (Sections 2.3.5.4 and 6.2). Considering an average α-tocopherol absorption from a usual diet of about 75 % (Section 2.3.1), an additional intake of 4.9 mg α-tocopherol/day would be assumed with the aim of fully compensating the amount of α-tocopherol secreted in human milk.

However, the Panel notes that the proposed AI for (non-lactating) women, derived from observed intakes in the EU, is close to or above the values which are suggested from available data on markers of α-tocopherol intake/status or on α-tocopherol kinetics and body pools (Sections 5.1.1.4 and 6.1). The Panel also notes the size of the theoretical α-tocopherol store in adipose tissue, that the increase in the percentage of red blood cell haemolysis up to ‘high’ values takes several months in depleted men receiving a basal diet providing about 3 mg/day of α-tocopherol, and the absence of any report about α-tocopherol deficiency during lactation (Section 5.2).

The Panel considers that a full compensation of the transitory secretion of α-tocopherol in breast milk is not justified for the derivation of DRVs for α-tocopherol for lactating women. The Panel therefore

considers that the AI for α-tocopherol for lactating women is the same as for non-lactating women, i.e. 11 mg/day.

CONCLUSIONS

The Panel concludes that Average Requirements (ARs) and Population Reference Intakes (PRIs) for α-tocopherol cannot be derived for adults, infants and children, and proposes Adequate Intakes (AIs) based on observed intakes. For children and adults, this approach considers the range of average intakes of α-tocopherol and α-tocopherol-equivalents estimated from dietary surveys in nine EU countries. For infants aged 7–11 months, the Panel proposes AIs based on estimated intakes in fully breast-fed infants and upward extrapolation by allometric scaling. The AI set for pregnant or lactating women is the same as for non-pregnant non-lactating women.

Table 5: Summary of Dietary Reference Values for α-tocopherol

Age	Adequate Intake (mg/day)
7–11 months	5
1–< 3 years	6
3–< 10 years	9
≥ 10 years, males	13
≥ 10 years, females [(a)]	11

(a): Including pregnant and lactating women

RECOMMENDATIONS FOR RESEARCH

The Panel suggests the development of food composition databases on α-tocopherol. The Panel also suggests undertaking studies on the suitability of various biomarkers of status as indicator of the requirement, and on the α-tocopherol requirement of all population groups, especially infants, children and pregnant women.

REFERENCES

Abbasi S, Ludomirski A, Bhutani VK, Weiner S and Johnson L, 1990. Maternal and fetal plasma vitamin E to total lipid ratio and fetal RBC antioxidant function during gestational development. Journal of the American College of Nutrition, 9, 314-319.

Abner EL, Schmitt FA, Mendiondo MS, Marcum JL and Kryscio RJ, 2011. Vitamin E and all-cause mortality: a meta-analysis. Current Aging Science, 4, 158-170.

Acuff RV, Thedford SS, Hidiroglou NN, Papas AM and Odom TA, Jr., 1994. Relative bioavailability of RRR- and all-rac-alpha-tocopheryl acetate in humans: studies using deuterated compounds. American Journal of Clinical Nutrition, 60, 397-402.

Acuff RV, Dunworth RG, Webb LW and Lane JR, 1998. Transport of deuterium-labeled tocopherols during pregnancy. American Journal of Clinical Nutrition, 67, 459-464.

Afssa (Agence française de sécurité sanitaire des aliments), 2001. Apports nutritionnels conseillés pour la population française. Editions Tec&Doc, Paris, France, 605 pp.

Afssa (Agence française de sécurité sanitaire des aliments), 2009. Étude Individuelle Nationale des Consommations Alimentaires 2 (INCA 2) (2006-2007). Rapport. 228 pp.

Aggett P, Bresson JL, Hernell O, Koletzko B, Lafeber H, Michaelson KF, Micheli JL, Ormisson A, de Sousa JS and Weaver L, 1998. Comment on the vitamin E content in infant formulas, follow-on

formulas, and formulas for low birth weight infants. ESPGHAN Committee on Nutrition. European Society for Paediatric Gastroenterology, Hepatology and Nutrition. Journal of Pediatric Gastroenterology and Nutrition, 26, 351-352.

Albanes D, Heinonen OP, Huttunen JK, Taylor PR, Virtamo J, Edwards BK, Haapakoski J, Rautalahti M, Hartman AM and Palmgren J, 1995. Effects of alpha-tocopherol and beta-carotene supplements on cancer incidence in the Alpha-Tocopherol Beta-Carotene Cancer Prevention Study. American Journal of Clinical Nutrition, 62, 1427S-1430S.

Alkhenizan A and Hafez K, 2007. The role of vitamin E in the prevention of cancer: a meta-analysis of randomized controlled trials. Annals of Saudi Medicine, 27, 409-414.

Amcoff E, Edberg A, Barbieri H, Lindroos A, Nälsén C, Pearson M and Lemming E (Livsmedelsverket), 2012. Livsmedels- och näringsintag bland vuxna i Sverige -Resultat från atvaneundersökning utförd 2010–11. 180 pp.

Andersen LF, Solvoll K, Johansson LR, Salminen I, Aro A and Drevon CA, 1999. Evaluation of a food frequency questionnaire with weighed records, fatty acids, and alpha-tocopherol in adipose tissue and serum. American Journal of Epidemiology, 150, 75-87.

Antonakou A, Chiou A, Andrikopoulos NK, Bakoula C and Matalas AL, 2011. Breast milk tocopherol content during the first six months in exclusively breastfeeding Greek women. European Journal of Nutrition, 50, 195-202.

Arain MA and Abdul Qadeer A, 2010. Systematic review on "vitamin E and prevention of colorectal cancer". Pakistan Journal of Pharmaceutical Sciences, 23, 125-130.

Arnlov J, Zethelius B, Riserus U, Basu S, Berne C, Vessby B, Alfthan G, Helmersson J and Uppsala Longitudinal Study of Adult Men S, 2009. Serum and dietary beta-carotene and alpha-tocopherol and incidence of type 2 diabetes mellitus in a community-based study of Swedish men: report from the Uppsala Longitudinal Study of Adult Men (ULSAM) study. Diabetologia, 52, 97-105.

Barkova EN, Nazarenko EV and Zhdanova EV, 2005. Diurnal variations in qualitative composition of breast milk in women with iron deficiency. Bulletin of Experimental Biology and Medicine, 140, 394-396.

Bates B, Lennox A, Prentice A, Bates C and Swan G, 2012. National Diet and Nutrition Survey. Headline results from Years 1, 2 and 3 (combined) of the Rolling Programme (2008/2009 – 2010/11). A survey carried out on behalf of the Department of Health and the Food Standards Agency, 79 pp.

Bates CJ, Prentice A and Finch S, 1999. Gender differences in food and nutrient intakes and status indices from the National Diet and Nutrition Survey of People Aged 65 Years and Over. European Journal of Clinical Nutrition, 53, 694-699.

Bender DA, 2003. Vitamin E: Tocopherols and Tocotrienols. In: Nutritional biochemistry of the vitamins. Ed Bender DA. Cambridge University Press, Cambridge, UK, 109-129.

Bidoli E, Talamini R, Zucchetto A, Bosetti C, Negri E, Lenardon O, Maso LD, Polesel J, Montella M, Franceschi S, Serraino D and La Vecchia C, 2009. Dietary vitamins E and C and prostate cancer risk. Acta Oncologica, 48, 890-894.

Bieri JG and Evarts RP, 1973. Tocopherols and fatty acids in American diets. The recommended allowance for vitamin E. Journal of the American Dietetic Association, 62, 147-151.

Bjelakovic G, Nikolova D, Gluud LL, Simonetti RG and Gluud C, 2007. Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis. Journal of the American Medical Association, 297, 842-857.

1593 Black AE, Wiles SJ and Paul AA, 1986. The nutrient intakes of pregnant and lactating mothers of
1594 good socio-economic status in Cambridge, UK: some implications for recommended daily
1595 allowances of minor nutrients. British Journal of Nutrition, 56, 59-72.

1596 Boersma ER, Offringa PJ, Muskiet FA, Chase WM and Simmons IJ, 1991. Vitamin E, lipid fractions,
1597 and fatty acid composition of colostrum, transitional milk, and mature milk: an international
1598 comparative study. American Journal of Clinical Nutrition, 53, 1197-1204.

1599 Bonner MR, McCann SE and Moysich KB, 2002. Dietary factors and the risk of testicular cancer.
1600 Nutrition & Cancer, 44, 35-43.

1601 Borel P, Moussa M, Reboul E, Lyan B, Defoort C, Vincent-Baudry S, Maillot M, Gastaldi M,
1602 Darmon M, Portugal H, Planells R and Lairon D, 2007. Human plasma levels of vitamin E and
1603 carotenoids are associated with genetic polymorphisms in genes involved in lipid metabolism.
1604 Journal of Nutrition, 137, 2653-2659.

1605 Borel P, Preveraud D and Desmarchelier C, 2013. Bioavailability of vitamin E in humans: an update.
1606 Nutrition Reviews, 71, 319-331.

1607 Bostick RM, Potter JD, McKenzie DR, Sellers TA, Kushi LH, Steinmetz KA and Folsom AR, 1993.
1608 Reduced risk of colon cancer with high intake of vitamin E: the Iowa Women's Health Study.
1609 Cancer Research, 53, 4230-4237.

1610 Boyer JL and Bloomer JR, 1974. Canalicular bile secretion in man. Studies utilizing the biliary
1611 clearance of (14C)mannitol. Journal of Clinical Investigation, 54, 773-781.

1612 Boyer JL, 2013. Bile formation and secretion. Comprehensive Physiology, 3, 1035-1078.

1613 Brigelius-Flohe R, Kelly FJ, Salonen JT, Neuzil J, Zingg JM and Azzi A, 2002. The European
1614 perspective on vitamin E: current knowledge and future research. American Journal of Clinical
1615 Nutrition, 76, 703-716.

1616 Brinkman MT, Karagas MR, Zens MS, Schned A, Reulen RC and Zeegers MP, 2010. Minerals and
1617 vitamins and the risk of bladder cancer: results from the New Hampshire Study. Cancer Causes &
1618 Control, 21, 609-619.

1619 Bruno RS, Ramakrishnan R, Montine TJ, Bray TM and Traber MG, 2005. {alpha}-Tocopherol
1620 disappearance is faster in cigarette smokers and is inversely related to their ascorbic acid status.
1621 American Journal of Clinical Nutrition, 81, 95-103.

1622 Bruno RS, Leonard SW, Park S, Zhao YY and Traber MG, 2006a. Human vitamin E requirements
1623 assessed with the use of apples fortified with deuterium-labeled alpha-tocopheryl acetate.
1624 American Journal of Clinical Nutrition, 83, 299-304.

1625 Bruno RS, Leonard SW, Atkinson J, Montine TJ, Ramakrishnan R, Bray TM and Traber MG, 2006b.
1626 Faster plasma vitamin E disappearance in smokers is normalized by vitamin C supplementation.
1627 Free Radical Biology and Medicine, 40, 689-697.

1628 Buettner GR, 1993. The pecking order of free radicals and antioxidants: lipid peroxidation, alpha-
1629 tocopherol, and ascorbate. Archives of Biochemistry and Biophysics, 300, 535-543.

1630 Buijsse B, Feskens EJ, Kwape L, Kok FJ and Kromhout D, 2008. Both alpha- and beta-carotene, but
1631 not tocopherols and vitamin C, are inversely related to 15-year cardiovascular mortality in Dutch
1632 elderly men. Journal of Nutrition, 138, 344-350.

1633 Bunnell RH, De Ritter E and Rubin SH, 1975. Effect of feeding polyunsaturated fatty acids with a
1634 low vitamin E diet on blood levels of tocopherol in men performing hard physical labor. American
1635 Journal of Clinical Nutrition, 28, 706-711.

1636 Burton GW, Traber MG, Acuff RV, Walters DN, Kayden H, Hughes L and Ingold KU, 1998. Human
1637 plasma and tissue alpha-tocopherol concentrations in response to supplementation with deuterated
1638 natural and synthetic vitamin E. American Journal of Clinical Nutrition, 67, 669-684.

1639 Butte NF, Lopez-Alarcon MG and Garza C, 2002. Nutrient adequacy of exclusive breastfeeding for
1640 the term infant during the first six months of life. World Health Organization, 57 pp.

1641 Cavalier L, Ouahchi K, Kayden HJ, Di Donato S, Reutenauer L, Mandel JL and Koenig M, 1998.
1642 Ataxia with isolated vitamin E deficiency: heterogeneity of mutations and phenotypic variability in
1643 a large number of families. American Journal of Human Genetics, 62, 301-310.

1644 Chappell JE, Francis T and Clandinin MT, 1985. Vitamin A and E content of human milk at early
1645 stages of lactation. Early Human Development, 11, 157-167.

1646 Cheeseman KH, Holley AE, Kelly FJ, Wasil M, Hughes L and Burton G, 1995. Biokinetics in humans
1647 of RRR-alpha-tocopherol: the free phenol, acetate ester, and succinate ester forms of vitamin E.
1648 Free Radical Biology and Medicine, 19, 591-598.

1649 Chiu BC, Ji BT, Dai Q, Gridley G, McLaughlin JK, Gao YT, Fraumeni JF, Jr. and Chow WH, 2003.
1650 Dietary factors and risk of colon cancer in Shanghai, China. Cancer Epidemiology, Biomarkers &
1651 Prevention, 12, 201-208.

1652 Cho JY, Kang DW, Ma X, Ahn SH, Krausz KW, Luecke H, Idle JR and Gonzalez FJ, 2009.
1653 Metabolomics reveals a novel vitamin E metabolite and attenuated vitamin E metabolism upon
1654 PXR activation. Journal of Lipid Research, 50, 924-937.

1655 Chuang JC, Matel HD, Nambiar KP, Kim SH, Fadel JG, Holstege DM and Clifford AJ, 2011.
1656 Quantitation of [5-14CH3]-(2R, 4'R, 8'R)-alpha-tocopherol in humans. Journal of Nutrition, 141,
1657 1482-1488.

1658 D-A-CH (Deutsche Gesellschaft für Ernährung, Österreichische Gesellschaft für Ernährung,
1659 Schweizerische Gesellschaft für Ernährungsforschung, Schweizerische Vereinigung für
1660 Ernährung), 2013. Referenzwerte für die Nährstoffzufuhr. Neuer Umschau Buchverlag, Neustadt
1661 an der Weinstraße, Germany, 292 pp.

1662 Davi G, Alessandrini P, Mezzetti A, Minotti G, Bucciarelli T, Costantini F, Cipollone F, Bon GB,
1663 Ciabattoni G and Patrono C, 1997. In vivo formation of 8-Epi-prostaglandin F2 alpha is increased
1664 in hypercholesterolemia. Arteriosclerosis, Thrombosis, and Vascular Biology, 17, 3230-3235.

1665 Davi G, Ciabattoni G, Consoli A, Mezzetti A, Falco A, Santarone S, Pennese E, Vitacolonna E,
1666 Bucciarelli T, Costantini F, Capani F and Patrono C, 1999. In vivo formation of 8-iso-
1667 prostaglandin f2alpha and platelet activation in diabetes mellitus: effects of improved metabolic
1668 control and vitamin E supplementation. Circulation, 99, 224-229.

1669 de Gaetano G and Collaborative Group of the Primary Prevention P, 2001. Low-dose aspirin and
1670 vitamin E in people at cardiovascular risk: a randomised trial in general practice. Collaborative
1671 Group of the Primary Prevention Project. Lancet, 357, 89-95.

1672 de Lira LQ, Ribeiro PP, Grilo EC, Lima MS and Dimenstein R, 2012. [Alpha-tocopherol level in
1673 serum and colostrum of breastfeeding women and association with maternal variables]. Revista
1674 Brasileira de Ginecologia e Obstetricia, 34, 362-368.

1675 Devereux G, Turner SW, Craig LC, McNeill G, Martindale S, Harbour PJ, Helms PJ and Seaton A,
1676 2006. Low maternal vitamin E intake during pregnancy is associated with asthma in 5-year-old
1677 children. American Journal of Respiratory and Critical Care Medicine, 174, 499-507.

1678 DH (Department of Health), 1991. Dietary reference values for food energy and nutrients for the
1679 United Kingdom. Report of the Panel on Dietary Reference Values of the Committee on Medical
1680 Aspects of Food Policy. HMSO, London, UK, 212 pp.

1681 DHSS (Department of Health and Social Security), 1980. Artificial feeds for the young infants.
1682 Reports on health and social subjects 18. HMSO, London, UK, 112 pp.

1683 Didenco S, Gillingham MB, Go MD, Leonard SW, Traber MG and McEvoy CT, 2011. Increased
1684 vitamin E intake is associated with higher alpha-tocopherol concentration in the maternal

circulation but higher alpha-carboxyethyl hydroxychroman concentration in the fetal circulation. American Journal of Clinical Nutrition, 93, 368-373.

Dixon LB, Subar AF, Wideroff L, Thompson FE, Kahle LL and Potischman N, 2006. Carotenoid and tocopherol estimates from the NCI diet history questionnaire are valid compared with multiple recalls and serum biomarkers. Journal of Nutrition, 136, 3054-3061.

Dju MY, Mason KE and Filer LJ, Jr., 1958. Vitamin E (tocopherol) in human tissues from birth to old age. American Journal of Clinical Nutrition, 6, 50-60.

Do MH, Lee SS, Jung PJ and Lee MH, 2003. Intake of dietary fat and vitamin in relation to breast cancer risk in Korean women: a case-control study. Journal of Korean Medical Science, 18, 534-540.

Duda G, Nogala-Kalucka M, Karwowska W, Kupczyk B and Lampart-Szczapa E, 2009. Influence of the lactating women diet on the concentration of the lipophilic vitamins in human milk. Pakistan Journal of Nutrition, 8, 629-634.

EFSA (European Food Safety Authority), 2011a. Report on the development of a food classification and description system for exposure assessment and guidance on its implementation and use. EFSA Journal 2011;9(12):2489, 84 pp. doi:10.2903/j.efsa.2011.2489

EFSA (European Food Safety Authority), 2011b. Use of the EFSA Comprehensive European Food Consumption Database in Exposure Assessment. EFSA Journal 2011;9(3):2097, 34 pp. doi:10.2903/j.efsa.2011.2097

EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition and Allergies), 2009. Scientific Opinion on the appropriate age for introduction of complementary feeding of infants. EFSA Journal 2009;7(12):1423, 38 pp. doi:10.2903/j.efsa.2009.1423

EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition and Allergies), 2010. Scientific Opinion on Dietary Reference Values for fats, including saturated fatty acids, polyunsaturated fatty acids, monounsaturated fatty acids, trans fatty acids, and cholesterol EFSA Journal 2010;8(3):1461, 107 pp. doi:10.2903/j.efsa.2010.1461

EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition and Allergies), 2011. Guidance on the scientific requirements for health claims related to antioxidants, oxidative damage and cardiovascular health. EFSA Journal 2011;9(12):2474, 13 pp. doi:10.2903/j.efsa.2011.2474

EFSA NDA Panel (EFSA Panel on Dietetic Products Nutrition and Allergies), 2013. Scientific Opinion on nutrient requirements and dietary intakes of infants and young children in the European Union. EFSA Journal 2013;11(10):3408, 103 pp. doi:10.2903/j.efsa.2013.3408

Eggermont E, 2006. Recent advances in vitamin E metabolism and deficiency. European Journal of Pediatrics, 165, 429-434.

El-Sohemy A, Baylin A, Ascherio A, Kabagambe E, Spiegelman D and Campos H, 2001. Population-based study of alpha- and gamma-tocopherol in plasma and adipose tissue as biomarkers of intake in Costa Rican adults. American Journal of Clinical Nutrition, 74, 356-363.

Etminan M, Gill SS and Samii A, 2005. Intake of vitamin E, vitamin C, and carotenoids and the risk of Parkinson's disease: a meta-analysis. Lancet Neurology, 4, 362-365.

Evans HM and Bishop KS, 1922. On the existence of a hitherto unrecognized dietary factor essential for reproduction. Science, 56, 650-651.

Evans J, 2008. Antioxidant supplements to prevent or slow down the progression of AMD: a systematic review and meta-analysis. Eye, 22, 751-760.

Fairfield KM, Hankinson SE, Rosner BA, Hunter DJ, Colditz GA and Willett WC, 2001. Risk of ovarian carcinoma and consumption of vitamins A, C, and E and specific carotenoids: a prospective analysis. Cancer, 92, 2318-2326.

FAO/WHO/UNU (Food and Agriculture Organization of the United Nations/World Health Organization/United Nations University), 2004. Human energy requirements. Report of a Joint FAO/WHO/UNU Expert Consultation: Rome, 17–24 October 2001. FAO food and nutrition technical report series, 103 pp.

Farrell PM, Bieri JG, Fratantoni JF, Wood RE and di Sant'Agnese PA, 1977. The occurrence and effects of human vitamin E deficiency. A study in patients with cystic fibrosis. Journal of Clinical Investigation, 60, 233-241.

Farrell PM, 1980. Deficiency states, pharmacological effects and nutrient requirements. In: Vitamin E, a comprehensive treatise. Ed Machlin LJ. Marcel Dekker, New-York, USA, 520-620.

Ferraroni M, La Vecchia C, D'Avanzo B, Negri E, Franceschi S and Decarli A, 1994. Selected micronutrient intake and the risk of colorectal cancer. British Journal of Cancer, 70, 1150-1155.

Frazier AL, Li L, Cho E, Willett WC and Colditz GA, 2004. Adolescent diet and risk of breast cancer. Cancer Causes & Control, 15, 73-82.

Freedman JE, Farhat JH, Loscalzo J and Keaney JF, Jr., 1996. Alpha-tocopherol inhibits aggregation of human platelets by a protein kinase C-dependent mechanism. Circulation, 94, 2434-2440.

Freudenheim JL, Marshall JR, Vena JE, Laughlin R, Brasure JR, Swanson MK, Nemoto T and Graham S, 1996. Premenopausal breast cancer risk and intake of vegetables, fruits, and related nutrients. Journal of the National Cancer Institute, 88, 340-348.

Fung TT, Hunter DJ, Spiegelman D, Colditz GA, Speizer FE and Willett WC, 2002. Vitamins and carotenoids intake and the risk of basal cell carcinoma of the skin in women (United States). Cancer Causes & Control, 13, 221-230.

Furie B, Bouchard BA and Furie BC, 1999. Vitamin K-dependent biosynthesis of gamma-carboxyglutamic acid. Blood, 93, 1798-1808.

Gao X, Wilde PE, Maras JE, Bermudez OI and Tucker KL, 2004. The maximal amount of alpha-tocopherol intake from foods alone in U.S. adults (1994-1996 CSFII): an analysis by linear programming. Annals of the New York Academy of Sciences, 1031, 385-386.

Gaziano JM, Glynn RJ, Christen WG, Kurth T, Belanger C, MacFadyen J, Bubes V, Manson JE, Sesso HD and Buring JE, 2009. Vitamins E and C in the prevention of prostate and total cancer in men: the Physicians' Health Study II randomized controlled trial. Journal of the American Medical Association, 301, 52-62.

Gee PT, 2011. Unleashing the untold and misunderstood observations on vitamin E. Genes & Nutrition, 6, 5-16.

Ghosh C, Baker JA, Moysich KB, Rivera R, Brasure JR and McCann SE, 2008. Dietary intakes of selected nutrients and food groups and risk of cervical cancer. Nutrition & Cancer, 60, 331-341.

Gregory J, Foster K, Tyler H and Wiseman M, 1990. The dietary and nutrition survey of British adults. HMSO, London, UK, 392 pp.

Haga P, Ek J and Kran S, 1982. Plasma tocopherol levels and vitamin E/beta-lipoprotein relationships during pregnancy and in cord blood. American Journal of Clinical Nutrition, 36, 1200-1204.

Handelman GJ, Epstein WL, Peerson J, Spiegelman D, Machlin LJ and Dratz EA, 1994. Human adipose alpha-tocopherol and gamma-tocopherol kinetics during and after 1 y of alpha-tocopherol supplementation. American Journal of Clinical Nutrition, 59, 1025-1032.

Harada M, Kumemura H, Harada R, Komai K and Sata M, 2005. Scleroderma and repeated spontaneous abortions treated with vitamin E--a case report. Kurume Medical Journal, 52, 93-95.

1774 Harris PL and Embree ND, 1963. Quantitative Consideration of the Effect of Polyunsaturated Fatty
1775 Acid Content of the Diet Upon the Requirements for Vitamin E. American Journal of Clinical
1776 Nutrition, 13, 385-392.

1777 Heinonen M, Kärkkäinen M, Riuttamäk MA, Piironen V, Lampi AM, Ollilainen V and Lamberg-
1778 Allardt C, 2012. Literature search and review related to specific preparatory work in the
1779 establishment of Dietary Reference Values. Preparation of an evidence report identifying health
1780 outcomes upon which Dietary Reference Values could potentially be based for vitamins A, C, E,
1781 and K1. Project developed on the procurement project CT/EFSA/NDA/2010/02. 331 pp.

1782 Helldán A, Raulio S, Kosola M, Tapanainen H, Ovaskainen ML and Virtanen S, 2013. Finravinto
1783 2012 -tutkimus - The National FINDIET 2012 Survey. THL. Raportti 16/2013, 217 pp.

1784 Hill KE, Motley AK, Li X, May JM and Burk RF, 2001. Combined selenium and vitamin E
1785 deficiency causes fatal myopathy in guinea pigs. Journal of Nutrition, 131, 1798-1802.

1786 Hodis HN, Mack WJ, LaBree L, Mahrer PR, Sevanian A, Liu CR, Liu CH, Hwang J, Selzer RH, Azen
1787 SP and Veaps Research G, 2002. Alpha-tocopherol supplementation in healthy individuals reduces
1788 low-density lipoprotein oxidation but not atherosclerosis: the Vitamin E Atherosclerosis
1789 Prevention Study (VEAPS). Circulation, 106, 1453-1459.

1790 Holman RT, 1954. Auto-oxidation of fats and related substances. In: Progress in the chemistry of fats
1791 and other lipids. Vol. 2. Eds Holman RT, Lundberg WO and Makin T. Academic Press, New
1792 York: , 51-98.

1793 Horwitt MK, Harvey CC, Duncan GD and Wilson WC, 1956. Effects of limited tocopherol intake in
1794 man with relationships to erythrocyte hemolysis and lipid oxidations. American Journal of Clinical
1795 Nutrition, 4, 408-419.

1796 Horwitt MK, 1960. Vitamin E and lipid metabolism in man. American Journal of Clinical Nutrition,
1797 8, 451-461.

1798 Horwitt MK and 1962. Interrelations between vitamin E and polyunsaturated fatty acids in adult men.
1799 Vitamins & Hormones, 20, 541-558.

1800 Horwitt MK, Century B and Zeman AA, 1963. Erythrocyte survival time and reticulocyte levels after
1801 tocopherol depletion in man. American Journal of Clinical Nutrition, 12, 99-106.

1802 Horwitt MK, Harvey CC, Dahm CH, Jr. and Searcy MT, 1972. Relationship between tocopherol and
1803 serum lipid levels for determination of nutritional adequacy. Annals of the New York Academy of
1804 Sciences, 203, 223-236.

1805 Horwitt MK, 1974. Status of human requirements for vitamin E. American Journal of Clinical
1806 Nutrition, 27, 1182-1193.

1807 Horwitt MK, 1980a. Interpretation of human requirements for vitamin E. In: Vitamin E, a
1808 comprehensive treatise. Ed Machlin LJ. Marcel Dekker, New-York, USA, 621-636.

1809 Horwitt MK, 1980b. Therapeutic uses of vitamin E in medicine. Nutrition Reviews, 38, 105-113.

1810 Hosomi A, Arita M, Sato Y, Kiyose C, Ueda T, Igarashi O, Arai H and Inoue K, 1997. Affinity for
1811 alpha-tocopherol transfer protein as a determinant of the biological activities of vitamin E analogs.
1812 FEBS Letters, 409, 105-108.

1813 Hu J, La Vecchia C, Negri E, DesMeules M, Mery L and Canadian Cancer Registries Epidemiology
1814 Research G, 2009. Dietary vitamin C, E, and carotenoid intake and risk of renal cell carcinoma.
1815 Cancer Causes & Control, 20, 1451-1458.

1816 Igarashi O, Yonekawa Y and Fujiyama-Fujihara Y, 1991. Synergistic action of vitamin E and vitamin
1817 C in vivo using a new mutant of Wistar-strain rats, ODS, unable to synthesize vitamin C. Journal
1818 of Nutritional Science and Vitaminology, 37, 359-369.

1819 Imai E, Tsuji T, Sano M, Fukuwatari T and Shibata K, 2011. Association between 24 hour urinary
1820 alpha-tocopherol catabolite, 2,5,7,8-tetramethyl-2(2'-carboxyethyl)-6-hydroxychroman (alpha-
1821 CEHC) and alpha-tocopherol intake in intervention and cross-sectional studies. Asia Pacific
1822 Journal of Clinical Nutrition, 20, 507-513.

1823 IOM (Institute of Medicine), 2000. Dietary reference intakes for vitamin C, vitamin E, selenium and
1824 carotenoids. Food and Nutrition Board. National Academy Press, Washington, D.C., USA, 531 pp.

1825 Iqbal J and Hussain MM, 2009. Intestinal lipid absorption. American Journal of Physiology.
1826 Endocrinology and Metabolism, 296, E1183-1194.

1827 IUNA, (Irish Universities Nutrition Alliance), online. National Adult Nutrition Survey. Available
1828 online: http://www.iuna.net/

1829 Jacobs EJ, Connell CJ, Patel AV, Chao A, Rodriguez C, Seymour J, McCullough ML, Calle EE and
1830 Thun MJ, 2001. Vitamin C and vitamin E supplement use and colorectal cancer mortality in a
1831 large American Cancer Society cohort. Cancer Epidemiology, Biomarkers & Prevention, 10, 17-
1832 23.

1833 Jacobs EJ, Henion AK, Briggs PJ, Connell CJ, McCullough ML, Jonas CR, Rodriguez C, Calle EE
1834 and Thun MJ, 2002. Vitamin C and vitamin E supplement use and bladder cancer mortality in a
1835 large cohort of US men and women. American Journal of Epidemiology, 156, 1002-1010.

1836 Jain SK, Wise R and Bocchini JJ, Jr., 1996. Vitamin E and vitamin E-quinone levels in red blood cells
1837 and plasma of newborn infants and their mothers. Journal of the American College of Nutrition,
1838 15, 44-48.

1839 Jansson L, Akesson B and Holmberg L, 1981. Vitamin E and fatty acid composition of human milk.
1840 American Journal of Clinical Nutrition, 34, 8-13.

1841 Jeanes YM, Hall WL, Ellard S, Lee E and Lodge JK, 2004. The absorption of vitamin E is influenced
1842 by the amount of fat in a meal and the food matrix. British Journal of Nutrition, 92, 575-579.

1843 Jeffrey GP, Muller DP, Burroughs AK, Matthews S, Kemp C, Epstein O, Metcalfe TA, Southam E,
1844 Tazir-Melboucy M, Thomas PK and et al., 1987. Vitamin E deficiency and its clinical significance
1845 in adults with primary biliary cirrhosis and other forms of chronic liver disease. Journal of
1846 Hepatology, 4, 307-317.

1847 Johnson CH, Slanar O, Krausz KW, Kang DW, Patterson AD, Kim JH, Luecke H, Gonzalez FJ and
1848 Idle JR, 2012. Novel metabolites and roles for alpha-tocopherol in humans and mice discovered by
1849 mass spectrometry-based metabolomics. American Journal of Clinical Nutrition, 96, 818-830.

1850 Kaempf-Rotzoll DE, Horiguchi M, Hashiguchi K, Aoki J, Tamai H, Linderkamp O and Arai H, 2003.
1851 Human placental trophoblast cells express alpha-tocopherol transfer protein. Placenta, 24, 439-
1852 444.

1853 Kang JH, Pasquale LR, Willett W, Rosner B, Egan KM, Faberowski N and Hankinson SE, 2003.
1854 Antioxidant intake and primary open-angle glaucoma: a prospective study. American Journal of
1855 Epidemiology, 158, 337-346.

1856 Kardinaal AF, van 't Veer P, Brants HA, van den Berg H, van Schoonhoven J and Hermus RJ, 1995.
1857 Relations between antioxidant vitamins in adipose tissue, plasma, and diet. American Journal of
1858 Epidemiology, 141, 440-450.

1859 Kasparova M, Plisek J, Solichova D, Krcmova L, Kucerova B, Hronek M and Solich P, 2012. Rapid
1860 sample preparation procedure for determination of retinol and alpha-tocopherol in human breast
1861 milk. Talanta, 93, 147-152.

1862 Kelleher J and Losowsky MS, 1968. The absorption of vitamin E in man. Biochemical Journal, 110,
1863 20P-21P.

1864 Kelly FJ, Rodgers W, Handel J, Smith S and Hall MA, 1990. Time course of vitamin E repletion in
1865 the premature infant. British Journal of Nutrition, 63, 631-638.

1866 Kersting M and Clausen K, 2003. Ernährungsphysiologische Auswertung einer repräsentativen
1867 Verzehrsstudie bei Säuglingen und Kleinkindern VELS mit dem Instrumentarium der DONALD
1868 Studie. Forschungsinstitut für Kinderernährung Dortmund, 103 pp.

1869 Kiely M, Cogan P, Kearney PJ and Morrissey PA, 1999. Relationship between smoking, dietary
1870 intakes and plasma levels of vitamin E and beta-carotene in matched maternal-cord pairs.
1871 International Journal for Vitamin and Nutrition Research, 69, 262-267.

1872 Kim J, Kim MK, Lee JK, Kim JH, Son SK, Song ES, Lee KB, Lee JP, Lee JM and Yun YM, 2010.
1873 Intakes of vitamin A, C, and E, and beta-carotene are associated with risk of cervical cancer: a
1874 case-control study in Korea. Nutrition & Cancer, 62, 181-189.

1875 Kirkpatrick CS, White E and Lee JA, 1994. Case-control study of malignant melanoma in Washington
1876 State. II. Diet, alcohol, and obesity. American Journal of Epidemiology, 139, 869-880.

1877 Kiyose C, Muramatsu R, Kameyama Y, Ueda T and Igarashi O, 1997. Biodiscrimination of alpha-
1878 tocopherol stereoisomers in humans after oral administration. American Journal of Clinical
1879 Nutrition, 65, 785-789.

1880 Klein EA, Thompson IM, Jr., Tangen CM, Crowley JJ, Lucia MS, Goodman PJ, Minasian LM, Ford
1881 LG, Parnes HL, Gaziano JM, Karp DD, Lieber MM, Walther PJ, Klotz L, Parsons JK, Chin JL,
1882 Darke AK, Lippman SM, Goodman GE, Meyskens FL, Jr. and Baker LH, 2011. Vitamin E and the
1883 risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Journal of
1884 the American Medical Association, 306, 1549-1556.

1885 Kodentsova VM and Vrzhesinskaya OA, 2006. Evaluation of the vitamin status in nursing women by
1886 vitamin content in breast milk. Bulletin of Experimental Biology and Medicine, 141, 323-327.

1887 Kristal AR, Darke AK, Morris JS, Tangen CM, Goodman PJ, Thompson IM, Meyskens FL, Jr.,
1888 Goodman GE, Minasian LM, Parnes HL, Lippman SM and Klein EA, 2014. Baseline selenium
1889 status and effects of selenium and vitamin e supplementation on prostate cancer risk. Journal of the
1890 National Cancer Institute, 106, djt456.

1891 Kune G and Watson L, 2006. Colorectal cancer protective effects and the dietary micronutrients
1892 folate, methionine, vitamins B6, B12, C, E, selenium, and lycopene. Nutrition & Cancer, 56, 11-
1893 21.

1894 Lammi-Keefe CJ, Jensen RG, Clark RM and Ferris AM, 1985. Alpha tocopherol, total lipid and
1895 linoleic acid contents of human milk at 2, 6, 12, and 16 weeks. In: Composition and physiological
1896 properties of human milk. Ed Schaub J. Elsevier Science, New-York, USA, 211-215.

1897 Lammi-Keefe CJ, Ferris AM and Jensen RG, 1990. Changes in human milk at 0600, 1000, 1400,
1898 1800, and 2200 h. Journal of Pediatric Gastroenterology and Nutrition, 11, 83-88.

1899 LASER Analytica, 2014. Comprehensive literature search and review of breast milk composition as
1900 preparatory work for the setting of dietary reference values for vitamins and minerals. EFSA
1901 supporting publication 2014:EN-629, 154 pp.

1902 Lebold KM, Ang A, Traber MG and Arab L, 2012. Urinary alpha-carboxyethyl hydroxychroman can
1903 be used as a predictor of alpha-tocopherol adequacy, as demonstrated in the Energetics Study.
1904 American Journal of Clinical Nutrition, 96, 801-809.

1905 Lecompte S, Szabo de Edelenyi F, Goumidi L, Maiani G, Moschonis G, Widhalm K, Molnar D,
1906 Kafatos A, Spinneker A, Breidenassel C, Dallongeville J, Meirhaeghe A and Borel P, 2011.
1907 Polymorphisms in the CD36/FAT gene are associated with plasma vitamin E concentrations in
1908 humans. American Journal of Clinical Nutrition, 93, 644-651.

Lennox A, Sommerville J, Ong K, Henderson H and Allen R, 2013. Diet and Nutrition Survey of Infants and Young Children, 2011. 107 pp.

Leo MA, Ahmed S, Aleynik SI, Siegel JH, Kasmin F and Lieber CS, 1995. Carotenoids and tocopherols in various hepatobiliary conditions. Journal of Hepatology, 23, 550-556.

Leppala JM, Virtamo J, Fogelholm R, Huttunen JK, Albanes D, Taylor PR and Heinonen OP, 2000a. Controlled trial of alpha-tocopherol and beta-carotene supplements on stroke incidence and mortality in male smokers. Arteriosclerosis, Thrombosis & Vascular Biology, 20, 230-235.

Leppala JM, Virtamo J, Fogelholm R, Albanes D, Taylor PR and Heinonen OP, 2000b. Vitamin E and beta carotene supplementation in high risk for stroke: a subgroup analysis of the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study. Archives of Neurology, 57, 1503-1509.

Li FJ, Shen L and Ji HF, 2012. Dietary intakes of vitamin E, vitamin C, and beta-carotene and risk of Alzheimer's disease: a meta-analysis. Journal of Alzheimer's Disease, 31, 253-258.

Lippman SM, Klein EA, Goodman PJ, Lucia Thompson IM, Ford LG, Parnes HL, Minasian LM, Gaziano JM, Hartline JA, Parsons JK, Bearden JD, Crawford ED, Goodman GE, Claudio J, Winquist E, Cook ED, Karp DD, Walther P, Lieber MM, Kristal AR, Darke AK, Arnold KB, Ganz PA, Santella RM, Albanes D, Taylor PR, Probstfield JL, Jagpal TJ, Crowley JJ, Meyskens FL, Baker LH and Coltman CA, 2009. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Journal of the American Medical Association, 301, 39-51.

Litonjua AA, Rifas-Shiman SL, Ly NP, Tantisira KG, Rich-Edwards JW, Camargo CA, Jr., Weiss ST, Gillman MW and Gold DR, 2006. Maternal antioxidant intake in pregnancy and wheezing illnesses in children at 2 y of age. American Journal of Clinical Nutrition, 84, 903-911.

MacMahon MT and Neale G, 1970. The absorption of alpha-tocopherol in control subjects and in patients with intestinal malabsorption. Clinical Science, 38, 197-210.

Mahabir S, Schendel K, Dong YQ, Barrera SL, Spitz MR and Forman MR, 2008. Dietary alpha-, beta-, gamma- and delta-tocopherols in lung cancer risk. International Journal of Cancer, 123, 1173-1180.

Major JM, Yu K, Chung CC, Weinstein SJ, Yeager M, Wheeler W, Snyder K, Wright ME, Virtamo J, Chanock S and Albanes D, 2012. Genome-wide association study identifies three common variants associated with serologic response to vitamin E supplementation in men. Journal of Nutrition, 142, 866-871.

Malila N, Virtamo J, Virtanen M, Albanes D, Tangrea JA and Huttunen JK, 1999. The effect of alpha-tocopherol and beta-carotene supplementation on colorectal adenomas in middle-aged male smokers. Cancer Epidemiology, Biomarkers & Prevention, 8, 489-493.

Manor D and Morley S, 2007. The alpha-tocopherol transfer protein. Vitamins and Hormones, 76, 45-65.

Maras JE, Bermudez OI, Qiao N, Bakun PJ, Boody-Alter EL and Tucker KL, 2004. Intake of alpha-tocopherol is limited among US adults. Journal of the American Dietetic Association, 104, 567-575.

Mariotti C, Gellera C, Rimoldi M, Mineri R, Uziel G, Zorzi G, Pareyson D, Piccolo G, Gambi D, Piacentini S, Squitieri F, Capra R, Castellotti B and Di Donato S, 2004. Ataxia with isolated vitamin E deficiency: neurological phenotype, clinical follow-up and novel mutations in TTPA gene in Italian families. Neurological Sciences, 25, 130-137.

Martindale S, McNeill G, Devereux G, Campbell D, Russell G and Seaton A, 2005. Antioxidant intake in pregnancy in relation to wheeze and eczema in the first two years of life. American Journal of Respiratory & Critical Care Medicine, 171, 121-128.

1955 Martysiak-Zurowska D, Szlagatys-Sidorkiewicz A and Zagierski M, 2013. Concentrations of alpha-
1956 and gamma-tocopherols in human breast milk during the first months of lactation and in infant
1957 formulas. Maternal and Child Nutrition, 9, 473-482.

1958 Mastaloudis A, Leonard SW and Traber MG, 2001. Oxidative stress in athletes during extreme
1959 endurance exercise. Free Radical Biology and Medicine, 31, 911-922.

1960 Meagher EA, Barry OP, Lawson JA, Rokach J and FitzGerald GA, 2001. Effects of vitamin E on lipid
1961 peroxidation in healthy persons. Journal of the American Medical Association, 285, 1178-1182.

1962 Mensink GB, Heseker H, Richter A, Stahl A and Vohmann C (Robert Koch-Institut & Universität
1963 Paderborn), 2007. Ernährungsstudie als KIGGS-Modul (EsKiMo). 143 pp.

1964 Meydani SN, Meydani M, Blumberg JB, Leka LS, Siber G, Loszewski R, Thompson C, Pedrosa MC,
1965 Diamond RD and Stollar BD, 1997. Vitamin E supplementation and in vivo immune response in
1966 healthy elderly subjects. A randomized controlled trial. Journal of the American Medical
1967 Association, 277, 1380-1386.

1968 Meydani SN, Meydani M, Blumberg JB, Leka LS, Pedrosa M, Diamond R and Schaefer EJ, 1998.
1969 Assessment of the safety of supplementation with different amounts of vitamin E in healthy older
1970 adults. American Journal of Clinical Nutrition, 68, 311-318.

1971 Meydani SN, Leka LS, Fine BC, Dallal GE, Keusch GT, Singh MF and Hamer DH, 2004. Vitamin E
1972 and respiratory tract infections in elderly nursing home residents: a randomized controlled trial.
1973 Journal of the American Medical Association, 292, 828-836.

1974 Miller ER, 3rd, Pastor-Barriuso R, Dalal D, Riemersma RA, Appel LJ and Guallar E, 2005. Meta-
1975 analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Annals of
1976 Internal Medicine, 142, 37-46.

1977 Miyake Y, Fukushima W, Tanaka K, Sasaki S, Kiyohara C, Tsuboi Y, Yamada T, Oeda T, Miki T,
1978 Kawamura N, Sakae N, Fukuyama H, Hirota Y, Nagai M and Fukuoka Kinki Parkinson's Disease
1979 Study G, 2011. Dietary intake of antioxidant vitamins and risk of Parkinson's disease: a case-
1980 control study in Japan. European Journal of Neurology, 18, 106-113.

1981 Molto-Puigmarti C, Castellote AI and Lopez-Sabater MC, 2009. Ultra-High-Pressure Liquid
1982 Chromatographic method for the analysis of tocopherols in human colostrum and milk. Journal of
1983 Chromatography A, 1216, 4388-4394.

1984 Molto-Puigmarti C, Permanyer M, Castellote AI and Lopez-Sabater MC, 2011. Effects of
1985 pasteurisation and high-pressure processing on vitamin C, tocopherols and fatty acids in mature
1986 human milk. Food Chemistry, 124, 697-702.

1987 Morrissey PA and Sheehy PJ, 1999. Optimal nutrition: vitamin E. Proceedings of the Nutrition
1988 Society, 58, 459-468.

1989 Muller-Schmehl K, Beninde J, Finckh B, Florian S, Dudenhausen JW, Brigelius-Flohe R and
1990 Schuelke M, 2004. Localization of alpha-tocopherol transfer protein in trophoblast, fetal
1991 capillaries' endothelium and amnion epithelium of human term placenta. Free Radical Research,
1992 38, 413-420.

1993 Muller DP, 1986. Vitamin E--its role in neurological function. Postgraduate Medical Journal, 62, 107-
1994 112.

1995 Murphy SP, Subar AF and Block G, 1990. Vitamin E intakes and sources in the United States.
1996 American Journal of Clinical Nutrition, 52, 361-367.

1997 Murtaugh MA, Ma KN, Benson J, Curtin K, Caan B and Slattery ML, 2004. Antioxidants,
1998 carotenoids, and risk of rectal cancer. American Journal of Epidemiology, 159, 32-41.

1999 Mustacich DJ, Vo AT, Elias VD, Payne K, Sullivan L, Leonard SW and Traber MG, 2007.
2000 Regulatory mechanisms to control tissue alpha-tocopherol. Free Radical Biology and Medicine,
2001 43, 610-618.

2002 Mustacich DJ, Leonard SW, Patel NK and Traber MG, 2010. Alpha-tocopherol beta-oxidation
2003 localized to rat liver mitochondria. Free Radical Biology and Medicine, 48, 73-81.

2004 Nagel G, Linseisen J, van Gils CH, Peeters PH, Boutron-Ruault MC, Clavel-Chapelon F, Romieu I,
2005 Tjonneland A, Olsen A, Roswall N, Witt PM, Overvad K, Rohrmann S, Kaaks R, Drogan D,
2006 Boeing H, Trichopoulou A, Stratigakou V, Zylis D, Engeset D, Lund E, Skeie G, Berrino F, Grioni
2007 S, Mattiello A, Masala G, Tumino R, Zanetti R, Ros MM, Bueno-de-Mesquita HB, Ardanaz E,
2008 Sanchez MJ, Huerta JM, Amiano P, Rodriguez L, Manjer J, Wirfalt E, Lenner P, Hallmans G,
2009 Spencer EA, Key TJ, Bingham S, Khaw KT, Rinaldi S, Slimani N, Boffetta P, Gallo V, Norat T
2010 and Riboli E, 2010. Dietary beta-carotene, vitamin C and E intake and breast cancer risk in the
2011 European Prospective Investigation into Cancer and Nutrition (EPIC). Breast Cancer Research and
2012 Treatment, 119, 753-765.

2013 Netherlands Food and Nutrition Council, 1992. Recommended Dietary Allowances 1989 in the
2014 Netherlands. 115 pp.

2015 Niki E, Tsuchiya J, Tanimura R and Kamiya Y, 1982. Regeneration of vitamin E from alpha-
2016 chromanoxyl radical by glutathione and vitamin C. Chemical Letters, 6, 789–792.

2017 Niki E, Noguchi N and Gotoh N, 1993. Dynamics of lipid peroxidation and its inhibition by
2018 antioxidants. Biochemical Society Transactions, 21, 313-317.

2019 Niki E, 2014. Role of vitamin E as a lipid-soluble peroxyl radical scavenger: in vitro and in vivo
2020 evidence. Free Radical Biology and Medicine, 66, 3-12.

2021 Nissen SB, Tjonneland A, Stripp C, Olsen A, Christensen J, Overvad K, Dragsted LO and Thomsen
2022 B, 2003. Intake of vitamins A, C, and E from diet and supplements and breast cancer in
2023 postmenopausal women. Cancer Causes & Control, 14, 695-704.

2024 No authors listed, 1994. The effect of vitamin E and beta carotene on the incidence of lung cancer and
2025 other cancers in male smokers. The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study
2026 Group. New England Journal of Medicine, 330, 1029-1035.

2027 Nordic Council of Ministers, 2014. Nordic Nutrition Recommendations 2012. Integrating nutrition
2028 and physical activity. Nordic Council of Ministers, Copenhagen, Denmark, 627 pp.

2029 Novotny JA, Fadel JG, Holstege DM, Furr HC and Clifford AJ, 2012. This kinetic, bioavailability,
2030 and metabolism study of RRR-alpha-tocopherol in healthy adults suggests lower intake
2031 requirements than previous estimates. Journal of Nutrition, 142, 2105-2111.

2032 NRC (National Research Council), 1989. Recommended dietary allowances. Subcommittee on the
2033 Tenth Edition of the Recommended Dietary Allowances, Food and Nutrition Board, Commission
2034 on Life Sciences. National Academy Press, Washington, D.C., USA, 277 pp.

2035 Ocke MC, Bueno-de-Mesquita HB, Feskens EJ, van Staveren WA and Kromhout D, 1997. Repeated
2036 measurements of vegetables, fruits, beta-carotene, and vitamins C and E in relation to lung cancer.
2037 The Zutphen Study. American Journal of Epidemiology, 145, 358-365.

2038 Orhon FS, Ulukol B, Kahya D, Cengiz B, Baskan S and Tezcan S, 2009. The influence of maternal
2039 smoking on maternal and newborn oxidant and antioxidant status. European Journal of Pediatrics,
2040 168, 975-981.

2041 Ouahchi K, Arita M, Kayden H, Hentati F, Ben Hamida M, Sokol R, Arai H, Inoue K, Mandel JL and
2042 Koenig M, 1995. Ataxia with isolated vitamin E deficiency is caused by mutations in the alpha-
2043 tocopherol transfer protein. Nature Genetics, 9, 141-145.

2044 Packer JE, Slater TF and Willson RL, 1979. Direct observation of a free radical interaction between
2045 vitamin E and vitamin C. Nature, 278, 737-738.

2046 Parker RS, 1988. Carotenoid and tocopherol composition of human adipose tissue. American Journal
2047 of Clinical Nutrition, 47, 33-36.

2048 Piironen V, Varo P, Syvaoja EL, Salminen K, Koivistoinen P and Arvilommi H, 1984. High-
2049 performance liquid chromatographic determination of tocopherols and tocotrienols and its
2050 application to diets and plasma of Finnish men. II. Applications. International Journal for Vitamin
2051 and Nutrition Research, 54, 41-46.

2052 Pope SA, Burtin GE, Clayton PT, Madge DJ and Muller DP, 2002. Synthesis and analysis of
2053 conjugates of the major vitamin E metabolite, alpha-CEHC. Free Radical Biology and Medicine,
2054 33, 807-817.

2055 Pressman EK, Cavanaugh JL, Mingione M, Norkus EP and Woods JR, 2003. Effects of maternal
2056 antioxidant supplementation on maternal and fetal antioxidant levels: A randomized, double-blind
2057 study. American Journal of Obstetrics and Gynecology, 189, 1720-1725.

2058 Preziosi P, Galan P, Herbeth B, Valeix P, Roussel AM, Malvy D, Paul-Dauphin A, Arnaud J, Richard
2059 MJ, Briancon S, Favier A and Hercberg S, 1998. Effects of supplementation with a combination of
2060 antioxidant vitamins and trace elements, at nutritional doses, on biochemical indicators and
2061 markers of the antioxidant system in adult subjects. Journal of the American College of Nutrition,
2062 17, 244-249.

2063 Quiles JL, Ochoa JJ, Ramirez-Tortosa MC, Linde J, Bompadre S, Battino M, Narbona E, Maldonado
2064 J and Mataix J, 2006. Coenzyme Q concentration and total antioxidant capacity of human milk at
2065 different stages of lactation in mothers of preterm and full-term infants. Free Radical Research, 40,
2066 199-206.

2067 Rautalahti MT, Virtamo JR, Taylor PR, Heinonen OP, Albanes D, Haukka JK, Edwards BK,
2068 Karkkainen PA, Stolzenberg-Solomon RZ and Huttunen J, 1999. The effects of supplementation
2069 with alpha-tocopherol and beta-carotene on the incidence and mortality of carcinoma of the
2070 pancreas in a randomized, controlled trial. Cancer, 86, 37-42.

2071 Reboul E, Trompier D, Moussa M, Klein A, Landrier JF, Chimini G and Borel P, 2009. ATP-binding
2072 cassette transporter A1 is significantly involved in the intestinal absorption of alpha- and gamma-
2073 tocopherol but not in that of retinyl palmitate in mice. American Journal of Clinical Nutrition, 89,
2074 177-184.

2075 Reboul E, Soayfane Z, Goncalves A, Cantiello M, Bott R, Nauze M, Tercé F, Collet X and Coméra C,
2076 2011. Respective contributions of intestinal Niemann-Pick C1-like 1 and scavenger receptor class
2077 B type I to cholesterol and tocopherol uptake: in vivo v. in vitro studies. British Journal of
2078 Nutrition, 20, 1-9.

2079 Refat M, Moore TJ, Kazui M, Risby TH, Perman JA and Schwarz KB, 1991. Utility of breath ethane
2080 as a noninvasive biomarker of vitamin E status in children. Pediatric Research, 30, 396-403.

2081 Riboli E, Gonzalez CA, Lopez-Abente G, Errezola M, Izarzugaza I, Escolar A, Nebot M, Hemon B
2082 and Agudo A, 1991. Diet and bladder cancer in Spain: a multi-centre case-control study.
2083 International Journal of Cancer, 49, 214-219.

2084 Richardson PD and Steiner M, 1993. Adhesion of human platelets inhibited by vitamin E. In: Vitamin
2085 E in Health and Disease. Eds Packer L and Fuchs J. Marcel-Dekker, New York, USA, pp. 297-311.

2086 Rigotti A, 2007. Absorption, transport, and tissue delivery of vitamin E. Molecular Aspects of
2087 Medicine, 28, 423-436.

2088 Roberts LJ, Oates JA, Linton MF, Fazio S, Meador BP, Gross MD, Shyr Y and Morrow JD, 2007.
2089 The relationship between dose of vitamin E and suppression of oxidative stress in humans. Free
2090 Radical Biology and Medicine, 43, 1388-1393.

Roe MA, Bell S, Oseredczuk M, Christensen T, Westenbrink S, Pakkala H, Presser K and Finglas PM, 2013. Updated food composition database for nutrient intake. Supporting Publications 2013:EN-355, 21 pp.

Romeu-Nadal M, Morera-Pons S, Castellote AI and Lopez-Sabater MC, 2006. Determination of gamma- and alpha-tocopherols in human milk by a direct high-performance liquid chromatographic method with UV-vis detection and comparison with evaporative light scattering detection. Journal of Chromatography A, 1114, 132-137.

Romeu-Nadal M, Castellote AI, Gaya A and Lopez-Sabater MC, 2008a. Effect of pasteurisation on ascorbic acid, dehydroascorbic acid, tocopherols and fatty acids in pooled mature human milk. Food Chemistry, 107, 434-438.

Romeu-Nadal M, Castellote AI and Lopez-Sabater MC, 2008b. Effect of cold storage on vitamins C and E and fatty acids in human milk. Food Chemistry, 106, 65-70.

Rotzoll DE, Scherling R, Etzl R, Stepan H, Horn LC and Poschl JM, 2008. Immunohistochemical localization of alpha-tocopherol transfer protein and lipoperoxidation products in human first-trimester and term placenta. European Journal of Obstetrics, Gynecology, and Reproductive Biology, 140, 183-191.

Satia-Abouta J, Galanko JA, Martin CF, Potter JD, Ammerman A and Sandler RS, 2003. Associations of micronutrients with colon cancer risk in African Americans and whites: results from the North Carolina Colon Cancer Study. Cancer Epidemiology, Biomarkers & Prevention, 12, 747-754.

SCF (Scientific Committee on Food), 1993. Nutrient and energy intakes for the European Community. Reports of the Scientific Committee for Food, 31st Series. Food - Science and Technique, European Commission, Luxembourg, 248 pp.

SCF (Scientific Committee on Food), 1997. Reports of the Scientific Committee for Food, 39th Series. Food - Science and Technique, European Commission, Luxembourg, 78 pp.

SCF (Scientific Committee on Food), 2003. Opinion of the Scientific Committee on Food on the Tolerable Upper Intake Levels of vitamin E. SCF/CS/NUT/UPPLEV/39 Final, 10 pp.

Schaefer EJ, Woo R, Kibata M, Bjornsen L and Schreibman PH, 1983. Mobilization of triglyceride but not cholesterol or tocopherol from human adipocytes during weight reduction. American Journal of Clinical Nutrition, 37, 749-754.

Schuelke M, Elsner A, Finckh B, Kohlschutter A, Hubner C and Brigelius-Flohe R, 2000. Urinary alpha-tocopherol metabolites in alpha-tocopherol transfer protein-deficient patients. Journal of Lipid Research, 41, 1543-1551.

Schultz M, Leist M, Petrzika M, Gassmann B and Brigelius-Flohe R, 1995. Novel urinary metabolite of alpha-tocopherol, 2,5,7,8-tetramethyl-2(2'-carboxyethyl)-6-hydroxychroman, as an indicator of an adequate vitamin E supply? American Journal of Clinical Nutrition, 62, 1527S-1534S.

Schweigert FJ, Bathe K, Chen F, Buscher U and Dudenhausen JW, 2004. Effect of the stage of lactation in humans on carotenoid levels in milk, blood plasma and plasma lipoprotein fractions. European Journal of Nutrition, 43, 39-44.

Sette S, Le Donne C, Piccinelli R, Arcella D, Turrini A and Leclercq C, 2010. The third Italian National Food Consumption Survey, INRAN-SCAI 2005-06 - Part 1: Nutrient intakes in Italy. Nutrition, Metabolism and Cardiovascular Diseases, 1-11.

Shargorodsky J, Curhan SG, Eavey R and Curhan GC, 2010. A prospective study of vitamin intake and the risk of hearing loss in men. Otolaryngology - Head & Neck Surgery, 142, 231-236.

Shichiri M, Takanezawa Y, Rotzoll DE, Yoshida Y, Kokubu T, Ueda K, Tamai H and Arai H, 2010. ATP-binding cassette transporter A1 is involved in hepatic alpha-tocopherol secretion. The Journal of Nutritional Biochemistry, 21, 451-456.

2137 Signorello LB, Buchowski MS, Cai Q, Munro HM, Hargreaves MK and Blot WJ, 2010. Biochemical
2138 validation of food frequency questionnaire-estimated carotenoid, alpha-tocopherol, and folate
2139 intakes among African Americans and non-Hispanic Whites in the Southern Community Cohort
2140 Study. American Journal of Epidemiology, 171, 488-497.

2141 Slattery ML, Edwards SL, Anderson K and Caan B, 1998. Vitamin E and colon cancer: is there an
2142 association? Nutrition & Cancer, 30, 201-206.

2143 Song Y, Xu Q, Park Y, Hollenbeck A, Schatzkin A and Chen H, 2011. Multivitamins, individual
2144 vitamin and mineral supplements, and risk of diabetes among older U.S. adults. Diabetes Care, 34,
2145 108-114.

2146 Sontag TJ and Parker RS, 2002. Cytochrome P450 omega-hydroxylase pathway of tocopherol
2147 catabolism. Novel mechanism of regulation of vitamin E status. Journal of Biological Chemistry,
2148 277, 25290-25296.

2149 Sontag TJ and Parker RS, 2007. Influence of major structural features of tocopherols and tocotrienols
2150 on their omega-oxidation by tocopherol-omega-hydroxylase. Journal of Lipid Research, 48, 1090-
2151 1098.

2152 Stamp GW and Evans DJ, 1987. Accumulation of ceroid in smooth muscle indicates severe
2153 malabsorption and vitamin E deficiency. Journal of Clinical Pathology, 40, 798-802.

2154 Stocker A and Azzi A, 2000. Tocopherol-binding proteins: their function and physiological
2155 significance. Antioxidants and Redox Signalling, 2, 397-404.

2156 Su LC, Bui M, Kardinaal A, Gomez-Aracena J, Martin-Moreno J, Martin B, Thamm M, Simonsen N,
2157 van't Veer P, Kok F, Strain S and Kohlmeier L, 1998. Differences between plasma and adipose
2158 tissue biomarkers of carotenoids and tocopherols. Cancer Epidemiology, Biomarkers and
2159 Prevention, 7, 1043-1048.

2160 Sziklai-Laszlo I, Majchrzak D, Elmadfa I and Cser MA, 2009. Selenium and vitamin e concentrations
2161 in human milk and formula milk from Hungary. Journal of Radioanalytical and Nuclear Chemistry,
2162 279, 585-590.

2163 Takahashi Y, Shitara H, Uruno K and Kimura S, 1978. Vitamin E and lipoprotein levels in the sera of
2164 pregnant women. Journal of Nutritional Science and Vitaminology, 24, 471-476.

2165 Tijerina-Saenz A, Innis SM and Kitts DD, 2009. Antioxidant capacity of human milk and its
2166 association with vitamins A and E and fatty acid composition. Acta Paediatrica, 98, 1793-1798.

2167 Tokusoglu O, Tansug N, Aksit S, Dinc G, Kasirga E and Ozcan C, 2008. Retinol and (alpha)-
2168 tocopherol concentrations in breast milk of Turkish lactating mothers under different socio-
2169 economic status. International Journal of Food Sciences and Nutrition, 59, 166-174.

2170 Tomten SE and Hostmark AT, 2009. Serum vitamin E concentration and osmotic fragility in female
2171 long-distance runners. Journal of Sports Sciences, 27, 69-76.

2172 Tornwall M, Virtamo J, Haukka JK, Aro A, Albanes D, Edwards BK and Huttunen JK, 1997. Effect
2173 of alpha-tocopherol (vitamin E) and beta-carotene supplementation on the incidence of intermittent
2174 claudication in male smokers. Arteriosclerosis, Thrombosis & Vascular Biology, 17, 3475-3480.

2175 Tornwall ME, Virtamo J, Haukka JK, Aro A, Albanes D and Huttunen JK, 1999. The effect of alpha-
2176 tocopherol and beta-carotene supplementation on symptoms and progression of intermittent
2177 claudication in a controlled trial. Atherosclerosis, 147, 193-197.

2178 Tornwall ME, Virtamo J, Haukka JK, Albanes D and Huttunen JK, 2001. Alpha-tocopherol (vitamin
2179 E) and beta-carotene supplementation does not affect the risk for large abdominal aortic aneurysm
2180 in a controlled trial. Atherosclerosis, 157, 167-173.

2181 Tornwall ME, Virtamo J, Korhonen PA, Virtanen MJ, Taylor PR, Albanes D and Huttunen JK,
2182 2004a. Effect of alpha-tocopherol and beta-carotene supplementation on coronary heart disease
2183 during the 6-year post-trial follow-up in the ATBC study. European Heart Journal, 25, 1171-1178.

2184 Tornwall ME, Virtamo J, Korhonen PA, Virtanen MJ, Albanes D and Huttunen JK, 2004b.
2185 Postintervention effect of alpha tocopherol and beta carotene on different strokes: a 6-year follow-
2186 up of the Alpha Tocopherol, Beta Carotene Cancer Prevention Study. Stroke, 35, 1908-1913.

2187 Traber MG and Kayden HJ, 1984. Vitamin E is delivered to cells via the high affinity receptor for
2188 low-density lipoprotein. American Journal of Clinical Nutrition, 40, 747-751.

2189 Traber MG and Kayden HJ, 1987. Tocopherol distribution and intracellular localization in human
2190 adipose tissue. American Journal of Clinical Nutrition, 46, 488-495.

2191 Traber MG and Kayden HJ, 1989. Preferential incorporation of alpha-tocopherol vs gamma-
2192 tocopherol in human lipoproteins. American Journal of Clinical Nutrition, 49, 517-526.

2193 Traber MG, Burton GW, Ingold KU and Kayden HJ, 1990. RRR- and SRR-alpha-tocopherols are
2194 secreted without discrimination in human chylomicrons, but RRR-alpha-tocopherol is
2195 preferentially secreted in very low density lipoproteins. Journal of Lipid Research, 31, 675-685.

2196 Traber MG, Burton GW, Hughes L, Ingold KU, Hidaka H, Malloy M, Kane J, Hyams J and Kayden
2197 HJ, 1992. Discrimination between forms of vitamin E by humans with and without genetic
2198 abnormalities of lipoprotein metabolism. Journal of Lipid Research, 33, 1171-1182.

2199 Traber MG, Ramakrishnan R and Kayden HJ, 1994. Human plasma vitamin E kinetics demonstrate
2200 rapid recycling of plasma RRR-alpha-tocopherol. Proceedings of the National Academy of
2201 Sciences of the United States of America, 91, 10005-10008.

2202 Traber MG and Atkinson J, 2007. Vitamin E, antioxidant and nothing more. Free Radical Biology and
2203 Medicine, 43, 4-15.

2204 Traber MG, 2007. Vitamin E regulatory mechanisms. Annual Review of Nutrition, 27, 347-362.

2205 Traber MG, 2013. Mechanisms for the prevention of vitamin E excess. Journal of Lipid Research, 54,
2206 2295-2306.

2207 Ulatowski L, Dreussi C, Noy N, Barnholtz-Sloan J, Klein E and Manor D, 2012. Expression of the
2208 alpha-tocopherol transfer protein gene is regulated by oxidative stress and common single-
2209 nucleotide polymorphisms. Free Radical Biology and Medicine, 53, 2318-2326.

2210 USP (The United States Pharmacopeia), 1979. The United States Pharmacopeia. National Formulary.
2211 United States Pharmacopeial Convention.

2212 USP (The United States Pharmacopeia), 1980. The United States Pharmacopeia. National Formulary.
2213 United States Pharmacopeial Convention.

2214 Valk EE and Hornstra G, 2000. Relationship between vitamin E requirement and polyunsaturated
2215 fatty acid intake in man: a review. International Journal for Vitamin and Nutrition Research, 70,
2216 31-42.

2217 Valtuena J, Breidenassel C, Folle J and Gonzalez-Gross M, 2011. Retinol, beta-carotene, alpha-
2218 tocopherol and vitamin D status in European adolescents; regional differences an variability: a
2219 review. Nutricion Hospitalaria, 26, 280-288.

2220 van Rossum CTM, Fransen HP, Verkaik-Kloosterman J, Buurma-Rethans EJM and Ocké MC, 2011.
2221 Dutch National Food Consumption Survey 2007-2010: Diet of children and adults aged 7 to 69
2222 years. RIVM Report number: 350050006/2011, National Institute for Public Health and the
2223 Environment, Bilthoven, 143 pp.

Van Zoeren-Grobben D, Schrijver J, Van den Berg H and Berger HM, 1987. Human milk vitamin content after pasteurisation, storage, or tube feeding. Archives of Disease in Childhood, 62, 161-165.

Wallstrom P, Wirfalt E, Lahmann PH, Gullberg B, Janzon L and Berglund G, 2001. Serum concentrations of beta-carotene and alpha-tocopherol are associated with diet, smoking, and general and central adiposity. American Journal of Clinical Nutrition, 73, 777-785.

Wang L, Sesso HD, Glynn RJ, Christen WG, Bubes V, Manson JE, Buring JE and Gaziano JM, 2014. Vitamin E and C supplementation and risk of cancer in men: posttrial follow-up in the Physicians' Health Study II randomized trial. American Journal of Clinical Nutrition, 100, 915-923.

Wang X and Quinn PJ, 1999. Vitamin E and its function in membranes. Progress in Lipid Research, 38, 309-336.

WCRF/AICR (World Cancer Research Fund/American Institute for Cancer Research), 2007. Food, Nutrition, Physical Activity, and the Prevention of Cancer: a Global Perspective. 517 pp.

Weiser H and Vecchi M, 1982. Stereoisomers of alpha-tocopheryl acetate. 2. Biopotencies of all 8 Stereoisomers, individually or in mixtures, as determined by rat resorption-gestation tests. International Journal for Vitamin and Nutrition Research, 52, 351-370.

WHO Multicentre Growth Reference Study Group (World Health Organization), 2006. WHO Child Growth Standards: Length/height-for-age, weight-for-age, weight-for-length, weight-for-height and body mass index-for-age: Methods and development. 312 pp.

WHO/FAO (World Health Organization/Food and Agriculture Organization), 2004. Vitamin and mineral requirements in human nutrition: report of a joint FAO/WHO expert consultation, Bangkok, Thailand, 21–30 September 1998. Geneva, 341 pp.

Witting LA and Horwitt MK, 1964. Effect of degree of fatty acid unsaturation in tocopherol deficiency-induced creatinuria. Journal of Nutrition, 82, 19-33.

Witting LA and Lee L, 1975. Dietary levels of vitamin E and polyunsaturated fatty acids and plasma vitamin E. American Journal of Clinical Nutrition, 28, 571-576.

Wright ME, Lawson KA, Weinstein SJ, Pietinen P, Taylor PR, Virtamo J and Albanes D, 2006. Higher baseline serum concentrations of vitamin E are associated with lower total and cause-specific mortality in the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study. American Journal of Clinical Nutrition, 84, 1200-1207.

Wright ME, Weinstein SJ, Lawson KA, Albanes D, Subar AF, Dixon LB, Mouw T, Schatzkin A and Leitzmann MF, 2007. Supplemental and dietary vitamin E intakes and risk of prostate cancer in a large prospective study. Cancer Epidemiology, Biomarkers & Prevention, 16, 1128-1135.

Wu JH and Croft KD, 2007. Vitamin E metabolism. Molecular Aspects of Medicine, 28, 437-452.

Wu K, Willett WC, Chan JM, Fuchs CS, Colditz GA, Rimm EB and Giovannucci EL, 2002. A prospective study on supplemental vitamin e intake and risk of colon cancer in women and men. Cancer Epidemiology, Biomarkers & Prevention, 11, 1298-1304.

Xu WH, Dai Q, Xiang YB, Zhao GM, Ruan ZX, Cheng JR, Zheng W and Shu XO, 2007. Nutritional factors in relation to endometrial cancer: a report from a population-based case-control study in Shanghai, China. International Journal of Cancer, 120, 1776-1781.

Yamauchi R, 2007. Addition products of alpha-tocopherol with lipid-derived free radicals. Vitamins and Hormones, 76, 309-327.

Yang M, Wang Y, Davis CG, Lee SG, Fernandez ML, Koo SI, Cho E, Song WO and Chun OK, 2014a. Validation of an FFQ to assess short-term antioxidant intake against 30 d food records and plasma biomarkers. Public Health Nutrition, 17, 297-306.

Yang M, Wang Y, Davis CG, Lee SG, Fernandez ML, Koo SI, Cho E and Chun OK, 2014b. Validation of an FFQ to assess antioxidant intake in overweight postmenopausal women. Public Health Nutrition, 17, 1467-1475.

Ylonen K, Alfthan G, Groop L, Saloranta C, Aro A and Virtanen SM, 2003. Dietary intakes and plasma concentrations of carotenoids and tocopherols in relation to glucose metabolism in subjects at high risk of type 2 diabetes: the Botnia Dietary Study. American Journal of Clinical Nutrition, 77, 1434-1441.

Yochum LA, Folsom AR and Kushi LH, 2000. Intake of antioxidant vitamins and risk of death from stroke in postmenopausal women. American Journal of Clinical Nutrition, 72, 476-483.

Yuan JM, Wang QS, Ross RK, Henderson BE and Yu MC, 1995. Diet and breast cancer in Shanghai and Tianjin, China. British Journal of Cancer, 71, 1353-1358.

Zamel R, Khan R, Pollex RL and Hegele RA, 2008. Abetalipoproteinemia: two case reports and literature review. Orphanet Journal of Rare Diseases, 3, 19.

Zhang J, Munger RG, West NA, Cutler DR, Wengreen HJ and Corcoran CD, 2006. Antioxidant intake and risk of osteoporotic hip fracture in Utah: an effect modified by smoking status. American Journal of Epidemiology, 163, 9-17.

Zhao Y, Lee MJ, Cheung C, Ju JH, Chen YK, Liu B, Hu LQ and Yang CS, 2010. Analysis of multiple metabolites of tocopherols and tocotrienols in mice and humans. Journal of Agricultural and Food Chemistry, 58, 4844-4852.

Zingg JM, Azzi A and Meydani M, 2008. Genetic polymorphisms as determinants for disease-preventive effects of vitamin E. Nutrition Reviews, 66, 406-414.

APPENDICES

Appendix A. Concentrations of α-tocopherol in breast milk of healthy mothers

Reference	n (number of samples)	Country	Maternal dietary intake (mg/day)	Stage of lactation	Alpha-tocopherol concentration in breast milk (mg/L)			Analytical method	Comments
			mean ± SD		mean ± SD	median	range		
Antonakou et al. (2011)	64(64)	Greece	7.2 ± 3.7 ('vitamin E')	1 month post partum	α-tocopherol 3.6 ± 1.5		1.3–9.5	HPLC (with UV and fluorescent detectors)	Three-day food record (1st, 3rd, 6th months post partum). Full-term infants. Mothers not supplemented with 'vitamin E' during pregnancy or post partum.
	39(39)		6.8 ± 3.5 ('vitamin E')	3 months post partum	α-tocopherol 3.5 ± 1.8		1.1–8.2		
	23(23)		10.9 ± 5.2 ('vitamin E')	6 months post partum	α-tocopherol 3.7 ± 2.0		1.0–9.2		
Duda et al. (2009)	30	Poland	7.7 ± 3.4 ('vitamin E')	Mature milk (~96 % of the women investigated were breast feeding for 2.5 months (average), during a period ranging from 1 to 12 months)	α-tocopherol 4.11 ± 3.48	3.48 3.55	1.52–9.47 1.21–9.87	HPLC (fluorescent detection)	24 h recalls (three consecutive days). No information on whether infants were born at term or not, and on possible maternal supplementation with 'vitamin E'. Exact stage of lactation not reported.
Kasparova et al. (2012)	12(12)	Czech Republic	Not reported	1–2 months post partum	α-tocopherol 3.96 ± 1.42			HPLC (diode array detector)	27 breastfeeding women were selected for the study. No information about the health of mothers, on whether infants were born at term or not, or on possible maternal supplementation with 'vitamin E'.
				3–4 months post partum	α-tocopherol 3.75 ± 1.68				
				5–6 months post partum	α-tocopherol 3.62 ± 1.51				
				9–12 months post partum	α-tocopherol 4.01 ± 1.34				

Reference	n (number of samples)	Country	Maternal dietary intake (mg/day)	Stage of lactation	Alpha-tocopherol concentration in breast milk (mg/L)			Analytical method	Comments
			mean ± SD		mean ± SD	median	range		
Martysiak-Zurowska et al. (2013)	48(93)	Poland	14.9 ± 8.3 (α-TE)					NP-HPLC (UV detector)	Three-day diary.
	(17)		Not reported	2 days post partum	α-tocopherol 9.99 ± 1.51		7.18–12.13		A woman could provide more than one milk sample at different stages of lactation.
	(30)		Food 8.20 ± 3.40 (α-TE) Supplementation 7.32 ± 8.34 (α-TE) (51.7 % women under vitamin supplementation at this stage of lactation)	14th day post partum	α-tocopherol 4.45 ± 0.95		2.23–6.47		No information on whether infants were born at term or not.
	(27)		Food 8.41 ± 3.38 (α-TE) Supplementation 6.69 ± 7.19 (α-TE) (51.9 % women under vitamin supplementation at this stage of lactation)	30th day post partum	α-tocopherol 2.92 ± 0.84		1.71–4.28		
	(19)		Food 9.33 ± 3.80 (α-TE) Supplementation 7.62 ± 3.02 (α-TE) (38.9 % women	90th day post partum	α-tocopherol 2.07 ± 0.66		0.94–2.80		

Reference	n (number of samples)	Country	Maternal dietary intake (mg/day)	Stage of lactation	Alpha-tocopherol concentration in breast milk (mg/L)			Analytical method	Comments
			mean ± SD		mean ± SD	median	range		
			under vitamin supplementation at this stage of lactation)						
Molto-Puigmarti et al. (2009)	10(10) 10(10)	Spain	Not reported	Colostrum Mature milk	α-tocopherol 37.84 ± 24.52 α-tocopherol 3.39 ± 2.12			UHPLC (PDA detector)	No information on whether infants were born at term or not and on possible maternal supplementation with 'vitamin E'. The exact stage of lactation was not reported.
Molto-Puigmarti et al. (2011)[)]	10	Spain	Not reported	Mature milk	α-tocopherol 7.17 ± 2.60			UHPLC (fluorescent detector)	The aim of the study was to investigate the effect of pasteurisation (heat treatment) on the concentration of vitamins in human milk. The values presented here are for milk untreated with heat. No information on whether infants were born at term or not and on possible maternal supplementation with 'vitamin E'. The exact stage of lactation was not reported.
Orhon et al. (2009)	40 20 non-smoking mothers	Turkey	Not reported	7 days post partum	α-tocopherol 13.3 ± 0.7 (SEM)			HPLC	Full-term infants (mean gestational age: 38.8 weeks in both groups). No information on possible maternal supplementation with 'vitamin E'. Data on smoking mothers are also reported in the study. Plasma α-tocopherol reported.

Reference	n (number of samples)	Country	Maternal dietary intake (mg/day)	Stage of lactation	Alpha-tocopherol concentration in breast milk (mg/L)			Analytical method	Comments
			mean ± SD		mean ± SD	median	range		
Quiles et al. (2006)	15	Spain	'Vitamin E' 6.1 ± 0.9	3 days post partum 8 days post partum 30 days post partum	α-tocopherol ~ 25 α-tocopherol ~ 16 α-tocopherol ~ 9			HPLC-EC	The aim of the study was to determine coenzyme Q10 concentration in breast milk. Four-day dietary records were collected. The article did not provide the exact figures of α-tocopherol concentration in breast milk, thus the values presented here were determined graphically. Full-term infants. No information on possible maternal supplementation with 'vitamin E'.
Romeu-Nadal et al. (2006)	Not reported	Spain	Not reported	Mature milk	α-tocopherol 4.7 ± 0.2 α-tocopherol 3.7 ± 0.2 α-tocopherol 3.7 ± 0.2			HPLC (UV detector) HPLC (UV detector, with saponification) HPLC-evaporative light scattening detection (with saponification)	The aim of the study was to compare the sensibility of methods of detection of α- and γ-tocopherols in human milk: UV detection and evaporating light scattering detection Full-term infants. The exact stage of lactation was not reported No information on possible maternal supplementation with 'vitamin E'.
Romeu-Nadal et al. (2008a)[j]	10(20)	Spain	Not reported	Mature milk	α-tocopherol 4.41 ± 0.16			HPLC (UV-visible detector)	The aim of the study was to investigate the effects of pasteurisation on human milk composition. The values presented here are for

Reference	n (number of samples)	Country	Maternal dietary intake (mg/day)	Stage of lactation	Alpha-tocopherol concentration in breast milk (mg/L)			Analytical method	Comments
			mean ± SD		mean ± SD	median	range		
									unpasteurised milk. Milk samples were pooled, divided in six groups containing each 10 aliquots. No information on whether infants were born at term or not and on possible maternal supplementation with 'vitamin E'.
Romeu-Nadal et al. (2008b)	5(10)	Not reported	Not reported	Mature milk	α-tocopherol 3.85 ± 0.16			RP-HPLC (UV detector)	The aim of the study was to investigate the effect of cold storage and time of storage on human milk composition. The values presented here are for fresh milk samples. Milk samples from five mothers were pooled and divided into 10 aliquots each. No information on whether infants were born at term or not and on possible maternal supplementation with 'vitamin E'.
Schweigert et al. (2004)	21	Germany	Not reported. 'Women on regular diet without supplements'	4 days post partum 19 days post partum	α-tocopherol 22.0 ± 13.4 α-tocopherol 5.7 ± 2.2			HPLC	Plasma α-tocopherol was determined at two days post partum: 42.3 ± 5.8 µmol/L and at 19 days post partum: 36.4 ± 7.2 µmol/L (mean ± SD). Full-term infants.

Reference	n (number of samples)	Country	Maternal dietary intake (mg/day)	Stage of lactation	Alpha-tocopherol concentration in breast milk (mg/L)			Analytical method	Comments
			mean ± SD		mean ± SD	median	range		
Sziklai-Laszlo et al. (2009)	12(12)	Hungary	Not reported	5-10 days post partum	α-tocopherol 4.1 ± 2.2	4.3	1.3–6.6	HPLC (UV/visible detector)	30 women participated in the study. Full-term infants.
	18(18)			14-280 days post partum	α-tocopherol 3.0 ± 1.2	2.8	1.8–5.0		No information on possible maternal supplementation with 'vitamin E'.
Tokusoglu et al. (2008)	92(92)	Turkey	Not reported	60-90 days post partum	α-tocopherol 9.8 ± 2.1			HPLC (UV detector)	Food frequency questionnaire completed by the mothers but α-tocopherol or 'vitamin E' intakes were not reported. Full-term infants. No use of α-tocopherol supplements.

Molecular mass of α-tocopherol = 430.71 Da.

HPLC-EC: High Performance Liquid Chromatography - ElectroChemical detection; NP-HPLC: normal-phase HPLC; PDA: Photodiode Array; RP-HPLC: Reversed-phase HPLC; SD: Standard Deviation; SEM: Standard Error of the Mean; α-TE: α-tocopherol equivalent; UV: Ultra-violet; UHPLC: Ultra-High Performance Liquid Chromatography.

NB:

- Studies explicitly and only dealing with breast milk composition of mothers of preterm infants identified through the comprehensive literature search (LASER Analytica, 2014) are not presented in this appendix table.
- Studies undertaken in non-European countries are not presented in this appendix table: Barkova et al. (2005); Kodentsova and Vrzhesinskaya (2006); de Lira et al. (2012), Tijerina-Saenz et al. (2009).

Appendix B. Dietary surveys in the EFSA Comprehensive European Food Consumption Database included in the nutrient intake calculation for α-tocopherol and α-tocopherol equivalents

Country	Dietary survey (Year)	Year	Method	Days	Age (years)	Number of subjects						
						Infants[a] < 1 year	Children 1–< 3 years	Children 3–< 10 years	Children 10–< 18 years	Adults 18–< 65 years	Adults 65–< 75 years	Adults ≥ 75 years
Finland/1	DIPP	2000–2010	Dietary record	3	< 1–6	499	500	750				
Finland/2	NWSSP	2007–2008	48-hour dietary recall[b]	2x2[b]	13–15				306			
Finland/3	FINDIET2012	2012	48-hour dietary recall[b]	2[b]	25–74					1295	413	
France	INCA2	2006–2007	Dietary record	7	3–79			482	973	2 276	264	84
Germany/1	EsKiMo	2006	Dietary record	3	6–11			835	393			
Germany/2	VELS	2001–2002	Dietary record	6	< 1–4	158	347	299				
Ireland	NANS	2008–2010	Dietary record	4	18–90					1274	149	77
Italy	INRAN-SCAI 2005-06	2005–2006	Dietary record	3	< 1–98	16 [c]	36[c]	193	247	2313	290	228
Latvia	FC_PREGNANTWOMEN 2011	2011	24-hour dietary recall	2	15–45				12[c]	991[d]		
Netherlands	DNFCS	2007–2010	24-hour dietary recall	2	7–69			447	1142	2 057	173	
Sweden	RISKMATEN	2010–2011	Dietary record (Web)[e]	4	18–80					1 430	295	72
United Kingdom/1	DNSIYC	2011	Dietary record	4	0.3–1.5	1 369	1 314					
United Kingdom/2	NDNS - Rolling Programme (Years 1–3 years)	2008–2011	Dietary record	4	1–94		185	651	666	1 266	166	139

DIPP, type 1 Diabetes Prediction and Prevention survey; DNFCS, Dutch National Food Consumption Survey; DNSIYC, Diet and Nutrition Survey of Infants and Young Children; EsKiMo, Ernährungsstudie als KIGGS-Modul; FINDIET, the national dietary survey of Finland; INCA, étude Individuelle Nationale des Consommations Alimentaires; INRAN-SCAI, Istituto Nazionale di Ricerca per gli Alimenti e la Nutrizione - Studio sui Consumi Alimentari in Italia; FC_PREGNANTWOMEN, food consumption of pregnant women in Latvia; NANS, National Adult Nutrition Survey; NDNS, National Diet and Nutrition Survey; NWSSP, Nutrition and Wellbeing of Secondary School Pupils; VELS, Verzehrsstudie zur Ermittlung der Lebensmittelaufnahme von Säuglingen und Kleinkindern für die Abschätzung eines akuten Toxizitätsrisikos durch Rückstände von Pflanzenschutzmitteln.

(a): Infants 1-11 months of age.

(b): A 48-hour dietary recall comprising two consecutive days.

(c): 5^{th} or 95^{th} percentile intakes calculated from fewer than 60 subjects require cautious interpretation as the results may not be statistically robust (EFSA, 2011b) and, therefore, for these dietary surveys/age classes, the 5^{th} and 95^{th} percentile estimates are not presented in the intake results.

(d): One subject was excluded from the dataset due to the fact that only one 24-hour dietary recall day was available, i.e. the final n = 990.

(e): The Swedish dietary records were introduced through the Internet.

Appendix C. Intakes of α-tocopherol (mg/day and mg/MJ) in males in different surveys, according to age class and country, based on Finnish and Swedish α-tocopherol composition data

Age class	Country	Survey	Intakes expressed in mg/day					Intakes expressed in mg/MJ				
			N[a]	Average	Median	P5	P95	N[a]	Average	Median	P5	P95
< 1 year [b]	Finland	DIPP_2001_2009	247	3.2	3.1	0.4	6.4	245	1.5	1.5	0.8	2.1
	Germany	VELS	84	4.5	4.3	2.2	7.2	84	1.4	1.3	0.7	2.5
	Italy	INRAN_SCAI_2005_06	9	4.9	5.3	[c]	[c]	9	1.7	1.7	[c]	[c]
	United Kingdom	DNSIYC_2011	699	5.4	5.3	3.4	7.8	699	1.6	1.6	1.1	2.1
1 to < 3 years	Finland	DIPP_2001_2009	245	4.4	4.2	2.1	7.1	245	1.2	1.2	0.7	1.8
	Germany	VELS	174	4.9	4.5	2.3	8.8	174	1.0	1.0	0.6	1.7
	Italy	INRAN_SCAI_2005_06	20	5.7	5.0	[c]	[c]	20	1.1	1.1	[c]	[c]
	United Kingdom	DNSIYC_2011	663	4.4	4.2	2.2	7.3	663	1.1	1.0	0.6	1.7
	United Kingdom	NDNS – Rolling Programme Years 1–3	107	5.4	4.9	2.7	9.4	107	1.1	1.1	0.6	1.7
3 to < 10 years	Finland	DIPP_2001_2009	381	7.3	7.0	4.4	11.7	381	1.2	1.2	0.8	1.7
	France	INCA2	239	8.7	8.0	4.2	15.7	239	1.4	1.3	0.8	2.3
	Germany	EsKiMo	426	8.1	7.6	4.5	13.7	426	1.1	1.0	0.6	1.8
	Germany	VELS	146	5.8	5.2	3.1	9.7	146	1.0	0.9	0.6	1.9
	Italy	INRAN_SCAI_2005_06	94	9.6	9.0	5.0	15.3	94	1.3	1.2	0.9	1.8
	Netherlands	DNFCS 2007-2010	231	10.9	10.0	5.3	19.2	231	1.2	1.2	0.7	1.9
	United Kingdom	NDNS – Rolling Programme Years 1–3	326	7.2	7.0	4.0	11.7	326	1.1	1.1	0.7	1.8
10 to < 18 years	Finland	NWSSP07_08	136	10.5	10.5	4.7	16.6	136	1.3	1.3	0.8	1.7
	France	INCA2	449	10.0	9.1	4.9	18.2	449	1.3	1.2	0.7	2.1
	Germany	EsKiMo	197	9.2	8.1	4.8	15.7	197	1.1	1.0	0.6	1.9
	Italy	INRAN_SCAI_2005_06	108	12.4	11.8	7.5	18.7	108	1.3	1.2	0.9	1.8
	Netherlands	DNFCS 2007-2010	566	14.3	12.7	6.1	29.0	566	1.3	1.3	0.8	2.0
	United Kingdom	NDNS – Rolling Programme Years 1–3	340	9.1	8.8	4.7	14.7	340	1.1	1.1	0.7	1.7
18 to < 65 years	Finland	FINDIET2012	585	12.4	11.5	5.0	22.9	585	1.3	1.3	0.7	2.1
	France	INCA2	936	10.5	9.6	4.8	19.8	936	1.2	1.1	0.7	2.0
	Ireland	NANS_2012	634	12.5	11.9	5.6	21.7	634	1.2	1.2	0.7	1.9
	Italy	INRAN_SCAI_2005_06	1 068	11.8	11.1	6.7	18.6	1 068	1.3	1.2	0.9	2.0
	Netherlands	DNFCS 2007-2010	1 023	16.0	15.0	6.9	28.5	1 023	1.4	1.4	0.8	2.1
	Sweden	Riksmaten 2010	623	11.6	11.0	4.8	20.3	623	1.2	1.1	0.6	1.9
	United Kingdom	NDNS – Rolling Programme Years 1–3	560	10.6	9.9	4.7	18.3	560	1.2	1.1	0.7	1.9
65 to < 75 years	Finland	FINDIET2012	210	11.3	10.4	4.4	20.8	210	1.4	1.3	0.7	2.1
	France	INCA2	111	11.6	10.8	5.2	21.5	111	1.4	1.2	0.7	2.7
	Ireland	NANS_2012	72	11.7	10.8	4.3	21.8	72	1.3	1.3	0.7	2.0
	Italy	INRAN_SCAI_2005_06	133	11.6	11.2	5.8	16.9	133	1.3	1.3	0.8	2.0

Age class	Country	Survey	Intakes expressed in mg/day					Intakes expressed in mg/MJ				
			N[(a)]	Average	Median	P5	P95	N[(a)]	Average	Median	P5	P95
	Netherlands	DNFCS 2007-2010	91	12.7	11.7	5.3	24.0	91	1.3	1.3	0.8	2.0
	Sweden	Riksmaten 2010	127	10.9	10.6	4.4	19.0	127	1.2	1.2	0.7	2.1
	United Kingdom	NDNS – Rolling Programme Years 1–3	75	10.8	9.8	5.2	17.6	75	1.3	1.2	0.7	2.3
≥ 75 years	France	INCA2	40	10.6	9.8	(c)	(c)	40	1.4	1.3	(c)	(c)
	Ireland	NANS_2012	34	9.8	8.6	(c)	(c)	34	1.3	1.0	(c)	(c)
	Italy	INRAN_SCAI_2005_06	69	10.8	10.6	6.0	17.1	69	1.3	1.2	0.8	2.0
	Sweden	Riksmaten 2010	42	11.4	10.5	(c)	(c)	42	1.3	1.3	(c)	(c)
	United Kingdom	NDNS – Rolling Programme Years 1–3	56	8.2	7.8	(c)	(c)	56	1.1	1.1	(c)	(c)

NB: The composition data was submitted to EFSA as 'vitamin E' data. The national database compilers of Finland and Sweden confirmed that their food composition database contains information for vitamin E as α-tocopherol.

(a): N: number of subjects.

(b): Infants between 1 and 11 months. The proportions of breast-fed infants were 58 % in the Finnish survey, 40 % in the German survey, 44 % in the Italian survey, and 21 % in the UK survey. Most infants were partially breast-fed. For the Italian and German surveys, breast milk intake estimates were derived from the number of breastfeeding events recorded per day multiplied by standard breast milk amounts consumed on an eating occasion at different age. For the UK survey, the amount of breast milk consumed was either directly quantified by the mother (expressed breast milk) or extrapolated from the duration of each breastfeeding event. As no information on the breastfeeding events was reported in the Finnish survey, breast milk intake was not taken into consideration in the intake estimates of Finnish infants.

(c): 5^{th} or 95^{th} percentile intakes calculated from fewer than 60 subjects require cautious interpretation as the results may not be statistically robust (EFSA, 2011b) and, therefore, for these dietary surveys/age classes, the 5^{th} and 95^{th} percentile estimates are not presented in the intake results.

Appendix D. Intakes of α-tocopherol (mg/day and mg/MJ) in females in different surveys, according to age class and country, based on Finnish and Swedish α-tocopherol composition data

Age class	Country	Survey	Intakes expressed in mg/day					Intakes expressed in mg/MJ				
			N[(a)]	Average	Median	P5	P95	N[(a)]	Average	Median	P5	P95
< 1 year [(b)]	Finland	DIPP_2001_2009	252	2.9	2.7	0.3	5.8	251	1.5	1.5	0.8	2.1
	Germany	VELS	75	4.7	4.1	2.5	8.9	75	1.6	1.5	0.9	2.8
	Italy	INRAN_SCAI_2005_06	7	4.4	3.9	[(c)]	[(c)]	7	1.6	1.7	[(c)]	[(c)]
	United Kingdom	DNSIYC_2011	670	4.9	4.8	2.7	7.1	670	1.6	1.6	1.0	2.1
1 to < 3 years	Finland	DIPP_2001_2009	255	4.0	3.7	1.9	6.6	255	1.2	1.1	0.7	1.7
	Germany	VELS	174	4.7	4.1	2.3	9.6	174	1.1	0.9	0.6	2.3
	Italy	INRAN_SCAI_2005_06	16	5.0	4.1	[(c)]	[(c)]	16	1.0	1.0	[(c)]	[(c)]
	United Kingdom	DNSIYC_2011	651	4.4	4.2	2.2	7.3	651	1.1	1.1	0.6	1.8
	United Kingdom	NDNS – Rolling Programme Years 1–3	78	4.5	4.2	2.1	8.1	78	1.0	0.9	0.6	1.5
3 to < 10 years	Finland	DIPP_2001_2009	369	6.6	6.5	3.7	10.0	369	1.2	1.2	0.8	1.7
	France	INCA2	243	8.0	7.3	4.1	14.4	243	1.4	1.3	0.9	2.4
	Germany	EsKiMo	409	7.4	6.9	3.8	13.7	409	1.1	1.0	0.6	1.8
	Germany	VELS	147	5.4	5.0	3.0	9.8	147	1.0	0.9	0.6	1.7
	Italy	INRAN_SCAI_2005_06	99	9.3	8.9	5.0	14.5	99	1.3	1.2	0.9	1.8
	Netherlands	DNFCS 2007-2010	216	10.3	9.4	5.0	19.6	216	1.2	1.2	0.7	1.8
	United Kingdom	NDNS – Rolling Programme Years 1–3	325	7.1	6.9	3.7	11.1	325	1.2	1.1	0.7	1.7
10 to < 18 years	Finland	NWSSP07_08	170	9.0	8.4	5.2	14.2	170	1.4	1.3	0.9	1.8
	France	INCA2	524	8.9	8.2	4.3	16.1	524	1.4	1.3	0.8	2.5
	Germany	EsKiMo	196	8.8	7.8	4.1	17.4	196	1.2	1.0	0.6	2.5
	Italy	INRAN_SCAI_2005_06	139	10.8	10.4	5.9	18.3	139	1.4	1.3	0.9	2.0
	Latvia[(d)]	FC_PREGNANTWOMEN_2011	12	13.2	13.4	[(c)]	[(c)]	12	1.4	1.3	[(c)]	[(c)]
	Netherlands	DNFCS 2007-2010	576	11.5	10.9	5.5	20.2	576	1.3	1.3	0.7	1.9
	United Kingdom	NDNS – Rolling Programme Years 1–3	326	8.2	7.9	4.2	14.1	326	1.2	1.2	0.7	1.9
18 to < 65 years	Finland	FINDIET2012	710	10.4	9.8	4.7	17.8	710	1.4	1.4	0.8	2.2
	France	INCA2	1 340	9.7	9.1	4.1	17.4	1 340	1.5	1.4	0.8	2.5
	Ireland	NANS_2012	640	10.2	9.8	4.9	17.8	640	1.4	1.3	0.8	2.1
	Italy	INRAN_SCAI_2005_06	1 245	10.1	10.0	5.5	15.3	1 245	1.4	1.4	0.9	2.0
	Latvia[(d)]	FC_PREGNANTWOMEN_2011	990	12.4	11.6	6.2	21.2	990	1.5	1.4	0.8	2.4
	Netherlands	DNFCS 2007-2010	1 034	12.5	11.5	5.6	22.1	1 034	1.5	1.4	0.8	2.3
	Sweden	Riksmaten 2010	807	10.5	9.5	4.5	18.9	807	1.5	1.3	0.8	2.2
	United Kingdom	NDNS – Rolling Programme Years 1–3	706	8.8	8.2	3.9	15.9	706	1.3	1.2	0.7	2.2
65 to < 75 years	Finland	FINDIET2012	203	9.0	8.1	4.1	15.6	203	1.4	1.3	0.8	2.1
	France	INCA2	153	9.9	9.1	4.3	18.1	153	1.6	1.5	1.0	2.8

Age class	Country	Survey	Intakes expressed in mg/day					Intakes expressed in mg/MJ				
			N[(a)]	Average	Median	P5	P95	N[(a)]	Average	Median	P5	P95
	Ireland	NANS_2012	77	9.3	8.7	5.4	15.2	77	1.4	1.3	0.8	2.1
	Italy	INRAN_SCAI_2005_06	157	9.7	9.7	4.9	15.5	157	1.4	1.3	0.9	2.1
	Netherlands	DNFCS 2007-2010	82	10.9	10.1	5.2	17.7	82	1.5	1.5	0.9	2.4
	Sweden	Riksmaten 2010	168	9.3	8.6	4.4	16.8	168	1.3	1.3	0.8	2.1
	United Kingdom	NDNS – Rolling Programme Years 1–3	91	8.6	8.4	4.6	15.4	91	1.4	1.4	0.8	2.3
≥ 75 years	France	INCA2	44	10.1	9.4	(c)	(c)	44	1.7	1.5	(c)	(c)
	Ireland	NANS_2012	43	8.9	8.5	(c)	(c)	43	1.4	1.3	(c)	(c)
	Italy	INRAN_SCAI_2005_06	159	8.8	8.5	4.7	13.7	159	1.3	1.3	0.9	2.0
	Sweden	Riksmaten 2010	30	9.3	9.4	(c)	(c)	30	1.3	1.3	(c)	(c)
	United Kingdom	NDNS – Rolling Programme Years 1–3	83	7.8	7.9	4.2	11.5	83	1.3	1.2	0.7	1.9

NB: The composition data was submitted to EFSA as 'vitamin E' data. The national database compilers of Finland and Sweden confirmed that their food composition database contains information for vitamin E as α-tocopherol.

(a): N: number of subjects.

(b): Infants between 1 and 11 months. The proportions of breast-fed infants were 58 % in the Finnish survey, 40 % in the German survey, 44 % in the Italian survey, and 21 % in the UK survey. Most infants were partially breast-fed. For the Italian and German surveys, breast milk intake estimates were derived from the number of breastfeeding events recorded per day multiplied by standard breast milk amounts consumed on an eating occasion at different age. For the UK survey, the amount of breast milk consumed was either directly quantified by the mother (expressed breast milk) or extrapolated from the duration of each breastfeeding event. As no information on the breastfeeding events was reported in the Finnish survey, breast milk intake was not taken into consideration in the intake estimates of Finnish infants.

(c): 5^{th} or 95^{th} percentile intakes calculated from fewer than 60 subjects require cautious interpretation as the results may not be statistically robust (EFSA, 2011a) and, therefore, for these dietary surveys/age classes, the 5^{th} and 95^{th} percentile estimates are not presented in the intake results.

(d): Pregnant women only.

Appendix E. Intakes of α-tocopherol equivalents (mg α-TE/day and mg α-TE/MJ) in males in different surveys, according to age class and country, based on α-TE composition data of five countries (France, Germany, Italy, Netherlands, UK)

Age class	Country	Survey	Intakes expressed in mg/day					Intakes expressed in mg/MJ				
			N[(a)]	Average	Median	P5	P95	N[(a)]	Average	Median	P5	P95
< 1 year[(b)]	Finland	DIPP_2001_2009	247	3.4	3.4	0.4	7.0	245	1.6	1.7	0.9	2.2
	Germany	VELS	84	4.6	4.3	2.3	7.7	84	1.4	1.4	0.7	2.6
	Italy	INRAN_SCAI_2005_06	9	5.4	3.5	[(c)]	[(c)]	9	1.8	1.3	[(c)]	[(c)]
	United Kingdom	DNSIYC_2011	699	5.9	5.7	3.5	8.5	699	1.7	1.8	1.1	2.3
1 to < 3 years	Finland	DIPP_2001_2009	245	4.7	4.4	2.0	7.9	245	1.3	1.2	0.7	2.0
	Germany	VELS	174	5.7	5.2	2.8	10.0	174	1.2	1.1	0.7	2.0
	Italy	INRAN_SCAI_2005_06	20	7.3	6.8	[(c)]	[(c)]	20	1.4	1.5	[(c)]	[(c)]
	United Kingdom	DNSIYC_2011	663	5.1	5.0	2.5	8.2	663	1.2	1.2	0.7	1.9
	United Kingdom	NDNS – Rolling Programme Years 1–3	107	6.0	5.5	3.2	9.9	107	1.2	1.1	0.7	1.9
3 to < 10 years	Finland	DIPP_2001_2009	381	7.4	7.1	4.4	11.8	381	1.3	1.2	0.8	1.7
	France	INCA2	239	9.4	8.6	4.5	16.6	239	1.5	1.4	0.8	2.3
	Germany	EsKiMo	426	9.4	8.8	4.9	15.7	426	1.2	1.2	0.7	2.0
	Germany	VELS	146	7.1	6.6	3.8	12.4	146	1.3	1.2	0.7	2.2
	Italy	INRAN_SCAI_2005_06	94	12.4	12.3	5.8	19.2	94	1.7	1.6	1.1	2.3
	Netherlands	DNFCS 2007-2010	231	11.7	10.7	5.3	20.7	231	1.3	1.3	0.7	2.0
	United Kingdom	NDNS – Rolling Programme Years 1–3	326	8.0	7.7	4.0	12.7	326	1.3	1.2	0.8	1.8
10 to < 18 years	Finland	NWSSP07_08	136	10.5	10.3	4.5	16.9	136	1.3	1.3	0.8	1.7
	France	INCA2	449	10.8	10.2	5.1	18.8	449	1.4	1.3	0.8	2.1
	Germany	EsKiMo	197	10.8	9.7	5.7	19.1	197	1.3	1.2	0.8	2.2
	Italy	INRAN_SCAI_2005_06	108	15.9	14.8	9.0	24.4	108	1.6	1.6	1.1	2.3
	Netherlands	DNFCS 2007-2010	566	14.3	12.8	6.1	27.6	566	1.3	1.2	0.7	2.1
	United Kingdom	NDNS – Rolling Programme Years 1–3	340	9.6	8.9	4.8	16.8	340	1.2	1.1	0.6	1.8
18 to < 65 years	Finland	FINDIET2012	585	13.7	12.6	5.5	25.5	585	1.5	1.4	0.8	2.4
	France	INCA2	936	10.9	10.0	4.5	20.2	936	1.2	1.2	0.7	2.1
	Ireland	NANS_2012	634	11.6	10.9	4.6	21.1	634	1.1	1.1	0.6	1.9
	Italy	INRAN_SCAI_2005_06	1 068	15.4	14.7	8.7	24.5	1 068	1.7	1.6	1.1	2.5
	Netherlands	DNFCS 2007-2010	1 023	16.0	15.1	6.8	28.9	1 023	1.4	1.4	0.7	2.2
	Sweden	Riksmaten 2010	623	13.3	12.5	5.4	23.3	623	1.3	1.3	0.7	2.1
	United Kingdom	NDNS – Rolling Programme Years 1–3	560	10.9	10.3	4.7	18.8	560	1.2	1.2	0.7	2.0
65 to < 75 years	Finland	FINDIET2012	210	12.8	11.5	4.9	24.3	210	1.5	1.5	0.8	2.5
	France	INCA2	111	11.6	11.0	4.6	22.2	111	1.4	1.2	0.6	2.8
	Ireland	NANS_2012	72	12.0	11.3	3.2	23.4	72	1.3	1.2	0.7	2.3
	Italy	INRAN_SCAI_2005_06	133	15.4	15.2	7.9	23.0	133	1.8	1.7	1.1	2.6

Age class	Country	Survey	Intakes expressed in mg/day					Intakes expressed in mg/MJ				
			N[(a)]	Average	Median	P5	P95	N[(a)]	Average	Median	P5	P95
	Netherlands	DNFCS 2007-2010	91	12.9	12.9	6.0	22.8	91	1.4	1.3	0.9	1.9
	Sweden	Riksmaten 2010	127	12.5	12.3	5.8	21.6	127	1.4	1.4	0.9	2.2
	United Kingdom	NDNS – Rolling Programme Years 1–3	75	12.5	11.0	5.0	22.0	75	1.5	1.5	0.6	2.2
≥ 75 years	France	INCA2	40	11.6	11.5	(c)	(c)	40	1.5	1.4	(c)	(c)
	Ireland	NANS_2012	34	10.4	8.6	(c)	(c)	34	1.3	1.1	(c)	(c)
	Italy	INRAN_SCAI_2005_06	69	14.2	13.8	8.8	22.1	69	1.7	1.6	1.1	2.6
	Sweden	Riksmaten 2010	42	13.0	13.0	(c)	(c)	42	1.5	1.5	(c)	(c)
	United Kingdom	NDNS – Rolling Programme Years 1–3	56	10.1	9.1	(c)	(c)	56	1.4	1.3	(c)	(c)

NB: The composition data was submitted to EFSA as 'vitamin E' data. The national database compilers of Finland and Sweden confirmed that their food composition database contains information for vitamin E as α-tocopherol.

(a): N: number of subjects.

(b): Infants between 1 and 11 months. The proportions of breast-fed infants were 58 % in the Finnish survey, 40 % in the German survey, 44 % in the Italian survey, and 21 % in the UK survey. Most infants were partially breast-fed. For the Italian and German surveys, breast milk intake estimates were derived from the number of breastfeeding events recorded per day multiplied by standard breast milk amounts consumed on an eating occasion at different age. For the UK survey, the amount of breast milk consumed was either directly quantified by the mother (expressed breast milk) or extrapolated from the duration of each breastfeeding event. As no information on the breastfeeding events was reported in the Finnish survey, breast milk intake was not taken into consideration in the intake estimates of Finnish infants.

(c): 5^{th} or 95^{th} percentile intakes calculated from fewer than 60 subjects require cautious interpretation as the results may not be statistically robust (EFSA, 2011b) and, therefore, for these dietary surveys/age classes, the 5^{th} and 95^{th} percentile estimates are not presented in the intake results.

Appendix F. Intakes of α-tocopherol equivalents (mg α-TE/day and mg α-TE/MJ) in females in different surveys, according to age class and country, based on α-TE composition data of five countries (France, Germany, Italy, Netherlands, UK)

Age class	Country	Survey	Intakes expressed in mg/day					Intakes expressed in mg/MJ				
			N[(a)]	Average	Median	P5	P95	N[(a)]	Average	Median	P5	P95
< 1 year[(b)]	Finland	DIPP_2001_2009	252	3.2	3.0	0.3	6.4	251	1.7	1.7	0.9	2.3
	Germany	VELS	75	4.8	4.2	2.6	10.0	75	1.7	1.5	0.9	3.1
	Italy	INRAN_SCAI_2005_06	7	5.3	4.5	[(c)]	[(c)]	7	1.9	1.3	[(c)]	[(c)]
	United Kingdom	DNSIYC_2011	670	5.2	5.2	2.9	7.9	670	1.7	1.7	1.0	2.3
1 to < 3 years	Finland	DIPP_2001_2009	255	4.4	4.1	1.9	7.5	255	1.3	1.2	0.7	1.9
	Germany	VELS	174	5.6	5.0	2.6	10.7	174	1.3	1.2	0.7	2.4
	Italy	INRAN_SCAI_2005_06	16	6.8	6.0	[(c)]	[(c)]	16	1.4	1.4	[(c)]	[(c)]
	United Kingdom	DNSIYC_2011	651	5.0	4.8	2.6	8.2	651	1.3	1.2	0.7	2.0
	United Kingdom	NDNS – Rolling Programme Years 1–3	78	5.5	5.1	2.5	9.6	78	1.2	1.2	0.7	1.9
3 to < 10 years	Finland	DIPP_2001_2009	369	6.7	6.5	3.7	10.1	369	1.3	1.2	0.8	1.8
	France	INCA2	243	8.9	8.3	4.4	15.6	243	1.6	1.5	1.0	2.4
	Germany	EsKiMo	409	8.8	8.2	4.2	15.7	409	1.3	1.2	0.7	2.1
	Germany	VELS	147	6.5	6.2	3.4	11.5	147	1.3	1.2	0.7	1.9
	Italy	INRAN_SCAI_2005_06	99	11.8	11.2	6.9	19.0	99	1.6	1.6	1.1	2.4
	Netherlands	DNFCS 2007-2010	216	10.7	9.8	5.6	20.0	216	1.3	1.2	0.8	2.1
	United Kingdom	NDNS – Rolling Programme Years 1–3	325	7.9	7.7	3.8	12.4	325	1.3	1.3	0.8	1.9
10 to < 18 years	Finland	NWSSP07_08	170	9.1	8.7	5.2	14.9	170	1.4	1.4	0.9	1.9
	France	INCA2	524	9.5	8.8	4.3	17.0	524	1.5	1.4	0.9	2.4
	Germany	EsKiMo	196	9.8	8.9	4.7	17.9	196	1.3	1.2	0.7	2.5
	Italy	INRAN_SCAI_2005_06	139	13.8	13.3	7.7	22.2	139	1.7	1.6	1.0	2.6
	Latvia[(d)]	FC_PREGNANTWOMEN_2011	12	12.8	12.1	a	a	12	1.3	1.3	a	a
	Netherlands	DNFCS 2007-2010	576	11.7	11.1	5.4	20.0	576	1.3	1.3	0.7	2.0
	United Kingdom	NDNS – Rolling Programme Years 1–3	326	8.8	8.2	4.1	14.7	326	1.3	1.2	0.8	2.0
18 to < 65 years	Finland	FINDIET2012	710	11.6	10.7	4.9	22.1	710	1.6	1.5	0.9	2.5
	France	INCA2	1340	10.3	9.5	4.4	18.7	1340	1.6	1.5	0.9	2.6
	Ireland	NANS_2012	640	9.8	9.1	4.2	16.9	640	1.3	1.3	0.7	2.0
	Italy	INRAN_SCAI_2005_06	1 245	13.5	13.2	7.2	20.9	1 245	1.9	1.8	1.1	2.7
	Latvia[(d)]	FC_PREGNANTWOMEN_2011	990	12.5	11.8	6.2	21.7	990	1.5	1.4	0.8	2.4
	Netherlands	DNFCS 2007-2010	1 034	12.3	11.4	5.3	21.8	1 034	1.5	1.4	0.8	2.4
	Sweden	Riksmaten 2010	807	12.3	11.3	5.4	23.7	807	1.8	1.5	0.9	2.7
	United Kingdom	NDNS – Rolling Programme Years 1–3	706	9.4	8.9	4.0	16.1	706	1.4	1.3	0.8	2.2
65 to < 75 years	Finland	FINDIET2012	203	10.2	9.1	4.3	20.0	203	1.6	1.5	0.9	2.5
	France	INCA2	153	10.3	9.0	4.5	20.2	153	1.6	1.5	0.9	2.8

Age class	Country	Survey	Intakes expressed in mg/day					Intakes expressed in mg/MJ				
			N[(a)]	Average	Median	P5	P95	N[(a)]	Average	Median	P5	P95
	Ireland	NANS_2012	77	9.4	8.7	4.7	20.7	77	1.4	1.3	0.8	2.3
	Italy	INRAN_SCAI_2005_06	157	13.1	12.9	6.5	21.5	157	1.9	1.8	1.2	2.9
	Netherlands	DNFCS 2007-2010	82	11.2	10.7	4.9	19.7	82	1.6	1.6	0.8	2.5
	Sweden	Riksmaten 2010	168	11.1	10.4	5.1	19.6	168	1.6	1.5	0.9	2.5
	United Kingdom	NDNS – Rolling Programme Years 1–3	91	9.1	9.1	4.6	14.4	91	1.5	1.5	0.9	2.3
≥ 75 years	France	INCA2	44	10.7	9.6	(c)	(c)	44	1.8	1.6	(c)	(c)
	Ireland	NANS_2012	43	10.3	9.4	(c)	(c)	43	1.6	1.5	(c)	(c)
	Italy	INRAN_SCAI_2005_06	159	11.8	11.4	5.9	18.1	159	1.8	1.7	1.1	2.5
	Sweden	Riksmaten 2010	30	11.3	11.2	(c)	(c)	30	1.6	1.6	(c)	(c)
	United Kingdom	NDNS – Rolling Programme Years 1–3	83	8.9	8.6	4.9	13.2	83	1.5	1.4	0.9	2.1

NB: The composition data was submitted to EFSA as 'vitamin E' data. The national database compilers of Finland and Sweden confirmed that their food composition database contains information for vitamin E as α-tocopherol.

(a): N: number of subjects.

(b): Infants between 1 and 11 months. The proportions of breast-fed infants were 58 % in the Finnish survey, 40 % in the German survey, 44 % in the Italian survey, and 21 % in the UK survey. Most infants were partially breast-fed. For the Italian and German surveys, breast milk intake estimates were derived from the number of breastfeeding events recorded per day multiplied by standard breast milk amounts consumed on an eating occasion at different age. For the UK survey, the amount of breast milk consumed was either directly quantified by the mother (expressed breast milk) or extrapolated from the duration of each breastfeeding event. As no information on the breastfeeding events was reported in the Finnish survey, breast milk intake was not taken into consideration in the intake estimates of Finnish infants.

(c): 5^{th} or 95^{th} percentile intakes calculated from fewer than 60 subjects require cautious interpretation as the results may not be statistically robust (EFSA, 2011b) and, therefore, for these dietary surveys/age classes, the 5th and 95th percentile estimates are not presented in the intake results.

(d): Pregnant women only.

Appendix G. Minimum and maximum percentage contribution of different food groups (FoodEx2 level 1) to α-TE intakes in males, based on α-TE composition data of five countries (France, Germany, Italy, Netherlands, UK)

Food groups	< 1 year	1 to < 3 years	3 to < 10 years	10 to < 18 years	18 to < 65 years	65 to < 75 years	≥ 75 years
Additives, flavours, baking and processing aids	< 1	< 1	0	0	0	0	0
Alcoholic beverages	0	0	0	0	0	0	0
Animal and vegetable fats and oils	4 – 21	10 – 44	14 – 55	14 – 56	14 – 59	14 – 60	16 – 59
Coffee, cocoa, tea and infusions	< 1	0 – 1	< 1 – 2	< 1 – 1	< 1 – 2	< 1 – 1	< 1 – 2
Composite dishes	< 1 – 2	< 1 – 14	< 1 – 12	< 1 – 13	1 – 23	< 1 – 21	1 – 19
Eggs and egg products	< 1	1 – 3	1 – 5	1 – 4	1 – 2	1 – 3	1 – 2
Fish, seafood, amphibians, reptiles and invertebrates	< 1 – 1	1 – 2	1 – 3	1 – 3	1 – 8	3 – 11	3 – 11
Food products for young population	44 – 62	4 – 30	< 1 – 1	< 1	< 1	–[a]	–[a]
Fruit and fruit products	2 – 12	7 – 10	3 – 6	2 – 5	2 – 6	4 – 8	3 – 9
Fruit and vegetable juices and nectars	< 1 – 6	1 – 17	2 – 18	2 – 17	1 – 5	< 1 – 5	< 1 – 4
Grains and grain-based products	< 1 – 11	10 – 29	8 – 33	8 – 25	10 – 25	9 – 31	10 – 31
Human milk	< 1[b] – 24	< 1 – 2	–[a]	–[a]	–[a]	–[a]	–[a]
Legumes, nuts, oilseeds and spices	< 1 – 4	< 1 – 2	1 – 6	1 – 5	1 – 6	1 – 5	< 1 – 3
Meat and meat products	< 1 – 1	1 – 3	2 – 4	2 – 4	2 – 4	1 – 4	2 – 3
Milk and dairy products	1 – 3	5 – 7	3 – 9	3 – 7	2 – 5	2 – 5	3
Products for non-standard diets, food imitates and food supplements or fortifying agents	< 1 – 1	0	< 1 – 2	< 1 – 1	< 1 – 4	< 1	< 1 – 2
Seasoning, sauces and condiments	< 1 – 3	< 1 – 8	1 – 10	1 – 13	2 – 14	1 – 11	1 – 12
Starchy roots or tubers and products thereof, sugar plants	< 1 – 3	1 – 5	1 – 12	1 – 12	< 1 – 10	< 1 – 8	< 1 – 14
Sugar, confectionery and water-based sweet desserts	0	< 1 – 1	1 – 2	1 – 2	< 1 – 2	< 1 – 1	< 1 – 1
Vegetables and vegetable products	1 – 5	5 – 8	3 – 8	3 – 9	3 – 11	3 – 11	4 – 11
Water and water-based beverages	0	0 – 1	< 1 – 1	< 1 – 1	< 1	< 1	< 1

(a): '-' means that there was no consumption event of the food group for the age and sex group considered, while '0' means that there were some consumption events, but that the food group does not contribute to the intake of the nutrient considered, for the age and sex group considered.
(b): The lower bound of this range corresponds to the data from the Finnish survey, which did not assess the amount of breast milk consumed.

Appendix H. Minimum and maximum percentage contribution of different food groups (FoodEx2 level 1) to α-TE intakes in females, based on α-TE composition data of five countries (France, Germany, Italy, Netherlands, UK)

Food groups	< 1 year	1 to < 3 years	3 to < 10 years	10 to < 18 years	18 to < 65 years	65 to < 75 years	≥ 75 years
Additives, flavours, baking and processing aids	0	0	0	0	0	0	0
Alcoholic beverages	0	0	0	0	0	0	0
Animal and vegetable fats and oils	4 – 24	11 – 49	13 – 55	13 – 54	11 – 57	10 – 57	10 – 53
Coffee, cocoa, tea and infusions	< 1	< 1 – 1	< 1 – 2	< 1 – 1	< 1 – 2	< 1 – 2	< 1 – 1
Composite dishes	< 1 – 3	< 1 – 12	< 1 – 12	1 – 13	1 – 25	< 1 – 21	< 1 – 24
Eggs and egg products	< 1 – 1	< 1 – 3	1 – 5	1 – 4	1 – 2	1 – 4	1 – 2
Fish, seafood, amphibians, reptiles and invertebrates	< 1 – 2	1 – 3	< 1 – 3	1 – 4	2 – 7	2 – 10	2 – 10
Food products for young population	46 – 61	6 – 25	< 1 – 1	< 1	<1	–[a]	< 1
Fruit and fruit products	4 – 12	6 – 10	3 – 7	3 – 8	4 – 7	7 – 11	5 – 11
Fruit and vegetable juices and nectars	< 1 – 5	1 – 16	2 – 17	3 – 15	1 – 4	< 1 – 5	< 1 – 7
Grains and grain-based products	1 – 7	9 – 30	8 – 31	9 – 30	11 – 30	10 – 28	10 – 27
Human milk	< 1[b] – 12	< 1 – 2	–[a]	–[a]	–[a]	–[a]	–[a]
Legumes, nuts, oilseeds and spices	< 1 – 1	< 1 – 2	1 – 4	< 1 – 7	1 – 8	1 – 6	1 – 5
Meat and meat products	< 1 – 1	1 – 3	2 – 4	2 – 4	2 – 4	2 – 3	1 – 2
Milk and dairy products	1 – 3	5 – 7	3 – 9	3 – 6	3 – 5	2 – 5	3 – 4
Products for non-standard diets, food imitates and food supplements or fortifying agents	< 1	< 1 – 1	0 – 2	< 1 – 1	< 1 – 3	0 – 1	< 1 – 1
Seasoning, sauces and condiments	< 1 – 2	< 1 – 8	1 – 11	1 – 17	1 – 16	1 – 14	1 – 13
Starchy roots or tubers and products thereof, sugar plants	< 1 – 3	< 1 – 6	1 – 12	1 – 12	< 1 – 8	< 1 – 8	< 1 – 6
Sugar, confectionery and water-based sweet desserts	0	< 1 – 2	1 – 2	1 – 3	< 1 – 2	< 1 – 1	< 1 – 1
Vegetables and vegetable products	3 – 5	5 – 8	3 – 8	3 – 9	4 – 11	5 – 12	6 – 12
Water and water-based beverages	0	0	< 1 – 1	0 – 1	< 1	< 1	< 1

(a): '-' means that there was no consumption event of the food group for the age and sex group considered, while '0' means that there were some consumption events, but that the food group does not contribute to the intake of the nutrient considered, for the age and sex group considered.
(b): The lower bound of this range corresponds to the data from the Finnish survey, which did not assess the amount of breast milk consumed.

ABBREVIATIONS

Afssa	Agence française de sécurité sanitaire des aliments
AI	Adequate Intake
AR	Average Requirement
ATBC	Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study
AVED	Ataxia with vitamin E deficiency
BMI	Body mass index
CD36	Cluster of differentiation 36
α-CEHC	2,5,7,8-tetramethyl-2-(2'-carboxyethyl)-6-hydroxychroman
CI	Confidence interval
α-CMBHC	α-carboxymethylbutyl hydrochroman
COMA	Committee on Medical Aspects of Food Policy
CV	Coefficient of variation
CVD	Cardiovascular disease
CYP	Cytochrome P
Da	Dalton
D-A-CH	Deutschland-Austria-Confoederatio Helvetica
DH	UK Department of Health
DHA	Docosahexaenoic acid
DIPP	Type 1 Diabetes Prediction and Prevention survey
DNA	Deoxyribonucleic acid
DNFCS	Dutch National Food Consumption Survey
DNSIYC	Diet and Nutrition Survey of Infants and Young Children
DRV	Dietary Reference Value
EAR	Estimated average requirement
EPA	Eicosapentaenoic acid
EsKiMo	Ernährungsstudie als KIGGS-Modul
EU	European Union
FAO	Food and Agriculture Organization
FFQ	Food frequency questionnaire
HDL	High-density lipoproteins
HPLC	High Performance Liquid Chromatography
HPLC-EC	High Performance Liquid Chromatography - ElectroChemical detection
IDL	Intermediate-density lipoproteins
INCA	Etude Individuelle Nationale des Consommations Alimentaires

INRAN-SCAI	Istituto Nazionale di Ricerca per gli Alimenti e la Nutrizione - Studio sui Consumi Alimentari in Italia
IOM	U.S. Institute of Medicine of the National Academy of Sciences
IU	International Unit
LDL	Low-density lipoproteins
LPL	Lipoprotein lipase
NANS	National Adult Nutrition Survey
NCM	Nordic Council of Ministers
NHANES	National Health and Nutrition Examination Survey
NDNS	National Diet and Nutrition Survey
NNR	Nordic Nutrition Recommendations
NOAEL	No Observed Adverse Effect Level
NP-HPLC	Normal-Phase HPLC
NRC	National Research Council
NWSSP	Nutrition and Wellbeing of Secondary School Pupils
OR	Odds ratio
PDA	Photodiode Array
PK	Protein kinase
PRI	Population Reference Intake
PUFA	Poly-unsaturated fatty acids
Q	Quintile
RBCs	Red blood cells
r	Correlation coefficient
RCT	Randomised controlled trials
RDA	Recommended Dietary Allowance
RI	Recommended Intake
RP-HPLC	Reversed-phase HPLC
RR	Relative risk
SCF	Scientific Committee for Food
SD	Standard Deviation
SE	Standard Error
SEM	Standard Error of the Mean
SR-BI	Scavenger Receptor Class B type I
SU.VI.MAX	Supplémentation en vitamines et minéraux antioxydants
α-TEs	alpha-tocopherol equivalents
TQ	Tocopherylquinone
α-TTP	alpha-tocopherol Transfer Protein

UHPLC	Ultra-High Performance Liquid Chromatography
UK	United Kingdom
UL	Tolerable Upper Intake Level
USDA	United States Department of Agriculture
UV	Ultra-violet
VELS	Verzehrsstudie zur Ermittlung der Lebensmittelaufnahme von Säuglingen und Kleinkindern für die Abschätzung eines akuten Toxizitätsrisikos durch Rückstände von Pflanzenschutzmitteln
VLDL	Very low-density lipoproteins
WCRF	World Cancer Research Fund
WHO	World Health Organization